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Abstract
Chronic Kidney Disease (CKD) is a major global public health problem and is one of the fastest
rising major causes of death. Worldwide moderate to severe CKD has a prevalence of ~11%,
whereas in the UK it is ~5%. The objective of our study was to identify key risk factors associated
with the progression of kidney disease both across and within primary kidney diseases; ultimately
this could lead to improvements in patient care and a reduction in disease burden.
We used data collected from secondary care patients who were recruited into the Salford Kidney
Study at Salford Royal NHS Foundation Trust, UK. This ongoing study which commenced
in 2002 is one of the largest of its kind worldwide, and consists of over 3000 non-dialysis
patients with moderate to severe CKD, who are followed-up annually until an end point of either
dialysis, kidney transplant or death. The data recorded at follow-up appointments included
comorbidities, medications, lifestyle factors, socio-demographic information and biochemical
marker measurements.
We used longitudinal modelling, specifically a linear mixed effects model which models population
effects alongside patient-specific variability. We identified risk factors within each of eight primary
disease categories including diabetic nephropathy, glomerulonephritis, hypertensive kidney disease,
renovascular disease, polycystic kidney disease and pyelonephritis. The key risk factors for lower
levels of eGFR are biochemical markers and medications, whereas lifestyle factors and physical
attributes are less important. Medications play an important role; in particular ACE inhibitors
and ARBs are key in diabetic nephropathy and glomerulonephritis, but not in the other diseases.
We found that more rapid progression of kidney disease is associated with biochemical markers
including cholesterol and proteinuria. In contrast, medications and comorbidities are not key in
rapid disease progression. We recommend future work should include more in-depth studies of
each disease category including splitting them into subcategories.
Word count approximately 31,000.
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1 Introduction and background
CKD is recognised as a major global public health problem with a high economic cost to health
systems (1). The 2015 Global Burden of Disease Study (2) reported kidney disease as the 12th
most common cause of death, with CKD mortality increasing by 31.7% between 2005-2015, it
is now one of the fastest rising major causes of death worldwide (3). This growth is generally
considered to be fuelled by overnutrition, inadequate physical inactivity, and ageing populations
(4,5). More broadly the World Health Organization confirms a global shift in which the majority
of global morbidity and mortality is now caused by chronic diseases as opposed to infectious
diseases (6,7). For moderate to severe CKD, stages 3 to 5, the global prevalence was reported
in 2016 to be 10.6% {95% CI: 9.2-12.2%}; see (8). In 2014 Public Health England estimates,
which took account of both diagnosed and undiagnosed cases, indicated a prevalence of 6.1%
{95% CI: 5.3-7.0%} for adults with CKD stages 3 to 5 who were resident in England (9). This
rate is similar to the actual diagnosed prevalence of 4.3% reported by the Quality and Outcomes
Framework during 2012-2013; see (10,11). The prevalence of CKD dramatically increases with
advancing age (12). For example, (13) reported in 2007 that the prevalence in the United States
of CKD stage 3 stratified by age was: 20-39 years (~1%); 40-59 years (~4%); 60-69 years (~14%);
> 70 years (~37%). This study also showed that stage 3 was by far the most prevalent out of all
the five stages of CKD.
CKD is generally associated with decreased quality of life along with an increased risk of
premature death and cardiovascular disease (14). It follows that a rapid decline in kidney function
is associated with an increased risk of both mortality and cardiovascular events (15,16). Conversely,
cardiovascular disease increases the risk of CKD hence these two diseases are closely interrelated
(17). CKD is also frequently comorbid with other common diseases including hypertension,
diabetes, anaemia and mineral/bone disorders (18,19), in fact diabetes and hypertension are
the leading causes of CKD (20,21). For example, during 2017, the United States Renal Data
System (USRDS) reported (in chapter 1) that given adults with CKD (stages 1-5), about 40%
had diabetes, ~32% had hypertension and ~42% had cardiovascular disease (18). The prevalence
of comorbidities increases as CKD progresses and a majority of patients with moderate to severe
CKD have at least one comorbidity (22). The primary causes of end-stage renal disease, as
reported by USRDS, are diabetes 38.2%, hypertension 25.5% and glomerulonephritis 16%; see
table 1.6 in (23). Mortality rates are also substantially higher for certain groups of CKD patients.
In particular the mortality rate for CKD patients with cardiovascular disease is about 2.5 times
higher than for those without cardiovascular disease or diabetes, similarly the mortality rate for
CKD patients with both cardiovascular disease and diabetes is about 3 times higher than for
those without cardiovascular disease or diabetes; see (23) chapter 3. Given that for CKD patients
the risk of complications increases with decreasing kidney function, early intervention aims to
ameliorate the risk of severe complications and reduce the number of patients progressing to
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dialysis or transplant e.g. see (24–26).
To determine how well the kidneys are functioning the level of creatinine in the blood is measured.
This measured value is then used to calculate the estimated glomerular filtration rate (eGFR).
Normal kidney function in healthy adults decreases with age; for example adults of 20-30 years
have an eGFR of ~115 mL/min/1.73m2 whereas it has decreased to ~85 mL/min/1.73m2 in the
60-69 year age group (27,28). The annual rate of decline of eGFR in the healthy population is
approximately 0.36-1.21 mL/min/1.73m2 per year; younger adults tend towards the lower value
and older individuals the upper value; see reviews (28) and (29). It should be noted that in the
general population the aforementioned values vary widely as they not only depend on factors such
age, ethnicity, gender but are also dependent on underlying comorbidities. The National Institute
for Health and Care Excellence (NICE), defines progressive CKD as either an annual fall in eGFR
of > 5 mL/min/1.73m2 or a fall of > 10 mL/min/1.73m2 within 5 years (30). Furthermore it is
generally accepted, as defined by KDIGO in 2012, that rapid progression is a sustained decline
of > 5 mL/min/1.73m2 per year (31). CKD can be divided into several primary disease types
including glomerulonephritis, diabetic nephropathy and polycystic kidney disease. These diseases
are expected to have different rates of decline in eGFR although exact values vary widely in the
literature and are often not directly comparable. However in 2012/13, (32) reported an average
annual decrease for diabetic nephropathy patients of 1.7 mL/min/1.73m2 whereas (33) found an
average annual decrease of about 3 mL/min/1.73m2 in polycystic kidney disease patients. This
suggests that the progression of CKD is nearly twice as fast in polycystic patients; both rates
were for patients with CKD stages 3 to 5.
In this thesis we study the progression of CKD using data collected by the ongoing Salford
Kidney Study (SKS) (34,35) run by Salford Royal NHS Foundation Trust (SRFT), UK. SKS has
one of the largest cohorts in the world of secondary care CKD patients, with over 3000 patient
records collected since 2002. The data includes patients with all primary kidney disease types.
The aims of the SKS are to investigate factors influencing outcomes and progression of renal
disease in CKD patients, including a focus on risk factors associated with more rapid disease
progression. In particular, SKS is a prospective observational study of outcomes of non-dialysis
adult patients with CKD stages 3 to 5 (10 < eGFR 6 60 mL/min/1.73m2). Patients referred
to the renal services at SRFT, and existing CKD patients attending the clinics, are approached
for inclusion in the study and enrolled if written informed consent is obtained. Patients are
followed up annually until they reached predefined study end-points, these are death or initiation
of renal replacement therapy (RRT). SKS defined RRT as chronic haemodialysis, peritoneal
dialysis or kidney transplant. At recruitment and annual nephrology follow-up appointments,
patient socio-demographic and lifestyle choices are recorded along with comorbidities. Concurrent
medications and additionally blood samples are taken and processed to obtain a comprehensive
set of biochemical marker measurements.
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In general, longitudinal data such as the SKS data, is comprised of multiple observations collected
over successive time periods on the same individuals. The data may also include baseline variables
that are collected once e.g. age at study entry. However repeated measurements on the same
individual will not be independent and this must be accounted for when building statistical models.
To this end mixed effects models are an appropriate statistical framework and a well-established
approach; for example see textbooks (36–38). These models consist of both fixed effects and
random effects, which explain the relationships between an outcome variable and explanatory
variables. Fixed effects describe the whole population whereas random effects are associated with
each individual and capture the dependence of repeated measurements. In terms of longitudinal
data the development of such models is attributed to Laird and Ware in 1982 (39); this paper
considers a causal link between air pollution and pulmonary function measured at specified time
intervals. Later in 1988 Diggle (40) introduced an approach whereby the correlation between
successive random effects is described by stationary Gaussian processes; this approach is applied
to two separate repeated measure studies, body weight of rats and blood pressure of rats.
Mixed effects models have been extensively used to study the progression of kidney disease over
time. A broad literature review of statistical methods used for investigating risk factors of CKD
progression is given by (41). One of their conclusions, given longitudinal data where the outcome
of interest is the entire trajectory of renal function over time, is that linear mixed models are
an appropriate tool for estimating both risk factors and their associated confidence intervals.
Given a choice between linear regression to estimate individual slopes and linear mixed effects
models, (42) concludes the latter are preferred for research questions regarding kidney disease
trajectories over time at population level. Similarly in the context of progression of kidney disease
(43) considers the comparative strengths and weaknesses of the Generalized Estimating Equations
(GEE) approach with linear mixed effects models, in part concluding that the mixed effects model
is preferred in relation to missing data since the GEE makes more restricted assumptions; for
details see Appendix 4 in the supplementary material of (44). A further comparative study by
(45) concludes that the linear mixed model is the preferred method for investigating risk factors
associated with renal function trajectories when individuals leave the study due to initiation of
renal replacement therapy.
In this thesis, we performed a longitudinal analysis of the SKS data, to identify markers for
progression in CKD. The patients were assigned to one of 8 subcategories of CKD, we refer to
these as primary disease categories. We applied a linear mixed model (LME) to analyse each of
the 8 primary disease categories separately, and used model selection techniques to identify the
most pertinent risk factors. As a result we were are able to make comparisons across the primary
disease categories.
We start, in Chapter 2, by exploring and summarising the SKS data. In Chapter 3 we define the
LME which forms the basis of all our modelling. In Chapter 4 we show how to interpret step
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changes in the LME model regression parameters in terms of eGFR (rather than log(eGFR)) and
also how to use to estimate the rate of change over time of eGFR from the LME model. We
describe our model selection procedures in Chapter 5 and then having selected the final model
for each primary disease category we then validate each model using diagnostic procedures before
presenting our results in Chapter 6. Our findings are reported in Chapter 7. In Chapter 8 we
discuss our models, results and future research directions. We close, in Chapter 9, with some
concluding remarks.
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2 Summary of SKS data
We begin by describing our procedures for cleaning the raw SKS data. This includes removing
obvious erroneous values and consolidating subsets of data into categories such as primary diseases,
comorbidities and medications. The cleaned dataset has approximately 40 potential risk factors
(explanatory variables) which we use during our exploratory analysis. Finally, after completing
the exploratory analysis, the number of complete records was significantly increased by imputing
missing values thereby increasing the power of our statistical models. Throughout this chapter,
unless otherwise stated, missing values are not imputed.
2.1 Data preparation and cleaning
Using the programming language R (46) we extracted and cleaned the SKS data from the
Microsoft Access database provided by the clinicians at Salford Royal NHS Foundation Trust. All
incorrect data were purged, for example a date with year 1066. The units of all measurements were
converted so as to be consistent e.g. patient heights were standardised to metres. We accounted
for spelling variations and commonly misspelt words e.g. medications ‘doxazosin’ and ‘doxasosin’
were both identified as α-blockers. To reduce the complexity of the data we, with guidance from
the clinicians, categorised various items; notably medications, comorbidities and primary kidney
diseases. The breakdown of these categories is given in Appendix A.1. The biochemical marker
data was provided separately from the Microsoft Access database, so where possible we matched
the biochemical data to each patient using their follow-up appointment dates; we allowed for
differences of up to six weeks between the recorded dates of the biochemical markers and follow-up
appointments. Full details regarding data cleaning are given in Appendix A.1.
2.2 Overview of SKS data
The data from 3,166 patients were collected between 01 October 2002 and 27 February 2017;
participants were recruited throughout this period. Of the patients in this study 37.6% were
female, and 95.7% declared their ethnicity as white.
At baseline, when the patient joined the study, a number of health indicators were recorded.
For example the cohort had 12.2% active smokers and 52.7% ex-smokers. Similarly within the
cohort 29.9% of patients declared they consumed 1 to 14 units of alcohol per week while another
14.7% declared they drank over 14 units per week. Further basic summary statistics of the cohort
at baseline are given in Table 1; note IQR refers to interquartile range. These show that the
cohort are on average older adults who are, as defined by NICE, overweight (47). Within the
general UK population pulse pressure (PP) for adults aged around 65 years is expected to be
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in the upper fifties (48) so the SKS cohort is a little worse than average but 87.1% are taking
antihypertensives.
Table 1: Baseline summary statistics
item units min max median IQR
age year 18.2 94.5 67.4 20.0
BMI kg/m2 13.3 59.9 28.0 7.8
DBP mmHg 40.5 137.0 74.5 14.0
PP mmHg 17.0 146.0 64.0 28.0
SBP mmHg 76.0 218.0 139.0 29.0
Given all patients, including those who have not reached an end point, the average time in the
study was 4.6 years, with 7 patients reaching 14 annual follow-up years. There were 606 patients
who left the study to undergo renal replacement therapy (RRT); in the SKS RRT is defined as
haemodialysis dialysis, peritoneal dialysis or kidney transplant. In addition 952 patients died
while part of the study, and 99 patients who were lost to follow-up. The average time patients
were in the study before RRT or death was 3.9 years. Of the remaining 1313 patients in the
study there were 699 with a time span of more than 2 years 6 months since their last follow-up
appointment.
2.3 Primary kidney disease types
We categorised the patients as having one of the following primary kidney diseases: diabetic
nephropathy, glomerulonephritis, hypertensive kidney disease, obstruction, other, polycystic
















Figure 1: Primary disease type frequency
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See the Appendix A.1.2 for the clinical breakdown of conditions/diseases within each primary
disease category. The basic characteristics of these diseases are:
• diabetic nephropathy (DN) - chronic loss of kidney function occurring in patients with
diabetes.
• glomerulonephritis (GN) - refers to several kidney diseases many of which are characterised
by inflammation within specific kidney sub-structures.
• hypertensive kidney disease (HKD) - chronic high blood pressure causes damage to the
kidney tissue. Usually these patients do not have a renal biopsy.
• obstruction - obstructive nephropathy - has a number of causes but is characterised by a
blockage in the flow of urine out of the kidney(s).
• polycystic kidney disease (PKD) - is a genetic disorder causing the growth of multiple cysts
within the kidneys.
• pyelonephritis (PN) - inflammation of the kidney often caused by a bacterial infection.
• renovascular disease (RVD) - has a number of causes and is characterised by a progressive
narrowing or blockage of the large renal arteries or veins.
• other - all other primary kidney diseases which are less common and as such they do not
fall into the aforementioned disease categories.
• unknown - refers to chronic renal failure when the aetiology is uncertain, unknown or
unavailable. This is a heterogeneous disease grouping whose common characteristic is that
the patient’s kidney disease is not clinically identified. For example given a patient with
exceptionally slow disease progression it may be unjustified to do an invasive procedure
such as a biopsy to confirm the cause of their disease.
2.4 Comorbidities
Comorbidities were recorded at baseline and thereafter at each follow-up. We collated comorbidities
into the following clinically relevant categories where percentages indicate the proportion of
patients recorded as having a given comorbidity at some point while in the study:
• 78.2% cardiovascular disease
• 35.4% diabetes
• 25.4% other
• 10.1% gastrointestinal disease
• 3.8% had cancer during the study. We note 16.3% had cancer either during the study or at
a previous time.
Under this classification 54.8% of patients have multiple comorbidities. The cancer, cardiovascular
and diabetes categories can be subdivided into specific diseases, for example of the patients with
diabetes 87.2% had type 2. Appendix A.1.3 gives details of the conditions/diseases which are
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included in each comorbidity category.
2.5 Medications
Medication and treatment data were also recorded at baseline and thereafter at annual follow-up
appointments. At baseline 87.1% were taking at least one antihypertensive. Here medications
are grouped as follows where percentages indicate the proportion of patients taking a given
medication at some time during the study:
• 69.2% angiotensin-converting-enzyme (ACE) inhibitor and/or angiotensin II receptor blocker
(ARB)
• 58.9% diuretic
• 54.3% calcium channel blocker (CCB)
• 42.1% β-blocker
• 38.6% α-blocker
• 32.4% vitamin D
• 27.4% EPO treatment (for anaemia)
• 24.4% iron taken orally
• 23.1% iron administered by injection
In addition we noted that 68.9% were on statins and 43.7% took aspirin. All other medications
not mentioned above occurred less frequently in the data than iron taken orally. Details of the
drugs in each category can be found in the Appendix A.1.4.
2.6 Biochemical markers
2.6.1 General biomarkers
In addition the study also measured biochemical markers from blood and urine samples during
annual follow-up appointments and other hospital visits e.g. AKI episodes. Standard laboratory
markers from blood samples included: full blood count (FBC), urea and electrolytes (U&E), liver
function test (LFT), calcium, phosphate, cholesterol, Parathyroid Hormone (PTH). Furthermore
EDTA whole blood, serum, plasma, and citrate plasma samples were processed and stored at
-800C. Table 2 lists the biochemicals pertinent to this thesis; except for creatinine they enter into
our models as explanatory (input) variables.
8
Table 2: Summary statistics for biochemical markers at baseline
biochemical units min max median IQR
CRP - c-reactive protein mg/L 0.10 195.0 3.4 6.2
CHO - total cholesterol mmol/L 2.10 16.0 4.4 1.5
CC - corrected calcium mmol/L 1.21 3.0 2.3 0.2
Cr - creatinine µmol/L 51.00 915.0 179.0 126.0
CO2 - total CO2 mmol/L 10.50 44.5 23.0 4.5
Hb - haemoglobin g/L 10.90 195.0 122.0 24.0
HbA1c - haemoglobin A1c mmol/mol 25.00 154.0 50.0 24.0
PO - phosphate mmol/L 0.43 3.2 1.1 0.3
PTH - parathyroid hormone pmol/L 0.32 99.1 7.1 8.7
Pu - proteinuria g/24hr 0.02 17.2 0.3 0.9
We assume the variables are independent in our statistical models, Table 3 confirms there is
no significant correlation between the biochemicals. The only exception is a strong negative
correlation between creatinine and eGFR which is to be expected given the formula for calculating
eGFR includes a creatinine term; see Equation 1.
Table 3: Correlation between biochemical markers for all follow-up years
CC CHO CO2 Cr CRP eGFR Hb HbA1c PO PTH Pu
CC 1 0.1 0.2 -0.2 0.0 0.1 0.0 0.0 -0.1 -0.2 -0.1
CHO 1.0 0.0 -0.2 0.0 0.2 0.1 0.0 -0.1 -0.1 0.2
CO2 1.0 -0.3 -0.1 0.3 0.1 0.1 -0.3 -0.2 -0.2
Cr 1.0 0.1 -0.8 -0.3 0.0 0.6 0.5 0.2
CRP 1.0 -0.1 -0.2 0.0 0 0.1 0.0
eGFR 1 0.3 0.0 -0.5 -0.4 -0.2
Hb 1.0 0.0 -0.4 -0.2 -0.1
HbA1c 1.0 0.1 0.0 0.1




2.6.2 Estimated glomerular filtration rate (eGFR)
Glomerular Filtration Rate (GFR) is a key indicator of renal function, its estimate eGFR is
derived from a patient’s serum creatinine level, age, sex and race. Creatinine is a compound
produced by metabolism of creatine and is excreted in the urine. In healthy individuals the kidneys
maintain blood creatinine in a normal range, an elevated creatinine level indicates impaired kidney
function. In our statistical models the outcome variable will be eGFR, our primary motivation
for using eGFR as opposed to creatinine is that clinicians advised us that they find eGFR easier
to interpret. Hence eGFR is a clinically reasonable indicator of kidney function. Table 4 gives
the standard definitions of CKD stages in terms of eGFR (30,31); stage 1 is mild impairment
whereas stage 5 signifies kidney failure.
stage 1 2 3 4 5
eGFR >90 89 - 60 59 - 30 29 - 15 <15
Table 4: CKD stage defined by eGFR (mL/min/1.73m2)
There are several equations for estimating GFR (49) however it is mostly agreed that in general the
CKD-EPI equation gives the best estimate (50–52). Additionally given NICE (30) recommends
this equation we use it for calculating eGFR in units mL/min/1.73m2
eGFR = 141×min(Scr/κ, 1)α ×max(Scr/κ, 1)−1.209 × 0.993age×
1.018[if female]× 1.159[if black]
(1)
where
• Scr is serum creatinine with units µmol/L
• κ is 61.9 for females and 79.6 for males
• α is -0.329 for females and -0.411 for males
• min(Scr/κ, 1) indicates the minimum of either Scr/κ or 1
• max(Scr/κ, 1) indicates the maximum of either Scr/κ or 1
• age has units of years
At follow-up appointments we find the median eGFR across all patients is 28.1 with interquartile
range (IQR) 23.3. Hence the patient’s generally have moderate to severe CKD; stages 3 and 4. In
contrast if we consider only acute kidney injury (AKI) episodes the overall median eGFR drops
to 14.6 with IQR 17.8.
Given all patients at follow-up, eGFR follows a right skewed distribution; e.g. ( meaneGFR = 31.5
) > ( medianeGFR = 28.1 ). Figure 2 is used for exploratory purposes only, the qq-plot in panel
10
(a) shows the distribution of the log of eGFR to be approximately normal; visual confirmation of
the distribution’s shape is given by the histogram. Applying the Shapiro–Wilk normality test
(53) to the log(eGFR) distribution yields a p-value <0.0001 hence we reject the null hypothesis
and conclude it significantly deviates from normality. In our statistical models we choose to use
log(eGFR) as the outcome variable. Given log(eGFR) is closer to a normal distribution than
eGFR it is expected to give a better empirical fit of our data to the models, for further details
see Chapter 3. From Equation 1 we note that log(eGFR) is equivalent to creatinine adjusted for
age and sex however in our models we will consider using age and sex as explanatory variables
because Equation 1 has been shown not to be optimal for all sub-populations; e.g. (49) and (54).
Note that when we write log(eGFR) this denotes loge(e−10 eGFR) where constant e0 equals 1 and
carries the same physical dimensions (units) as eGFR, this ensures the argument of the logarithm

























Figure 2: Distribution of log(eGFR) for all patients at follow-up
Considering all log(eGFR) values from a random selection of patients, in Figure 3 we see that the
progression of CKD over time is far from a smooth monotonic function. However these figures
include measurements taken between follow-up appointments when the patients will in some
cases be experiencing an acute episode of illness e.g. AKI. Grouped by disease Appendix A.2,
Figures 54 to 62, depicts Trellis plots for an arbitrary selection of patients showing the log of
their eGFR at each follow-up year; these figures show although there is much individual variation
most patients have an approximately linear downward trend in log(eGFR) as time passes.
Given each primary kidney disease, Figure 4 (a) shows log(eGFR) values for every patient at each
follow-up, where red points are the marginal means at each follow-up time. Figure 4 (b) depicts
the corresponding variances. We note that both the mean and variance are less informative when
there are fewer observations for example in later follow-up years. We observe, in Figure 4 (a), that
successive marginal means (red points) for most disease categories exhibit an overall downward
trend as the number of follow-up years increase. If we naively ignore the correlation between
observations on the same individual and fit straight lines through the marginal mean points for
each disease we find, for instance, that on average PKD patients loose kidney function 1.8 times
faster than those with diabetic nephropathy.
11
In Chapter 3 we will use rigorous statistical modelling to explore the progression of disease














Figure 3: eGFR progression of an arbitrary sample of 10 patients
2.7 Imputation
Prior to this section we have not imputed missing values. In our cleaned version of the SKS
dataset we assumed all missing data values were missing completely at random unless there was
evidence to the contrary. In particular we assumed each missing value was: independent of the
values of other variables (fields); independent of the value of the observation; and independent of
time. The proportion of missing values in our cleaned dataset was 7.4%. This level of missing
values diminishes the potential statistical power of our models. Therefore to improve statistical
power imputation methods were employed. Appendix A.3 lists all continuous and categorical
variables for which missing values were imputed.
Popular imputation methods include Multiple Imputation (55,56) and Expectation-Maximization
(57) of which there are many extensions and algorithms, two examples respectively are Multivariate
Imputation by Chained Equations (58) and Amelia (59). All such methods are intended for
multivariate data and rely on correlations between variables (inter-variable) to estimate missing
values. In our case we treat each variable (field) for a given patient as a timeseries consequently
these methods cannot be directly applied because a timeseries is univariate and exhibits inter-
time (intra-variable) correlations; for example see (60) for an overview of timeseries imputation
methods. In this thesis we employ imputation algorithms which are specifically intended for use
with timeseries data; in particular we use the R-package imputeTS (61) to impute all missing
values.
For continuous variables (e.g. BMI) we use Kalman smoothing on a structural model fitted by
maximum likelihood; for example (62,63) give methodological details. By design this imputation
method accounts for temporal trends, hence it is appropriate for our data where we often observe
trends e.g. a patient’s BMI may gradually increases/deceases over several successive follow-up years.
All our continuous variables have values which are always positive so to overcome the problem
12
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(a) individual traces (black) with mean (red) at each follow−up
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(b) variance at each follow−up
Figure 4: eGFR values of study cohort grouped by disease
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of the imputation producing negative values we did the following: (a) use logarithm function
to transform the variable onto the logarithm scale; (b) impute missing values; (c) transform
the variable back to its original scale with the antilogarithm function. In terms of categorical
variables (e.g. weekly alcohol intake) missing values are estimated with Last Observation Carried
Forward/Backward methods where priority is given to Forward imputation, in other words where
possible the last observed value is carried forward in time to subsequent follow-up appointments.
The SKS data explicitly recorded the existence of a comorbidity but did not explicitly record
if it was not present; an empty comorbidity field implied the patient did not have the given
comorbidity at a particular follow-up year. Each patient’s comorbidities were frequently not, or
only partially, recorded at each follow-up. Consequently, the data suggested that many patients
recovered from, and were often subsequently re-inflicted with, long-term health conditions such
as dementia. Since this is implausible for long-term conditions we assumed that each patient’s
condition(s) persisted for all future time after the follow-up at which it was first recorded; this
approach was applied to all comorbidities listed in Appendix A.1.3. Prior to the first instance of
a comorbidity being recorded we assumed that the patient did not have the condition.
At each follow-up all the medications for each patient were typically documented; we assume if
at least one drug/supplement was recorded then all drugs/supplements were recorded. At a given
follow-up, if at least one medication is recorded then we assign the patient as either taking, or not
taking, a drug/supplement in each of our medication categories. Conversely, if no medications
are recorded we impute using the same approach as we used for comorbidities. This is the reason
all medication categories, except for EPO treatment, have the same number of missing records
before imputation (and also after imputation); see Table 5. We dealt with both EPO treatment
and parenteral iron separately from the other medications as these are not recorded as part of
the SKS medication lists. These are administered intermittently so unless recorded we assume
the patient did not receive the treatment.
Biochemical measurements were recorded at follow-up appointments but unlike the rest of the
SKS data they were also recorded at other hospital/clinic visits. The data recorded outside of
follow-up appointments would sometimes relate to episodes of acute illness (e.g. AKI). During
acute illness some, or all, of the biochemical measurements could potentially be very different, for
example as discussed in Section 2.6.2 the cohort median eGFR is 38% lower during identifiable
AKI episodes compared with follow-up appointments. Finding a method to robustly identify
all acute episodes is beyond the scope of this thesis. Consequently to impute missing values at
follow-up appointments we only used measurements recorded at either past or future follow-ups.
In instances where a patient had no recorded values for a given field (over all their follow-ups) we
did not impute values; creating imputation models for these rare instances was beyond the scope
of this thesis. If a patient’s timeseries had only one recorded value we duplicated this value at
all points in the series, we did this for all relevant continuous and categorical variables except
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medications and comorbidities.
Table 5 shows the proportion of missing values for each variable before and after imputation,
as can be seen imputation substantially reduces the number of missing values. In this table we
include the proportion of missing creatinine values because this directly affects, and is the main
contributor to, the proportion of missing eGFR values.
As is seen in Table 5 HbA1c has a very high number of missing values; this is because it is generally
only recorded in patients with diabetic nephropathy. In this sub-group before imputation the
percentage of missing HbA1c is 68.3% and after imputation 30.7%. In the next chapter we will
only use HbA1c for models relating to diabetic nephropathy patients, however given the high
quantity of missing data it may adversely affect the statistical power of such models and given
the large quantity of imputed values it may not be informative; we reserve judgement until we
obtain the model results.
Summary statistics for each continuous variable before and after imputation confirm the imputed
values did not significantly alter the overall distribution of any continuous variable; see results
tabulated in Table 6. For a given patient and follow-up year we define a ‘complete record’ as
having all values for every variable of interest. If HbA1c is omitted, then before imputation
there were 2024 complete records and after 3121, therefore the imputation of missing values will
substantially increase the statistical power of our models. For the remainder of this thesis we use
the cleaned SKS data augmented with imputed values.
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Table 5: Proportion of missing values before and after imputation over all follow-up years
group item Before (%) After (%)
BMI 16.1 4.3
DBP 4.0 0.8
number of antihypertensives 4.9 0.4
PP - pulse pressure 4.0 0.8
general
SBP 3.8 0.8
CC - corrected calcium 1.9 0.1
CHO - total cholesterol 22.2 3.9
CO2 - total CO2 16.0 2.3
Cr - creatinine 0.0 —
CRP - c-reactive protein 30.9 4.2
eGFR 0.7 —
Hb - haemoglobin 1.6 0.2
HbA1c - haemoglobin A1c 87.8 64.9
PO - phosphate 2.7 0.2
PTH - parathyroid hormone 20.8 2.5
biochemical
Pu - proteinuria 11.4 2.3
comorbidity cancer 3.8 0.1
comorbidity cardiovasular 3.9 0.0
comorbidity diabetes 4.2 0.1
comorbidity gastrointestinal 4.8 0.0
comorbidity other 3.8 0.1
medication ACE and/or ARB 5.3 0.6
medication alpha blockers 5.3 0.6
medication beta blockers 5.3 0.6
medication CCBs 5.3 0.6
medication diuretics 5.3 0.6
medication EPO 7.8 0.0
medication oral iron 5.3 0.6
medication other 5.3 0.6
medication parenteral iron 4.1 0.3
medication vitamin D 5.3 0.6
categorical
weekly alcohol intake 43.2 4.3
16
Table 6: Summary statistics, over all follow-up years, for continuous variables before and
after imputation
Before After
item units min max median IQR min max median IQR
general
anti-HT * 0.0 8.0 2.0 2.0 0.0 8.0 2.0 2.0
BMI kg/m2 13.3 65.3 27.9 7.6 13.3 65.3 27.8 7.6
DBP mmHg 40.5 141.5 72.5 15.0 40.0 142.0 72.0 15.0
PP mmHg 17.0 188.0 63.0 26.5 17.0 188.0 63.0 27.0
SBP mmHg 76.0 255.0 137.0 28.0 76.0 281.0 137.0 28.0
biochemical
CC mmol/L 1.0 3.3 2.3 0.2 1.0 3.3 2.3 0.2
CHO mmol/L 2.1 16.0 4.3 1.4 1.9 16.0 4.3 1.4
CO2 mmol/L 6.0 44.5 22.8 4.7 6.0 44.5 22.8 4.5
CRP mg/L 0.1 471.5 3.4 6.4 0.0 471.5 3.3 6.1
Hb g/L 10.9 204.0 123.0 22.0 11.0 220.0 123.0 22.2
HbA1c mmol/mol 24.6 159.0 48.6 22.8 24.6 192.2 44.3 19.4
PO mmol/L 0.2 4.2 1.1 0.3 0.2 4.2 1.1 0.3
PTH pmol/L 0.2 250.4 8.1 9.7 0.1 250.4 7.6 9.1
Pu † g/24hr 0.0 18.5 0.3 0.8 0.0 18.5 0.3 0.8
* number of antihypertensives
† Due to rounding minimum Pu displays as 0.0 whereas before and after imputation it is actually
0.02.
2.8 Baseline variables
There are a number of reasons that a variable may only be present at baseline e.g. it never changes
over time or was only recorded at the first appointment. However in some instances due to the
sparseness of data we reduced a variable to a baseline value using the first recorded instance of
the variable in the patient’s data. For example, if the variable was not recorded at baseline but
was instead recorded at the first follow-up appointment we used this value as if it were recorded
at baseline. Variables reduced to baseline variables were: occupation, smoking status and weekly
alcohol intake.
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3 Linear mixed effects model
We have longitudinal data where each experimental unit (patient) consists of temporally correlated
measurements over consecutive follow-up years. Classic multivariate models are not appropriate
for analysing this grouped and correlated data. Standard extensions, for longitudinal data, to
classical statistical procedures which estimate the parameters in regression models include the
Generalised Estimating Equations (GEEs) (e.g. see (38,64)) and mixed effects models. A GEE is
used to estimate the parameters of a generalised linear model. Specifically it aims to estimate the
average response over the population rather than the regression parameters, the latter enables
prediction of the effect of changing one or more explanatory variables on a given unit. GEEs are a
widely used alternative to the likelihood-based mixed effects model which have the disadvantage
of being more sensitive to the specification of the variance structure. However in our context
we rejected the GEE approach because it is not robust to missing data due to patients missing
follow-up appointments and/or spend differing lengths of time in the study. Our data contains
both of these characteristics in abundance so we turn our attention to mixed effects models as
they are able to accommodate this variability. In general mixed effects models are a commonly
used class of statistical models that are applicable to a wide range of data structures which include
correlated and/or clustered observations, repeated measurements and longitudinal measurements.
It is not uncommon for longitudinal data to be modelled with mixed effects models consequently
there exists an extensive literature; for example see texts (36–39,65).
Mixed effects models consist of both fixed effects and random effects, they describe the relationships
between an outcome variable and explanatory variables. Fixed effects are associated with the
whole population. There can be one or more layers of random effects when the data are grouped
according to one or more classification levels. In this thesis we associate the random effects with
individual experimental units drawn at random from a population. This model allows for clear
identification of both population and individual patient characteristics. From this point onwards
we consider only linear mixed effects (LME) models where the outcome variable is described by a
linear function of the parameters.
Given the dataset described in Section 2 the data are sub-divided into disease categories and
grouped at patient level. The LME model outcome variable is log(eGFR) and all the remaining
variables are potential explanatory variables. In this thesis the combination of fixed effects plus
random effects is interpreted as representing the unobserved GFR, therefore the LME model will
express eGFR as a noisy version of GFR.
Event data which describe patients leaving the study (dropout, RRT or death) are not explicitly
included in the model as we assume these events are missing at random; we did not test this
assumption. It was beyond the scope of this thesis to explore models, e.g. survival models, which
include this time to event data. For reviews relating to event data in the context CKD and mixed
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effects models see for example (41,45).
We consider the following LME model for longitudinal trajectories given i = 1, . . . ,M patients
and j = 1, . . . , ni observations per patient
Yij = µi(tij) + Ui(tij) + ij . (2)
The outcome for patient i at time tij > 0 is denoted Yij . The time since baseline measurement is
tij , both ni and tij vary among patients. This allows us to include patients with intermittent
missing data and/or dropout, and also account for the actual individual measurement times. The
expected value of the outcome is a multiple linear regression of the form µi(tij) = Xi(tij)β. Term
µi(tij) captures the fixed effects with a set of known explanatory variables Xi (ni × p regressor
matrix) and corresponding set of unknown fixed effects regression parameters β (p-dimensional
vector) which are to be estimated. We assume any measurement errors in the explanatory
variables are very much less than ij .
The variability between patients which cannot be explained by the fixed effects is captured by
the random effects described by a second linear regression Ui(tij) = X∗i (tij)bi with a known
regressor matrix X∗i (size ni × q) and corresponding vector of unknown random variables bi
(size q-dimensional vector) which are to be estimated. The distribution of bi are assumed to be
mutually independent multivariate normal random variables with mean zero, that is bi ∼ N(0,Ψ)
where Ψ is a symmetric positive definite (non-degenerate) matrix hence is invertible. In particular
we choose an intercept-and-slope model, the so-called Laird and Ware model (39), as such
X∗i (tij) = (1ni , ti) where ni-dimensional vector ti has elements tij . The first term does not
depend on time so represents the time-constant differences between patients and the second term
represents the time dependent differences (variations in linear slope) between patients.
Random variables ij are mutually independent with ij ∼ N(0, σ2), given outcome Yij they
account for the fact that eGFR is a noisy estimate of GRF. We refer to i = (i1, . . . , ij , . . . , ini)T
as within-group errors therefore without placing further constraints on Equation 2 it follows that
i ∼ N(0, σ2 Ini) where I denotes identity matrix. The errors are assumed to be independent
for different groups (patients); independent of repeated measurements within the same group i;
independent of random effects bi; and homoscedastic, that is having constant variance for both
different groups and repeated measurements within the same group.
Given repeated measurements on patient i it may be necessary to take into account the correlation
and variance of within-group errors to explain the change over time of outcome Yij not explained
by the aforementioned linear regressions. To this end let
i ∼ N(0, σ2Λi) (3)
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with variance-covariance matrix Λi. This matrix is symmetric positive definite and decomposed
such that
Λi = V iCiV i. (4)
The variance matrix V i is diagonal and the correlation matrix Ci has diagonal elements equal
to one. This decomposition therefore allows the variance and correlation structures of the
within-group errors to be modelled separately. It follows that
var(ij) = σ2[V i]2jj (5)
and
cor(ij , ij′) = [Ci]jj′ (6)
with j′ = 1, . . . , ni. Hence the correlation structure accounts for repeated measurements within
group i. This formulation assumes i is independent for different groups i and independent of
random effects bi. In our study we assume the variance structure is homoscedastic var(ij) = σ2
as we found no evidence to the contrary, therefore in the following we will now focus on the
correlation structure. The correlation between two within-group errors ij and ij′ is assumed to
depend on the magnitude of their temporal distance. In particular the correlation structure is
assumed to be isotropic so it depends only on relative distances and not the temporal positions.
This distance is described by the function δ = d(pij ,pij′) where pij , pij′ are position vectors for
ij , ij′ respectively. With reference to Equation 6 let the correlation structure be defined by
cor(ij , ij′) = h(δ,ρ) (7)
where autocorrelation function h(·) takes values between -1 and 1 and ρ is a vector of correlation
parameters. Note 1: if we assume no correlation structure then h(·) will be zero everywhere
except on the diagonal. Note 2: h(·) is defined such that if the distance between the position
vectors is zero then h(0,ρ) = 1. Given repeated measurements on each patient i a natural choice
of correlation structure would be a zero mean continuous-time stochastic process, such as a first
order continuous-time autoregressive model (CAR1). This model is defined by h(s, ρ) = ρs where
ρ > 0 and the magnitude of the time difference s > 0 (e.g. s = |tij+1 − tij |). It can be seen that
the correlation function decreases in absolute value exponentially with decay constant τ = −1/lnρ
since h(s, ρ) = eslnρ = e−s/τ ; i.e. events close together are more correlated than distant events.
20
Alternatively given many patients have very few follow-up measurements (see Figures 54 to 62) a
compound symmetry (CS) structure may be more suitable, as suggested by Pinheiro and Bates
(66) (see Chapter 5) who state that CS may be useful if each group’s timeseries is short. The
CS model is defined as 0 6 ρ 6 1 with h(k, ρ) = ρ ∀j 6= j′ otherwise h(k, ρ) = 1; integer time
differences are denoted by k = 1, 2, . . . ,. In Section 5.4 we investigate whether there is sufficient
evidence to include a correlation structure in our models.
To fit the model in Equation 2 when i ∼ N(0, σ2 Ini) we need to estimate β, bi, Ψ and σ. If we
find enough evidence for within-group error correlations then i ∼ N(0, σ2Λi) hence additional
parameters associated with Ci will need estimating. We fit these LME models within the
maximum likelihood framework using R-package nlme (66,67). This approach uses the conditional
modes of the random effects given the data. A full mathematical description is given in Chapter
2 of (66).
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4 Inferences regarding changes in eGFR
Our primary interest is to determine, for each disease model, the degree to which the fixed
effect explanatory variables explain the outcome at population level. As is usual we inspect each
regression parameter value along with its corresponding statistical significance when reporting the
results in Chapter 7. However these results are relative to log(eGFR), it is not possible to directly
interpret them in terms of eGFR which is the unit that clinicians are typically familiar with. As
a consequence results expressed in log(eGFR) are not fully accessible to the intended audience
of this research; for example a clinician may be interested in the benefits in terms of eGFR of
prescribing a given medication. In Section 4.1 we address this by introducing methodology to
assess the average effect on eGFR of a small step change in a given explanatory variable; we make
use of this when reporting our results in Chapter 7. It may also be of interest to interpret the
model in terms of how quickly the model outcome is on average changing over time, therefore in
Section 4.2 we introduce methodology for investigating the temporal trajectory of both log(eGFR)
and eGFR.
With reference to Equation 2 we rewrite the fitted LME model in component form, with intercept-
and-slope random effect, as follows





i (tij) + bˆi0 + bˆi1tij (8)
where the model parameters have been estimated by maximum likelihood. The intercept and
slope random effects terms are defined respectively as bˆi0 and bˆi1. The outcome Yˆij represents
loge(e−10 eGFR(t)). The constant e0 = 1 has units identical to eGFR, this ensures the argument
of the logarithm does not carry physical dimensions (units). The outcome in terms of eGFR(t) is
Yˆ ∗ij = e0eYˆij . (9)
4.1 Step changes in explanatory variables
4.1.1 Step changes on log(eGFR) scale
A standard interpretation of Equation 8 is that if we hold all terms constant except one, e.g. variable
X
(r)
i (tij), then for every additional increase of one unit in X
(r)
i (tij) we expect the outcome to
change by an average of βˆr. In other words given a change from X(r)i (tij) to X
(r)
i (tij) + θr, we
define ∆rYˆi = Yˆ θij − Yˆij where Yˆij = βˆ0 + βˆrX(r)i (tij) + . . . and Yˆ θij = βˆ0 + βˆr(X(r)i (tij) + θr) + . . .;
therefore for the rth regression term ∆rYˆi = θrβˆr. The term ∆rYˆi describes the amount Yˆij shifts
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when subjected to a change of size θr. Given θr is a constant over time then Yˆij and Yˆ θij have
identical time derivatives therefore a step change of size θr affects only the value of log(eGFR)
and not its rate of change. If θr is applied to the rth explanatory variable across all i patients, it
follows that on average log(eGFR) changes by
∆rYˆ = θrβˆr. (10)
Note that ∆rYˆi and ∆rYˆ are dimensionless.
We could set θr = 1 for all explanatory variables but given there are orders of magnitude
differences between our variables this could be very misleading when assessing the degree to which
each explanatory variable contributes to changes in either log(eGFR) or eGFR. In practice we
suggest assigning a value to θr which is commensurate with a typical change in the explanatory
variable of interest. One possibility, for the rth explanatory variable from all patients, would be
to set θr equal to the mean of the differences in the absolute value between successive follow-up
appointments; i.e. find the mean of |X(r)i (tij) −X(r)i (ti j+1)| over all i and j. However in this
thesis we use the standard statistical approach of setting θr equal to one standard deviation
of the distribution of observations from the rth explanatory variable; i.e. for a given r, one
standard deviation of the distribution of X(r)i (tij) over all i and j. The exception is categorical
variables which always have θr = 1. Furthermore if (non-categorical) explanatory variables are
standardised then for each such variable θr = 1. Note that standardisation is the process of
putting the variables on the same scale, in this thesis standardisation is performed for each
variable by subtracting the mean and dividing by the standard deviation.
4.1.2 Step changes on eGFR scale
We now extend the ideas in Section 4.1.3 to estimating changes in eGFR as opposed to log(eGFR).
Specifically we want to determine how eGFR varies given a change of size θr in an explanatory
variable. We considered three approaches for estimating this change:
• Proportional change, this is obtained by directly transforming ∆rYˆi (see Equation 10) to






=Yˆ ∗θij /Yˆ ∗ij
(11)
where Yˆ ∗θij = e0eYˆ
θ
ij and Yˆ ∗ij = e0eYˆij . This is a ratio in eGFR, i.e. Yˆ ∗θij /Yˆ ∗ij , that is the
proportional change in eGFR induced by a change of size θr. We will not use this approach
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when reporting results as we seek a quantity which represents the difference (not a ratio)
in eGFR induced by a change in θr. Two such approaches are given in the following two
bullet points.
• Absolute difference, this is obtained by first considering the expression ∆rYˆ ∗ij = Yˆ ∗θij − Yˆ ∗ij .
Writing this out in full we obtain ∆rYˆ ∗ij = e0 exp(βˆ0 + βˆr(X
(r)
i (tij) + θr) + . . . )− e0 exp(βˆ0 +
βˆrX
(r)
i (tij) + . . . ), from which it follows that
∆rYˆ ∗ij = Yˆ ∗ij(eβˆrθr − 1). (12)
As such we can assess the effect of θr on ∆rYˆ ∗ij . The absolute difference in eGFR at
population level could be defined as
E(∆rYˆ ∗) = E(Yˆ ∗ij)(eβˆrθr − 1) (13)
where E(Yˆ ∗ij) is the expected value of Yˆ ∗ij over the population and all time. For our dataset
E(Yˆ ∗ij) = 31.5 mL/min/1.73m2. However a shortcoming of this approach is that the value
of E(Yˆ ∗ij) is dataset specific and Yˆ ∗ij is highly variable across the population. We therefore
do not report results using this approach.
• Relative change in eGFR, given Equation 12, is defined as
∆rYˆ ∗ = ∆rYˆ ∗ij/Yˆ ∗ij = eβˆrθr − 1 (14)
This approach is not subject to the aforementioned shortcomings therefore we use it when
reporting results in section 7.
Note that Yˆ ∗ij , ∆rYˆ ∗ij and ∆rYˆ ∗ have the same physical dimensions as eGFR.
4.1.3 Summary of Step changes approaches
Given clinicians typically work on the eGFR scale, and not on the log scale, we report our
results relating to step changes in θr using the relative change approach given in Equation 14.
As described in section 4.1.3 we use θr equal to one standard deviation of the rth explanatory
variable distribution, i.e. the distribution of X(r)i (tij) over all i and j. It follows that if this
distribution is standardised then the step size will equal one since the standard deviation is one.
4.2 Rates of change over time
The LME model given in Equation 2 has an error term ij ∼ N(0, σ2), as already discussed.
This term may have within-group correlations described by a stochastic process such as the
aforementioned CAR1 model. The time derivative of Equation 2 would necessarily need to account
for the stochasticity of the error term. However it is beyond the scope of this current work to
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consider fitting such models. Here we circumvent this issue by focusing on the time derivative of
the fitted model i.e. the derivative of Equation 8.
The trajectory of explanatory variable X(r)i (tij) through time may be constant, continuous or
piecewise continuous:
• Each baseline explanatory variable, e.g. ethnicity, is constant over all time hence its time
derivative is zero.
• Each explanatory variable which changes smoothly over time, e.g. biochemical markers, are
continuous functions of time. Although we only have observations at fixed points in time
we may interpolate, e.g. with a spline, between observations; hence the spline’s derivative
represents the variable’s time derivative.
• Each categorical variable which varies over time is a piecewise continuous function in time.
The derivative of such a variable exists everywhere except at time points where it changes
level; at these points there exists a discontinuity. Outside of the discontinuities the variable
is constant with respect to time hence its derivative is zero.
• In this section we consider interaction terms of the form tijX(r)i (tij) to be a special case
of X(r)i (tij). An interaction term between time and a categorical variable is piecewise
continuous function of time whose derivative exists everywhere except where the categorical
variable changes levels; outside of the discontinuities the time derivative1 of tijX(r)i (tij)
equals X(r)i (tij).
4.2.1 Time derivative on log(eGFR) scale







i (tij) + bˆi1 (15)
where dot denotes the first order time derivative e.g. X˙ = dX/dt. We assume X(r)i (tij) can be
represented by a continuous function which is differentiable. Time independent and categorical
variables essentially have time derivatives of zero. The regression parameters are not estimated
from Equation 15. They are estimated in the usual way, as described in Chapters 3 and 5, including
those whose corresponding explanatory variable has a time derivative of zero in Equation 15.
The additive nature of Equation 15 allows us to focus on the rth regression term of patient i; its









(t.X(t)) = t.X˙(t) + t˙.X(t) = t.0 + 1.X(t) = X(t).
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We do not compute X˙(r)i (tij) using a statistical model, for example an intercept-and-slope linear
model, as estimation of the LME model parameters in Equation 2 assumes explanatory variable
observations exhibit negligible noise (e.g. measurement error) compared with the error terms ij .
Here we calculate X˙(r)i (tij) by performing a cubic spline interpolation around the explanatory
variable’s data points, and then compute the spline’s time derivative which we denote S˙(r)i (Xt)




i (t) = βˆrS˙
(r)
i (Xt). (17)
The average trajectory is ξˆ(r)i = 1T
∫
T




i = βˆr ξˆ
(r)
i . (18)
At population level, the average rate of change over time of the rth explanatory variable is
estimated by taking its expected value over all patients
E( ˙ˆY (r)i ) = βˆrE(ξˆ
(r)
i ). (19)
Moreover the distribution of all ˙ˆY (r)i for the rth explanatory variable can be used to estimate
confidence intervals.
Similarly we estimate the average trajectory over time of the outcome variable, log(eGFR), as
follows. Given Equation 15 for patient i, we perform spline interpolation on all regression terms,
then sum over all terms and finally calculate the ith average trajectory by integrating over time.
The population’s overall trajectory is then the expected value of all the ith average trajectories,
which we denote E( ˙ˆYi).




i ) and E(
˙ˆ
Yi) have dimensions of one over time. In our study the unit of
time is a year.
4.2.2 Time derivative on eGFR scale
It follows from Equations 8, 9 and 15 that the time derivative in terms of eGFR(t) for patient i
is2
˙ˆ














ij = Yˆ ∗ij βˆrX˙
(r)
i (tij). (21)
For patient i, as above performing spline interpolation, leads to ˙ˆY ∗(r)i (t) = Si(Yˆ ∗) βˆrS˙
(r)
i (Xt);
given patient i then Si(Yˆ ∗) denotes the spline interpolation of the outcome’s fitted values. Given
the average trajectory ξˆ∗(r)i = 1T
∫
T




i = βˆr ξˆ
∗(r)
i . (22)
The analogue at population level is given by the expected value of ξˆ∗(r)i over all i
E( ˙ˆY ∗(r)i ) = βˆrE(ξˆ
∗(r)
i ) (23)
and distribution of all ˙ˆY ∗(r)i will be used to estimate confidence intervals. In the results section
7.4 we report rates using Equation 23 and corresponding confidence intervals based on a bootstrap
method which does not assume a normal distribution.
Given Equation 20 the expected average trajectory of the outcome, eGFR, for the population,
denoted E( ˙ˆY ∗i ), is estimated as previously described (see paragraph after Equation 19) i.e. pop-
ulation’s overall trajectory is then the expected value of all the ith average trajectories. This
quantity is also reported in the results section 7.4.




i ) and E(
˙ˆ
Y ∗i ) have units of eGFR per unit time.
4.3 Interpreting sign of regression parameters in terms of temporal
progression
Here we rewrite Equation 8 with an explicit fixed effect explanatory variable for time, that is





i (tij) + bˆi0 + bˆi1tij . (24)
In our data all continuous explanatory variables always have positive values. We focus on
the first three terms of Equation 24 and rewrite it in terms of eGFR(t) as follows Yˆ ∗ij(t) =
e0exp(βˆ0 + βˆ1tij + βˆ2X(2)i (tij) + . . . ). The prefactor e0 exp(βˆ0) determines the intercept at t = 0.
The middle term exp(βˆ1tij) with βˆ1 < 0 gives an exponential rate of decay of eGFR(t) over time,
hence larger values of |βˆ1| result in faster decay rates: consequently kidney function deteriorates
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more rapidly. If βˆ1 > 0 this would indicate an improvement in kidney function. The last term
exp(βˆ2X(2)i (tij)) will indicate decreasing eGFR(t) over time when βˆ2 < 0 and x
(2)
i (t) > 0 is
monotonically increasing over all time. Likewise kidney function will be worsening if βˆ2 > 0 and
x
(2)
i (t) > 0 is monotonically decreasing. Consequently the sign of the regression parameter and
the explanatory variable’s trajectory over time determine whether the regression term contributes
towards an improvement or deterioration in kidney function.
4.4 Interpretion of fixed effects temporal interaction terms
With respect to the log(eGFR) model and its time derivative we consider the interpretation of
the fixed effects interaction terms. In this thesis all interactions are with follow-up time.
4.4.1 Regression model for log(eGFR)
We use interaction terms between a given explanatory variable and follow-up time, which we
denote by explanatoryVariable : followupTime; in mathematical notation this is may be written
x(t) t. For every interaction term we also include the corresponding explanatory variables as
separate terms for example β1t+ β2x(t) + β3x(t) t, hence rearranging gives β1t+ (β2 + β3t)x(t).
The factor (β2 + β3t) describes the time-independent (β2) and time-dependent (β3t) effects on
x(t).
4.4.2 Regression model for rate of change in log(eGFR) over time
A regression model for the rate of change over time of outcome eGFR will be computed by taking
the time derivative of terms such as β1t+ β2x(t) + β3x(t) t, the time derivative of this expression
is β1 + (β2 + β3 t)x˙(t) + β3x(t). Similarly to Section 4.4.1 the factor (β2 + β3 t) describes the
time-independent (β2) and time-dependent (β3t) effects on x˙(t) however there is an additional
time-dependent effect through the β3x(t) term. If x(t) is a categorical variable then x˙(t) = 0
everywhere except at any discontinuities where it is undefined; therefore β1+(β2+β3 t)x˙(t)+β3x(t)
reduces to β1 +β3x(t) hence in terms of this rates of change model β2 has no effect. Another way of
looking at this is when y(t) = β1t+β2x(t)+β3x(t) t+ . . . is differentiated with respect to time, i.e.
y˙(t) = β1 + β2x˙(t) + β3d(x(t) t)/dt+ . . ., the parameters quantify the rate of change of log(eGFR)
per unit time (year). Although we do not fit the differentiated model this interpretation stands.
4.5 Standardised model
From this point onwards, unless otherwise stated, all regression models will use standardised
continuous explanatory variables. The rationale being that this will allow us to assess the relative
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importance of the fixed effects regression parameters once the model is fitted. To standardise
each variable we subtract its mean and divide by its standard deviation. Standardisation is a
widely used technique when comparing model parameters but is open to criticism, for example
the meaning of one standard deviation may be open to debate especially for small sample sizes or
non-normal distributions. In this thesis we consider standardisation to be a pragmatic method of
rescaling the continuous explanatory variables to the same scale. The standardised variables are
dimensionless (no units of measure).
To aid interpretation follow-up time and baseline age are not standardised hence retain their units
of time i.e. years. Given follow-up time is not standardised the model can still be interpreted
in relation to disease progression per year. Furthermore the outcome variable log(eGFR) is not
standardised.
With reference to Section 4.1 when the variables are standardised a unit step change in the
standardised explanatory variable results in a one standard deviation change in the (unstandard-
ised) variable of interest. It follows that, with the standardised quantities denoted by dash, then








r = θr/σr; i.e. if θ
′
r = 1 then θr = σr.
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5 Model selection
First we checked if there existed any significant dependence between the risk factors. To identify
the factors in our models which best describe the progression of kidney disease for each disease we
used a bi-directional selection procedure (based on the Akaike information criterion) on multiple
bootstrap samples; this allows us to gauge parameter uncertainty and helps to guard against
overfitting to the SKS data.
5.1 Dependence among model variables
In our regression models we need to avoid multicollinearity, that is the phenomenon by which one
variable can be linearly predicted from other variable(s) with a substantial degree of accuracy.
Multicollinearity occurs when two or more covariates are highly correlated which leads to unreliable
and unstable estimates of regression parameters.
To assess the strength of correlation between all pairs of covariates we computed the correlation
matrix; results are tabulated in Tables 31 to 36 of Appendix A.4.1. We did not find any
unexpectedly strong correlations. As expected covariates which were computed from, or strongly
related to, other covariates had strong correlations in particular: log(eGFR) and Cr; PP and
SBP; past cancer and no cancer.
To detect multicollinearity among covariates we used the variance inflation factor (VIF) which is
one of the most widely used methods (68). VIF is calculated for each covariate by performing a
linear regression of that covariate on all the other covariates, and then obtaining the coefficient
of determination R2 from that regression. VIF for a given covariate is defined as 1/(1 − R2)
and has a range from 1 upwards where 1 indicates the covariate is completely uncorrelated with
all other covariates. Hence VIF estimates how much the variance of a regression coefficient is
inflated due to its covariate’s association with all the other covariates; for example if the VIF is
1.9 then the variance of the given regression coefficient is 90% larger than would be expected if its
associated covariate was completely uncorrelated with all the others. To compute VIF values for
all potential covariates we employed an algorithm which uses a stepwise procedure, in particular
we use function vifstep from R-package usdm (69). First, the algorithm calculated the VIF for
every variable, then it excluded the variable with the highest VIF provided its VIF exceeded a
predefined threshold, this procedure was repeated until there were no remaining variables with a
VIF greater than the threshold. It is generally agreed that a VIF greater than 10 indicates too
much multicollinearity (e.g. Section 9.4 in (68)) but some authors consider there is too much if
VIF is higher than 5 and others if higher than 2.5; for example see discussion by (70). For our
data with a threshold set at 5 this method excluded SBP, reducing the threshold to 2.5 then
resulted in the exclusion of the number of antihypertensives patients were taking. In addition the
indicator variables derived from the categorical variable for disease also showed some high VIF
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values. Appendix A.4.2 lists the excluded variables and tabulates VIF values for variables whose
VIF values are less than the aforementioned thresholds; see Tables 37 and 38.
In conclusion, having assessed the strength of dependence between variables we decided to exclude
SBP as the clinicians advised their preferred blood pressure measure in the context of this research
was PP. Our VIF analysis indicates that with a threshold of 2.5 we should consider excluding
the number of antihypertensives however we opt to use this variable in our models as the SKS
clinicians advise us of its importance. In this sense we are effectively using a VIF with a threshold
of 5. Some of the indicator variables derived from the categorical variable for disease had relatively
high VIF values however there was an indicator variable for every disease category so some degree
of correlation or anti-correlation is to be expected therefore multicollinearity in this context it is
not a cause for concern. Given log(eGFR) is the outcome variable in our models we will not use
Cr as a covariate, the strong correlation between the two arises because Cr is used to compute
eGFR (Equation 1); if Cr was included it could obscure the effects from other variables which are
our primary interest. We note sex and ethnicity were not strongly correlated with log(eGFR).
This is probably because sex is a small effect in the eGFR formula (Equation 1) and although
ethnicity is a slightly larger effect the vast majority of the SKS cohort were classified as ‘white’
thereby obscuring any strong association.
5.2 Stepwise regression with bidirectional selection and bootstrapping
With the exception of considering dependencies among covariates in the previous section all the
covariate selection has up to this point in the thesis been based on the guidance and expertise
of the renal clinicians at Salford Royal NHS Foundation Trust who designed the SKS study.
This expert knowledge is invaluable for assisting with model selection, but creating statistical
models with a large number of covariates, as we have here, could potentially lead to overfitting.
An overfitted model would describe some of the residual variation (noise) as if this variation
represented part of the underlying model structure or physical process. Hence such models
exaggerate minor fluctuations in the data. Usually there is a trade-off between goodness-of-fit
and parsimony since models with many parameters tend to have a better model fit to the data
but will perform poorly when predicting from other datasets.
Our objective is to create parsimonious models; the simplest models with the least number of
covariates but with greatest explanatory power. There are various methods to estimate the
balance between parsimony and goodness-of-fit, popular methods include:
• Akaike’s Information Criterion, AIC - introduced by Akaike 1973 (71–73) - given the
number of estimated parameters k and the maximum value Lˆ of the likelihood function of a
candidate model then AIC = 2k − 2lnLˆ. Hence AIC rewards goodness-of-fit as determined
by the likelihood function but includes a penalty which increases with k that suppresses
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overfitting. The best model from a set of candidate models is the one with the lowest AIC.
Note that AIC does not describe model quality so given a set of poor models the AIC will
select the best one from the poor-quality set.
• Bayesian Information Criterion, BIC - introduced by Schwarz 1978 (74) - uses a penalty
term, similar to AIC, for the number of parameters in the model but the penalty term is
larger hence BIC will often favour fewer parameters; BIC = kln(n)− 2lnLˆ where n is the
number of data points.
Other popular methods include ‘minimum description length’ and ‘Bayes factors’; for a description
and comparison of these methods, see (75).
In this thesis we use AIC. First, AIC is considered asymptotically optimal for selecting the
regression model (with the least mean squared error) from the set of candidates under the
assumption that this set does not contain the ‘true model’ (i.e the process that generated the
data). In contrast under this assumption BIC is not asymptotically optimal; see for example the
comparison of AIC and BIC given by (76) in relation to regression models. Secondly, the risk of
selecting a bad model is minimised with AIC compared with BIC which carries a significant risk
of selecting a poor model from the candidate models; e.g. see simulation study by (77). Lastly,
(77) suggests AIC is preferred when the ‘true model’ is complex relative to all candidate models,
that is when all the candidates substantially oversimplify the underlying physical processes; this is
most likely the case with our dataset as it is very doubtful we have all the required covariates to
completely model the physical processes driving changes in renal function. It is also improbable
that the complexities of renal function are fully described by the simple structure of our linear
regression models.
To assist with model selection we used stepwise regression which is a method of fitting regression
models in which the choice of covariates is carried out by a systematic procedure. In each step of
the algorithm a covariate is considered for addition to, or subtraction from, the set of covariates
based on AIC. We use, from the R-package MASS (78), the function stepAIC which is briefly
described in (78) on page 175. This function implements a bidirectional selection procedure. To
the author’s knowledge neither (78) or the MASS documentation describe the algorithm so its
steps are outlined here:
1. it computes AIC for the regression model with all covariates;
2. it removes each covariate one at a time (backward selection) from the regression model and
calculates the AIC for each model then selects the one with lowest AIC;
3. it again removes covariates one at a time (backward selection) but also in turn adds
covariates in one at a time which were previously removed (forward selection), then the
regression model with the lowest AIC is selected;
4. the combination of backward-forward selection in step 3. is repeated until the model with
the lowest AIC is found.
32
An exhaustive search where regression models are computed for every possible combination of
covariates will find the global minima in AIC (or whichever statistic is used) but such a search is
computationally impractical for the number of covariates in our dataset. The aforementioned
bidirectional selection procedure, although typically more robust than applying only a forward or
a backward selection procedure, still presents the risk of unknowingly selecting a model with a
local minima in AIC rather than the desired model with the global AIC minima.
To gauge the level of model selection uncertainty we employed a bootstrap method; the principles of
which were first published by Efron 1979 (79) and are now widely used e.g. see texts (80,81). This
method, which is distribution-independent, is a resampling technique which estimates statistics on
an unobserved population by sampling the observed dataset with replacement. In particular the
observed dataset is randomly resampled with replacement, the bootstrap distribution is generated
by repeating this resampling procedure a number of times. Provided the observed dataset is a
representative sample from the true population the bootstrap method works by treating the true
distribution as being analogous to the bootstrap distribution. It is therefore possible to assess
the properties of the unobserved distribution of the population.
The bootstrapping technique typically assumes all observations are from an independent and
identically distributed population. However this assumption is violated by longitudinal data.
There are multiple observations per patient (cluster), and the data are independent between
patients but temporally correlated within each patient’s records. We respect this data structure
by using the so-called m-out-of-n bootstrap where there are a total of n records grouped into m
clusters; for example (81) page 140 and (82) discuss this type of bootstrap. In terms of our data
the patients, i.e. m clusters, are randomly resampled with replacement while the observations for
each patient remained unchanged so as to preserve temporal correlations. It follows that each
bootstrap sample has the same number of patients (clusters) as the original data although some
patients would almost surely occur more than once.
In summary, for a given dataset the final model will be obtained by using the bootstrap to
estimate selection stability for each explanatory variable under bidirectional stepwise regression.
The exact procedure is summarised below in Section 5.4.
5.3 Training and validation data
To help detect the presence of any under- or over-fitting in the aforementioned model selection
procedures, described in Section 5.2, were performed on a subset of data, training data, and the
resulting model was then validated using the remaining data, validation data. Commonly, training
data consists of 75-80% of the entire dataset and the remaining 25-20% forms the validation
data. In our case, for a given dataset, we obtained the training data by randomly selecting the
desired number of patients (without replacement), therefore the remaining patient data formed
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the validation data. The idea is that if the model selected fits similarly to both the training and
validation data then we surmise that the model adequately describes the data without under- or
over-fitting.
Note that the use of training and validation data is no more than a weak test of overfitting. For
a discussion on its limitations see Section 8.3.
5.4 Summary of model selection procedure
We create a separate LME model for each primary kidney disease group (diabetic nephropathy,
glomerulonephritis, hypertensive kidney disease, obstruction, other, polycystic kidney disease,
pyelonephritis, renovascular disease, unknown) with the exception of obstruction which is excluded
because of too little data. Additionally we make an overall model, called ‘single model all diseases’,
which uses the entire dataset including patients with obstruction. We select our final models for
each disease category as followings:
Step 1. Using the full dataset, strong correlations between covariates were eliminated by completely
discarding several covariates; details given above in Section 5.1.
Step 2. Given Equation 2, for each disease we initially use a parsimonious LME model with random
effect X∗i = 1ni and i ∼ N(0, σ2 Ini). Each model is fitted by maximising the log-likelihood
so that we can compare models using AIC. Fixed effects for each disease model are selected as
follows:
1. Wherever the dataset was large enough we apportioned 80% of patients (randomly selected)
to the training data and the remaining 20% to the validation data. With this ratio the PKD
and pyelonephritis disease models contained too few patients in the validation data so we
apportioned 75% of patients to the training data and the remaining 25% to the validation
data.
2. We generated 100 bootstrap samples from the training data.
3. The bidirectional model selection procedure was applied to each bootstrap sample. Given
each bootstrap sample a regression model with the lowest AIC was estimated and its fixed
effect regression parameters recorded.
4. We assessed regression model stability across all bootstrap samples by computing the
proportion of samples in which each explanatory variable was included in the regression.
The final model for each disease category was selected using explanatory variables which
occurred in more than 50% of bootstrap samples.
5. The final models were fitted using the validation data to check the robustness of the model
fit to the data.
Step 3. Given our interest is in the progression of disease over time, we augmented the fixed
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effects with interaction terms between each time varying explanatory variable and time since
follow-up. This allows us to estimate the effects on the slope of log(eGFR) over time. The
rationale for not including interaction terms during Step 2. was to limit the size of the parameter
space so as to reduce the chance of overfitting and/or selecting models in a local, rather than a
global, minima. From this point onwards all models include such interactions which we denote as
expanatoryVariable:followupTime. Note that we do not consider all possible interactions between
all explanatory variables as again the parameter space would become too large potentially leading
to sub-optimal models.
Step 4. The fixed effects selected in Step 2. and 3. were for a model with random effect design
matrix X∗i = 1ni and i ∼ N(0, σ2 Ini); below we refer to this as ‘Model A’. Using these fixed
effects we investigated the model fit by undertaking rudimentary exploratory analysis using
log-likelihood estimates. As is customary in longitudinal analysis we considered models with
different random effects and correlation structures including compound symmetry (CS). The
CS results are not presented here as they did not significantly improve the model fit. Here we
consider the following additional complexities to the model structure:
• Model B: X∗i (tij) = 1ni with correlation Ci described by a CAR1 model
• Model C: X∗i (tij) = (1ni , ti) without within-group correlation
• Model D: X∗i (tij) = (1ni , ti) with correlation Ci described by a CAR1 model
Given the training data the log-likelihood estimates for all models are tabulated in Table 7.
Table 7: Comparison of log-likelihood for different models
Model A Model B Model C Model D
random effect X∗i 1ni 1ni (1ni , ti) (1ni , ti)
correlation Ci none CAR1 none CAR1
diabetic nephropathy -17.7 -0.3 -0.8 1.5
glomerulonephritis -79.1 -55.6 -43.2 -41.0
HKD 45.5 57.5 51.6 58.9
other 12.8 16.5 21.4 22.0
PKD 24.5 34.7 42.8 45.9
pyelonephritis 64.7 67.9 79.0 78.5
renovascular 51.8 61.2 59.5 64.8
unknown -23.7 -23.7 -20.0 -20.1
single model all diseases -488.3 -333.2 -325.8 -302.9
Note: For each disease, the fixed effects derived from Model A are
used in Models B to D.
The model which maximises the log-likelihood for each disease category and so gives the best fit
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to the data is Model D; see Table 7. Model C generally has a higher log-likelihood than Models
A and B, except for diabetic nephropathy, HKD and renovascular where Models C and B have
very similar log-likelihoods.
We acknowledge that simply comparing log-likelihood values between models is naive and that
from a statistical standpoint model comparison requires likelihood ratio tests. However our model
choice is more pragmatic than statistical, in that we took into consideration the known structure
of the data (i.e. we expected to need intercept and slope random effects) and although we would
have preferred to properly consider correlation in the form of a CAR1 model this could not be
achieved within the scope of this thesis as explained below in the second bullet point. Given every
disease category, for our final model structure we chose the more parsimonious model, Model C,
over Model D. This decision was based on the following considerations:
• Given the aforementioned caveats relating to exploring within-group correlations and
likelihood ratio tests we note that the log-likelihood for Model C was only marginally less
than Model D, but still approximately matches or is better than models A and B.
• We encountered problems which we could not resolve when fitting Model D to many of the
bootstrap samples, specifically the R function nlme::lme() for fitting the mixed effects model
reported singularity errors. It is possible that Model D was too complex; a full and detailed
investigation was beyond the scope of this thesis. In contrast a model fit was possible for
all randomly generated bootstrap samples when using Model C.
• For a given fixed effect parameter all 95% confidence intervals overlapped when comparing
these intervals between Models A, B, C and D; note that parameters were selected using
Model A. This comparison held true for all fixed effect parameters in all our disease
categories. We conclude that these parameter distributions are not statistically different
between the models. This means the choice of random effect does not dramatically alter
the distribution of the fixed effect parameter values, therefore from this perspective Models
A to D are all viable choices.
Step 5. Lastly, given the final choice of model, Model C, we repeated the procedure stated in
bullet points of Step 2. above. There was little change in the selected fixed effect terms when
fitting Model C compared with A.
Finally, for the remainder of this thesis we use Model C where the random effects are accounted
for by intercept and slope (followupTime) terms.
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6 Diagnostics
In this chapter we verify the robustness of our models, and hence results, by subjecting them to
diagnostic tests which predominantly aim to check the linear mixed model assumptions.
6.1 LME Model assumptions
Before reporting results we check the models for each disease are robust and adhere to the basic
LME model assumptions, which are:
1. Within-group errors i are independent and identically normally distributed, with zero
mean and constant variance.
2. Random effects are normally distributed, with mean zero and covariance matrix Ψ, and are
also independent of within-group errors.
We mostly follow diagnostic tests recommended by (66) (e.g. Chapter 4.3) so predominantly
concentrate on displaying diagnostic information in plots since, as (66) points out, they are rarely
contradicted by hypothesis tests.
6.2 Tests using validation data
When considering model fits to the validation data we note the limitations raised in Section 8.3.
In particular we acknowledge that the tests detailed below offer no more than a weak test of
overfitting.
On a parameter-by-parameter basis, we compared model estimates fitted using training data with
those fitted using validation data; in particular we examined fixed effect parameter estimates,
standard errors and confidence intervals. All estimates were very similar, with almost all (training
and validation data) confidence intervals overlapping for each parameter.
We examined the residuals of each disease model fit using diagnostic plots (not shown) similar to
those in Section 6.6, Figures 8-16. When fitting the models with either the training or validation
data we did not find any concerning autocorrelations or deviations from normality. Moreover the
plots displayed very similar characteristics for each dataset, these characteristics can also be seen
in Figures 8-16 which were created when fitting models to the full dataset.
In summary, there was no concerning evidence of overfitting to the training data For the remainder
of this thesis we use the full dataset unless otherwise stated.
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6.3 Examination of confidence intervals
Very wide or indeterminate confidence intervals for the LME model parameters indicate numerical
instability, consequently the fitted model could not be expected to reliably describe the data.
Tables 8 and 9 confirm the confidence intervals for the random effects variance-covariance
parameters and σ, give no cause for concern. Figure 5 displays correlation values from Table 8, it
clearly shows PKD has a relatively high correlation. The fixed effect confidence intervals, not
shown, were also acceptable for each model.
We note in Table 8 that the correlation between random effects is computed from the variance-
covariance matrix S i.e. correlation matrix R = D−1/2 SD−1/2 where D = diag(S) and the
elements of D1/2 are standard deviations.
Table 8: 95% confidence intervals for random effects variance-
covariance parameters
random effects lower CI estimate upper CI
diabetic nephropathy
sd(Intercept) 0.284 0.318 0.356
sd(followupTime) 0.043 0.056 0.074
cor(Intercept,followupTime) -0.174 0.065 0.296
glomerulonephritis
sd(Intercept) 0.359 0.398 0.441
sd(followupTime) 0.044 0.056 0.071
cor(Intercept,followupTime) -0.046 0.193 0.412
HKD
sd(Intercept) 0.299 0.334 0.373
sd(followupTime) 0.028 0.042 0.062
cor(Intercept,followupTime) -0.219 0.102 0.403
other
sd(Intercept) 0.310 0.345 0.384
sd(followupTime) 0.029 0.040 0.057
cor(Intercept,followupTime) -0.179 0.101 0.366
PKD
sd(Intercept) 0.403 0.472 0.554
sd(followupTime) 0.054 0.077 0.110
cor(Intercept,followupTime) 0.383 0.778 0.932
pyelonephritis
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Table 8: 95% confidence intervals for random effects variance-
covariance parameters (continued)
random effects lower CI estimate upper CI
sd(Intercept) 0.298 0.350 0.410
sd(followupTime) 0.023 0.033 0.046
cor(Intercept,followupTime) -0.267 -0.017 0.236
renovascular disease
sd(Intercept) 0.295 0.342 0.396
sd(followupTime) 0.034 0.048 0.066
cor(Intercept,followupTime) -0.059 0.331 0.633
unknown
sd(Intercept) 0.280 0.314 0.352
sd(followupTime) 0.028 0.041 0.061
cor(Intercept,followupTime) -0.476 -0.169 0.174
single model all diseases
sd(Intercept) 0.350 0.365 0.380
sd(followupTime) 0.048 0.053 0.058
cor(Intercept,followupTime) -0.047 0.012 0.071
Table 9: 95% confidence intervals for within-group standard deviation for parameter σ
σ lower CI estimate upper CI
diabetic nephropathy 0.142 0.152 0.164
glomerulonephritis 0.155 0.165 0.175
HKD 0.126 0.136 0.147
other 0.155 0.165 0.177
PKD 0.103 0.116 0.130
pyelonephritis 0.113 0.123 0.135
renovascular 0.125 0.137 0.149
unknown 0.148 0.160 0.173














Figure 5: Correlation between intercept and slope random effects
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6.4 Observed versus fitted values
For each disease category we show the relationship between the model fitted values and observed
values i.e. log(eGFR). Figure 6 depicts observed values plotted against fitted values obtained
using a model with fixed effects only (excluding random effects). This gives a summary of the
overall quality of the model fixed effects; in all plots there is a reasonable degree of correlation.
When using the full model the fitted values include both fixed and random effects, in Figure 7
we observe a marked increase in correlation across all disease categories. This provides evidence
that random effects are needed in our models to help explain log(eGFR). For example, given the
category ‘single model all diseases’ the correlation between observed and fitted values without
random effects is 0.73, whereas when random effects are included the correlation increases to 0.97.
Given Figure 6 we observe, that compared with the other diseases, PKD has a noticeably wider
spread of values. We attribute this to the fixed effects describing the data less well. The dominant
determinant for the progression of kidney disease in PKD patients is typically the extent and rate
of growth of cysts in the kidneys. Our data does not contain information relating to kidney cysts,
therefore this factor cannot be included in the PKD model fixed effects. This possibly explains
why we observe a wider spread in values in Figure 6. This wide spread of values for PKD is not
seen in Figure 7 hence the inclusion of the random effects accounts for the additional variability
















































































































































single model all diseases

















































































































































single model all diseases
Figure 7: Observed values plotted against fitted values obtained using full model with fixed and
random effects
43
6.5 Assessment of residual distributional assumptions
Standardised (or Pearson) residuals are found by subtracting the estimated fitted value vector
from the outcome vector, then dividing through by the corresponding estimated within-group
standard errors. Fitted values are obtained by adding the estimated contributions from both fixed
and random effects vectors. We expect the standardised residuals to follow a standard normal
distribution.
In Figures 8-16 we assess, for each disease, the normality assumptions of the residuals using a
panel of four plots:
• Left plot - standardised (or Pearson) residuals against fitted values. From these plots we
report that the residuals in our LME models are reasonable given the within-group error
assumptions: the residuals are symmetrically distributed around zero with approximately
constant variance.
• Left middle plot - qq-plot with standardised residual quantiles against theoretical quantiles.
These plots confirm that our models have residuals which are plausible under the assumption
of normality. However outside of about -2 to 2 quantiles there are more than expected
extreme positive and negative residuals hence our distributions have long tails. Clearly our
models do not adequately explain the extremes however this is not a significant issue given
our objective is to identify fixed effect parameters and not to make predictions (note that
with our model’s predictions based on the extremes would be poor).
• Right middle plot - cumulative probability for both the standard normal distribution (dotted
black) and standardised residual (solid blue). These plots confirm that our residuals do not
indicate any significant violations of the normality assumption.
• Right plot - empirical autocorrelation function for standardised residuals where lag is the
difference between follow-up years and the shaded area is the 95% CI. These plots show that
there exists some autocorrelation which is not accounted for by the LME model however
we consider this amount of autocorrelation to be acceptable. The large correlations at
large lags are most likely due to the small numbers patients followed-up over many years
e.g. PKD has less than 20 patients beyond four follow-up years. For reference, the number



















































































































































































































































































































































































































































































































































































































































































Figure 16: Residuals - single model all diseases
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Appendix A.5, Figures 63-71, show there is no systematic trend in the mean of the residuals over
time and furthermore the majority of 95% confidence intervals cover zero.
Despite the aforementioned weaknesses we conclude for each disease category that the residuals do
not show any concerning deviation from normality. With reference to Section 6.1 we conclude that
assumption 1 is sufficiently true; i.e. errors are independent and identically normally distributed,
with zero mean and constant variance.
Removing outliers
When we present the results in Chapter 7 we will exclude the following outliers:
• given figure 8 the record with the residual value of 4.1 will be removed from diabetic
nephropathy
• given figure 13 the record with the residual value of 3.3 will be removed from pyelonephritis
• given figure 15 the record with the residual value of 3.2 will be removed from disease
unknown
These outliers were far from any other observations within their disease category and therefore
might skew the parameter estimation. We took this approach since we are unable to determine if
the outliers were due to: a) natural variability not accounted for by our model; b) measurement
error; c) data recording error; or d) sub-optimal imputation. Future work should carefully
investigate outliers as they may be medically informative if caused by unusual but interesting
biological mechanisms not accounted for within our models. However we note that the removal of
the aforementioned outliers made negligible difference to our parameter estimates.
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6.6 Assessment of random effect distributional assumptions
Given each disease category the mean value of each estimated random effect vector is, as required,
approximately zero; range -1.2e-14 to 1.3e-13.
Figures 17 and 18 respectively show the qq-plots of the estimated random effects for slope and
intercept, it can be seen that the assumption of marginal normality is plausible although the


































































































































































single model all diseases



































































































































































single model all diseases
Figure 18: qq-plot for standardised random effect slope term
Despite the aforementioned weaknesses we conclude for each disease category that the random
effects do not show any concerning deviation from normality, with reference to Section 6.1 we
conclude that assumption 2 is plausible; i.e. random effects are normally distributed, with mean
zero.
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As an aside we investigate the extent to which there are correlations between the estimated
random effects terms i.e. intercept and slope. We expect that there may be some correlations,
although in terms of our model fitting this is not a concern. For most diseases there is no


































































































single model all diseases
cor = 0.17
Figure 19: Estimated random effects plotted against each other
50
6.7 Robustness of fixed effect parameters and conclusions relating to
diagnostic results
In this thesis our primary interest is in fixed effects therefore we consider how they are influenced
by the choice of random effects. We rewrite Equation 2 such that
Y i = Xiβ +X∗i bi + i
= Xiβ + ∗i
(25)
where ∗i = X∗i bi + i and bi ∼ N(0,Ψ). Both X∗i bi and i are independently distributed as
multivariate normal vectors hence their sum ∗i is an independently distributed multivariate normal
vector with mean zero and variance-covariance matrix σ2Σi = X∗iΨ(X∗i )T + σ2I. Consequently
Y i are independent multivariate normal random vectors with variance-covariance matrix σ2Σi
and mean Xiβ i.e. Y i|Xi ∼ N(Xiβ, σ2Σi). The density is
P (Y i|β, σ2) = (2piσ2)−
ni
2 exp
(−(Y i −Xiβ)TΣ−1i (Y i −Xiβ)2−1σ−2) |Σi|− 12 (26)
where |Σi| is the determinant of Σi. The log-likelihood is
l(β, σ2|y) = C +
M∑
i=1
((Y i −Xiβ)TΣ−1i (Y i −Xiβ)|Σi|−
1
2 ) (27)
and we note, using matrix algebra, that
(Y i −Xiβ)TΣ−1i (Y i −Xiβ) = Y Ti Σ−1i Y i − 2βTXTi Σ−1i Y i + βTXTi Σ−1i Xiβ. (28)
Differentiating the log-likelihood with respect to β, equating to zero, and evaluating at β = βˆ








XTi Σ−1i Y i. (29)












It follows that the estimator of fixed effects parameter β is unbiased where the only assumption
required is E(Y i|Xi,X∗i ) = Xiβ. This result shows that the LME model gives unbiased estimates
of βˆ even if the random effects and residual assumptions are violated. For example, our intercept-
and-slope random effects assume linear slopes over time but if the patient’s have longitudinal
trajectories which are actually non-linear we will still obtain unbiased estimates of βˆ despite the
departure from normality as depicted in Figure 18; here we assume reasonable fixed effects terms.
Even if the random effects and/or residuals, are not normally distributed, and/or the variances
are not constant, we still obtain unbiased estimates of βˆ but we should be careful when drawing
inferences; estimating standard errors, and calculating confidence intervals and p-values.
If one or more of the LME assumptions are violated our inferences relating to the fixed effects
should still be valid since, as discussed above these models are robust to such violations. We
therefore conclude that our LME model diagnostics do not reveal any deviations from normality





We present our results based on the LME models for each disease category that we fitted in
Chapter 5. In Section 7.2 we give an overview of regression parameter estimates and report their
details in Section 7.3. These two sections constitute our main findings regarding the key factors
affecting kidney disease. As discussed in Section 4.5 all continuous explanatory variables have
been standardised except for follow-up time and baseline age. For reference only, the equivalent
regression parameter estimates in which variables are not standardised are given in Appendix
A.7. In Section 7.4 we report the rates at which the variables change over time; these results are
of secondary importance relative to Sections 7.2 and 7.3 .
The regression parameter estimates are difficult to interpret from a clinical perspective because
they are relative to the log(eGFR) scale, most clinicians work in terms of eGFR. We therefore
report the relative change in eGFR induced by a step change in the variable of interest, see
Equation 14. A relative change of 5% in eGFR is generally considered to be a clinically significant.
Given standardised variables we set θ′r = 1 therefore the parameter effects are comparable. In
this thesis a superscript dash is never used to denote a derivative, here we use a superscript dash,
e.g. θ′r, to denote that the term belongs to the standardised model as described in Section 4.5.
When we report p-value estimates for regression parameter values the null hypothesis is that the
parameter is zero valued i.e. the parameter has no effect on the outcome. We choose to reject
the null hypothesis at the 5% significance level, hence with this interpretation a p-value < 0.05
indicates changes in the predictor are associated with meaningful changes in the outcome.
For each disease model the details of the fixed effect parameter estimates are given in Tables
10 to 20. Additionally Figures 20 to 37 summarise the relative change in eGFR for θ′r = 1 and
indicate the clinically significant level of a 5% change in eGFR.
When reporting the regression parameters for a given disease we split them into two categories as
follows:
• average effects - describe the average behaviour of the population. These effects related to
explanatory variables which do not have an interaction with time. Parameters with positive
values indicate a higher level in eGFR (less severe kidney disease) whereas negative values
indicate a lower level in eGFR (more severe kidney disease).
• temporal effects - describe the explicit time dependent behaviour of the population. These
effects relate to explanatory variables which have an interaction with follow-up time, that is
X
(r)
i (ti,j) ti,j or equivalently we denote such terms as explanatoryVariable : followupTime
(this is the notation used by R-package nlme). As shown in Section 7.4.1 the eGFR is
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on average decreasing over time, i.e. it has a negative slope over time, for each disease
category. It follows that parameters with positive values reduce the gradient of the slope
of eGFR, that is the slope is less negative (more shallow), which suggests a less rapid
decline in kidney function. Conversely, negative parameter values indicate an increase in
the slope of eGFR, that is the slope is more negative (steeper), which suggests a more rapid
decline in kidney function. Mathematically this can be seen by considering the linear model
y(x, t) = ax + bt + cxt = ax + (b + cx)t where the slope with respect to t is (b + cx). It
follows that if b is negative, then for positive c an increase in x leads to a slope which is less
steep. Conversely for negative b and c, an increase in x results in a slope that is steeper.
The clinicians advised that, within the following three groups, the variables are clinically strongly
associated:
• med.VitaminD, CC, PO, PTH,
• med.ACE.ARB, numberAntihypertensives, DBP, PP and Pu
• med.iron (iron taken orally), med.ParenteralIron, med.Epo and Hb
If one or more variables within a given group are selected by our model selection procedure (see
Section 5.4) then all variables from that group will be used when reporting the results. The
reasoning behind these strong associations is that within each of these groups the medications




In Tables 10 and 11 we present a summary of the fixed effect regression parameters for each disease
model. In these tables the ‘single model all diseases’ column is the model which encompasses
all disease categories including the obstruction category. If a parameter is present in a given
model it is denoted by either star(s) or tilde. One or more stars indicate that we reject the null
hypothesis, hence the parameter is statistically significant. Three stars indicate we reject the null
hypothesis at the significance level of 0.001, two stars at a level of 0.001-0.01 and one star at a
level of 0.01-0.05. Tilde indicates although we do not reject the null hypothesis we still include
the parameter in the model as it has a small effect. The plus and minus signs inside the brackets
indicate the sign of the estimated parameter, for example (-)*** denotes the given parameter
estimate has a negative value and is statistically significant at the 0.001 level.
Key messages
As expected there is much variation across disease categories. Purely in terms of parameter
p-values for the average effects, given in Table 10, we observe the following:
• In every disease model parameters baseline age, vitamin D, Hb, PO and PTH are typically
highly statistically significant.
• Medications play a stronger role than comorbidities.
• Baseline lifestyle parameters (living alone, occupation, smoking and weekly alcohol intake)
do not play as strong a role as we might have anticipated.
• Physical attributes such as BMI, sex and ethnicity generally have a very weak effect.
• Each of the CC, DBP, Hb, PO, PP, Pu, PTH, total Cholesterol and total CO2 factors are
statistically significant in at least one disease category, the exception is CRP which is not
statistically significant anywhere.
• medication med.ACE.ARB is statistically significant for diabetic nephropathy and less so
for glomerulonephritis but it is not significant for the other diseases.
Considering the temporal effects, given in Table 11, we observe:
• The majority of these variables the steepness of their slopes are not statistically significant.
For example the comorbidities very weakly influence the progression of disease.
• In some cases follow-up time is significant, especially so for PKD. This most likely indicates
there are other risk factors which are not in our model.
• For some diseases, the biomarkers DBP, Hb and PTH have a positive effect on the slope
indicating less rapid progression of disease. In contrast PO, Pu, total cholesterol and total
CO2 have a negative effect indicating a more rapid progression of disease.
Where anomalies occur in the signs of parameters they are discussed in detail with reference to
each primary kidney disease within Section 7.3.
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Average effects

























































































(Intercept) (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗
age0 (−)∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗ (−)∗ (−)∗∗∗ (−)∗∗∗
bodyMassIndex (−)∗∗ (+)∼
CC (−)∗∗ (+)∼ (−)∼ (−)∗ (−)∼ (−)∼ (−)∼ (−)∼ (−)∗∗
comorbidityCancercurrent (+)∼ (−)∼ (+)∼ (+)∼
comorbidityCancerprevious (−)∗ (−)∼ (+)∼ (−)∼
comorbidityCV1 (−)∗ (−)∼ (+)∼ (−)∼ (−)∼ (−)∗
comorbidityCVover 1 (−)∗ (−)∼ (−)∼ (+)∼ (−)∗ (−)∗∗
comorbidityDiabetestype1 (−)∼ (−)∼
comorbidityDiabetestype2 (+)∼ (+)∼ (+)∼
comorbidityGastrointestinal (+)∼ (+)∼
comorbidityOther (+)∼
CRP (+)∼ (+)∼ (−)∼ (+)∼
DBP (+)∗ (−)∼ (+)∼ (+)∼ (+)∼ (+)∼ (+)∗ (+)∗































































































disease polycystic kidney disease (−)∗∗∗
disease pyelonephritis (−)∗∗
disease renovascular disease (−)∼
disease unknown (−)∼
ethnicitynonWhite (+)∼
familyHistoryIHD0 (−)∼ (+)∼ (+)∼
Hb (+)∼ (+)∗∗ (+)∗∗∗ (+)∗∗∗ (+)∼ (+)∗ (+)∗∗ (+)∗∗∗ (+)∗∗∗
med.ACE.ARB (+)∗∗∗ (+)∗∗ (+)∼ (+)∼ (+)∼ (−)∼ (−)∼ (+)∗∗
med.AlphaBlockers (−)∼ (−)∼ (+)∼ (−)∼
med.BetaBlockers (+)∼ (−)∼ (−)∼ (+)∼
med.CCBs (−)∗∗ (−)∼ (+)∼ (+)∼ (+)∼ (−)∗
med.Diuretics (+)∼ (−)∗ (−)∗∗
med.Epo (−)∗∗ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼ (−)∗∗ (−)∗ (−)∗∗∗
med.Iron (−)∼ (+)∼ (+)∼ (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼
med.Other (−)∗
med.ParenteralIron (−)∗ (−)∼ (−)∼ (−)∼ (−)∗ (+)∼ (+)∗ (−)∼ (−)∼
med.VitaminD (−)∗∗∗ (−)∗∗∗ (−)∗∗ (−)∗∗∗ (−)∼ (−)∗∗ (−)∗ (−)∗∗ (−)∗∗∗
numberAKIepisodes (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∗ (−)∼
numberAntihypertensives (−)∗ (−)∼ (−)∗∗ (−)∼ (−)∗∗ (+)∼ (−)∼ (−)∼
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numberClinicVisits (−)∼ (+)∗ (+)∼ (+)∼ (−)∼
occupation0ManagerialProfessional (+)∼ (−)∼ (+)∼
occupation0Intermediate (+)∼ (+)∼ (+)∼
occupation0NeverWorkedUnemployed (+)∼ (−)∼ (+)∼
PO (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗
PP (+)∗ (+)∼ (+)∼ (+)∗ (−)∼ (+)∗∗ (+)∼ (+)∗
PTH (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗ (−)∼ (−)∗∗ (−)∗∗∗ (−)∗∗∗
Pu (+)∼ (+)∗∗ (−)∼ (−)∗ (+)∼ (−)∼ (−)∗ (+)∼
sexfemale (−)∼
smokingStatus0active (−)∼ (−)∼ (−)∼
smokingStatus0ex-smoker (−)∼ (+)∼ (−)∼
totalCholesterol (+)∼ (+)∼ (+)∼ (+)∼ (+)∗
totalCO2 (+)∗∗∗ (+)∗∗ (+)∗∗∗ (+)∗ (+)∗∗ (+)∗∗ (+)∗∗∗
weeklyAlcohol01 to 14 (−)∗ (−)∼ (−)∼ (−)∼
weeklyAlcohol0over 14 (−)∼ (+)∗ (+)∼ (+)∼
Note:
regression parameter sign: positive (+); negative (-)
p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *; >0.05 ∼
1 ‘all’ denotes ‘single model all diseases’
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Temporal effects


























































































CC:followupTime (+)∼ (−)∼ (+)∼ (+)∼ (−)∼ (+)∼ (+)∼ (−)∼ (−)∼
comorbidityCancercurrent:followupTime (+)∼ (+)∼ (+)∼ (−)∼
comorbidityCancerprevious:followupTime (+)∼ (+)∼ (−)∼ (+)∼
comorbidityCV1:followupTime (+)∼ (−)∼ (−)∼ (+)∼ (+)∼ (+)∼
comorbidityCVover 1:followupTime (+)∼ (+)∼ (+)∼ (−)∼ (+)∼ (+)∼
comorbidityDiabetestype1:followupTime (−)∼ (+)∼
comorbidityDiabetestype2:followupTime (+)∼ (+)∼ (+)∼
comorbidityGastrointestinal:followupTime (+)∼ (−)∼
comorbidityOther:followupTime (−)∼
CRP:followupTime (+)∼ (−)∼ (+)∼ (−)∼
DBP:followupTime (−)∼ (+)∗ (+)∼ (−)∼ (−)∼ (+)∗ (−)∼ (+)∼
followupTime (−)∗∗ (−)∼ (−)∗ (−)∼ (−)∗∗∗ (−)∼ (−)∼ (+)∼ (−)∗∗∗
Hb:followupTime (+)∗∗ (+)∼ (+)∼ (−)∼ (+)∗ (+)∗ (+)∼ (+)∼ (+)∗∗
med.ACE.ARB:followupTime (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼ (−)∼
med.AlphaBlockers:followupTime (−)∼ (+)∼ (+)∗∗ (−)∼
med.BetaBlockers:followupTime (−)∼ (−)∼ (−)∼ (−)∼
med.CCBs:followupTime (+)∼ (+)∼ (−)∼ (−)∼ (−)∼ (−)∼
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med.Diuretics:followupTime (−)∼ (+)∼ (+)∼
med.Epo:followupTime (+)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼ (+)∼ (−)∼
med.Iron:followupTime (+)∼ (−)∼ (−)∼ (−)∼ (+)∼ (+)∼ (−)∼ (+)∼ (−)∗
med.Other:followupTime (+)∼
med.ParenteralIron:followupTime (+)∗∗ (−)∼ (+)∼ (−)∼ (+)∼ (−)∼ (−)∼ (+)∼ (+)∼
med.VitaminD:followupTime (+)∼ (−)∼ (+)∼ (+)∼ (+)∼ (+)∼ (−)∼ (−)∼ (+)∼
numberAKIepisodes:followupTime (+)∼ (+)∼ (−)∼ (−)∼ (+)∼ (−)∼ (−)∼
numberAntihypertensives:followupTime (−)∼ (−)∼ (+)∼ (+)∼ (+)∼ (−)∼ (+)∗ (−)∼
numberClinicVisits:followupTime (−)∗∗∗ (−)∼ (+)∼ (+)∼ (−)∼
PO:followupTime (+)∼ (−)∼ (−)∼ (−)∗∗ (−)∼ (−)∼ (+)∼ (−)∗∗∗ (−)∗∗
PP:followupTime (−)∼ (+)∼ (+)∼ (+)∼ (+)∼ (−)∼ (−)∼ (+)∼
PTH:followupTime (+)∼ (+)∗∗∗ (−)∼ (+)∗∗ (+)∼ (+)∼ (+)∼ (+)∗∗∗ (+)∗∗∗
Pu:followupTime (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (+)∼ (−)∗∗∗ (−)∼ (−)∼ (−)∗∗∗
totalCholesterol:followupTime (−)∼ (−)∼ (−)∗∗ (+)∼ (−)∼
totalCO2:followupTime (−)∼ (−)∼ (+)∼ (−)∼ (−)∗ (−)∼ (−)∗∗∗
Note:
regression parameter sign: positive (+); negative (-)
p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *; >0.05 ∼
1 ‘all’ denotes ‘single model all diseases’
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7.3 Detailed Estimates of regression parameters
For each disease category, the figures in this section show the relative change in eGFR, these
values are computed using Equation 14. The tables also report regression parameter estimates,
standard errors and the proportion of bootstraps in which each variable was selected.
7.3.1 Diabetic nephropathy
Average effects
The key average effects are:
• Lower levels of eGFR are associated with having EPO treatment, vitamin D supplements,
PO and PTH. It is known that iron levels drop as kidney disease worsens, so patients
requiring EPO treatment have lower levels of eGFR. Similarly vitamin D drops as kidney
function worsens, so it is reasonable that these patients require vitamin D supplements.
Poor kidney function can result in higher levels PO and PTH and hence lower levels of
eGFR.
• Lower levels of CC are associated with lower levels of eGFR and therefore indicate poorer
kidney function; this is medically plausible.
• An older age at baseline and higher body mass index are both associated with lower levels
of eGFR. Note that increased body mass index is associated with type 2 diabetes.
• The ACE inhibitors and ARBs (med.ACE.ARB) are associated with higher levels of eGFR.
This suggests that patients taking ACE inhibitors and/or ARBs have better kidney function
compared with those who are not taking these drugs. We note that if eGFR drops to a
very low value then the patient is taken off these drugs.
PP and DBP are less statistically significant (level 0.01-0.05) then the key results stated above.
However we note that from a medical perspective it is expected that PP will increase with
ageing, worsening CKD and increasing cardiovascular disease. Our PP results are consistent with
this view. However as PP increases it is generally expected that DBP will fall; our results are
counterintuitive in this regard.
If HbA1c is included in the model then its corresponding parameter is positive but it has a




















−10 0 10 20
( ∆r Y^  *)%  = 100(exp( β^ 'r θ 'r )−1)  with θ 'r = 1
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05




The key temporal effects are:
• Follow-up time is negative. This means that the level of eGFR is falling off over time. This
is to be expected. The significance of follow-up time may indicate that there are additional
risk factors which are not included in the SKS dataset.
• Hb and parenteral iron are associated with slower disease progression (less negative slope in
eGFR). Note that Hb levels can fall as renal disease worsens.
• Pu is associated with a steeper decline in eGFR
If HbA1c is included in the model then its corresponding interaction term HbA1c:followupTime
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( ∆r Y^  *)%  = 100(exp( β^ 'r θ 'r )−1)  with θ 'r = 1
p−value significance:  <0.001    0.001−0.01    >0.05




Table 12: Standardised model summary for disease diabetic nephropathy
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 3.5808 1.2e-01 0.000 ***
age0 0.98 -0.0057 1.8e-03 0.002 ** -0.56
bodyMassIndex 0.52 -0.0623 1.8e-02 0.001 ** -6.04
bodyMassIndex:followupTime 0.0093 5.7e-03 0.102 0.93
CC 0.76 -0.0357 1.3e-02 0.005 ** -3.51
CC:followupTime 0.0019 3.6e-03 0.605 0.19
DBP 0.88 0.0238 1.1e-02 0.033 * 2.41
DBP:followupTime -0.0014 3.8e-03 0.709 -0.14
followupTime 1.00 -0.0378 1.2e-02 0.003 ** -3.71
Hb 0.99 0.0145 1.3e-02 0.269 1.46
Hb:followupTime 0.0140 4.6e-03 0.002 ** 1.41
med.ACE.ARB 0.95 0.1268 3.4e-02 0.000 *** 13.51
med.ACE.ARB:followupTime -0.0178 1.1e-02 0.096 -1.76
med.BetaBlockers 0.51 0.0583 3.3e-02 0.077 6.01
med.BetaBlockers:followupTime -0.0073 9.9e-03 0.463 -0.73
med.Epo 0.98 -0.0865 2.8e-02 0.002 ** -8.28
med.Epo:followupTime 0.0082 8.4e-03 0.332 0.82
med.Iron -0.0285 3.1e-02 0.355 -2.81
med.Iron:followupTime 0.0078 1.1e-02 0.457 0.79
med.ParenteralIron -0.0518 2.6e-02 0.050 * -5.04
med.ParenteralIron:followupTime 0.0260 9.0e-03 0.004 ** 2.64
med.VitaminD 1.00 -0.1334 3.0e-02 0.000 *** -12.49
med.VitaminD:followupTime 0.0035 8.5e-03 0.685 0.35
numberAKIepisodes 0.80 -0.0155 1.2e-02 0.207 -1.54
numberAKIepisodes:followupTime 0.0016 2.7e-03 0.550 0.16
numberAntihypertensives 0.86 -0.0394 1.7e-02 0.018 * -3.87
numberAntihypertensives:followupTime -0.0025 5.2e-03 0.634 -0.25
PO 1.00 -0.1004 1.4e-02 0.000 *** -9.55
PO:followupTime 0.0057 4.1e-03 0.166 0.57
PP 0.72 0.0290 1.2e-02 0.013 * 2.94
PP:followupTime -0.0014 4.2e-03 0.733 -0.14
PTH 1.00 -0.0761 1.5e-02 0.000 *** -7.33
PTH:followupTime 0.0020 2.9e-03 0.483 0.20
Pu 0.0256 1.6e-02 0.105 2.59
Pu:followupTime -0.0174 4.8e-03 0.000 *** -1.73
totalCholesterol 0.60 0.0201 1.5e-02 0.174 2.03
totalCholesterol:followupTime -0.0006 5.0e-03 0.909 -0.06
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *




The key average effects are:
• Medication med.ACE.ARB is associated with higher levels of eGFR; this indicates better
kidney function.
• Lower levels of eGFR are associated with taking CCBs medication and vitamin D supple-
ments, and also PO and PTH. This is reasonable since hypertension (in part treated with
CCBs) and vitamin D deficiency are associated with poor kidney function. Similarly higher
levels of PO and PTH are associated with poor kidney function.
• Higher levels of Hb and total CO2 are associated with higher levels of eGFR. That is better
kidney function. This is reasonable since low levels of Hb and total CO2 are associated
with poor kidney function.
• Older baseline age is associated with lower eGFR.
• A higher level of Pu is associated with a higher level of eGFR. This result is counterintuitive
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p−value significance:  <0.001    0.001−0.01    >0.05




The key temporal effects are:
• DBP is associated with a slower decline in eGFR. This is reasonable since higher levels of
DBP are associated with better renal function in conjunction with better cardiovascular
function.
• Pu is associated with a faster decline in eGFR. This is to be expected since protein in the
urine is associated with poorer kidney function.
• PTH is associated with slower progression of kidney disease i.e. shallower slope in eGFR over
time. This result is counterintuitive as higher levels of PTH are associated with worsening
kidney function.
Although follow-up time is not statistically significant its regression parameter is negative, therefore
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Table 13: Standardised model summary for disease glomerulonephritis
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 3.8879 1.1e-01 0.000 ***
age0 0.91 -0.0060 1.7e-03 0.000 *** -0.60
CC 0.0073 1.3e-02 0.560 0.73
CC:followupTime -0.0019 3.1e-03 0.538 -0.19
CRP 0.92 0.0219 1.6e-02 0.169 2.21
CRP:followupTime 0.0009 4.0e-03 0.823 0.09
DBP -0.0163 1.1e-02 0.152 -1.62
DBP:followupTime 0.0070 3.2e-03 0.026 * 0.71
followupTime 0.96 -0.0131 1.2e-02 0.277 -1.31
Hb 1.00 0.0477 1.4e-02 0.001 ** 4.89
Hb:followupTime 0.0044 4.2e-03 0.290 0.44
med.ACE.ARB 0.82 0.1015 3.6e-02 0.005 ** 10.69
med.ACE.ARB:followupTime -0.0137 9.2e-03 0.136 -1.37
med.AlphaBlockers 0.60 -0.0294 3.8e-02 0.434 -2.90
med.AlphaBlockers:followupTime -0.0052 1.0e-02 0.608 -0.52
med.BetaBlockers 0.76 -0.0569 3.6e-02 0.119 -5.53
med.BetaBlockers:followupTime -0.0019 1.1e-02 0.865 -0.19
med.CCBs 0.98 -0.1106 3.4e-02 0.001 ** -10.47
med.CCBs:followupTime 0.0002 8.8e-03 0.982 0.02
med.Epo 0.86 -0.0417 3.3e-02 0.202 -4.09
med.Epo:followupTime -0.0064 8.4e-03 0.447 -0.63
med.Iron 0.0350 4.1e-02 0.388 3.56
med.Iron:followupTime -0.0173 1.2e-02 0.143 -1.71
med.ParenteralIron -0.0136 3.4e-02 0.687 -1.35
med.ParenteralIron:followupTime -0.0062 9.6e-03 0.518 -0.62
med.VitaminD 1.00 -0.1598 3.8e-02 0.000 *** -14.77
med.VitaminD:followupTime -0.0112 1.0e-02 0.262 -1.11
numberAKIepisodes 0.53 -0.0067 1.2e-02 0.569 -0.67
numberAKIepisodes:followupTime 0.0019 3.5e-03 0.580 0.19
numberAntihypertensives -0.0056 2.2e-02 0.799 -0.56
numberAntihypertensives:followupTime -0.0006 5.5e-03 0.912 -0.06
PO 1.00 -0.1404 1.5e-02 0.000 *** -13.10
PO:followupTime -0.0017 4.2e-03 0.685 -0.17
PP 0.0138 1.2e-02 0.256 1.39
PP:followupTime 0.0001 3.4e-03 0.977 0.01
PTH 0.98 -0.0918 1.7e-02 0.000 *** -8.77
PTH:followupTime 0.0173 4.8e-03 0.000 *** 1.74
Pu 0.0397 1.3e-02 0.002 ** 4.05
Pu:followupTime -0.0169 4.2e-03 0.000 *** -1.68
totalCO2 1.00 0.0506 1.3e-02 0.000 *** 5.19
totalCO2:followupTime -0.0042 3.3e-03 0.207 -0.42
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Table 13: Standardised model summary for disease glomerulonephritis (contin-
ued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *
c (∆rYˆ ∗)% = 100(exp(βˆ′rθ′r)− 1) with θ′r = 1
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7.3.3 Hypertensive kidney disease
Average effects
The key average effects are:
• Taking higher numbers of antihypertensive drugs is associated with lower eGFR levels. This
is reasonable because poor kidney function is known to be associated with hypertension.
• Having more than one type of cardiovascular (CV) disease is associated with lower levels of
eGFR. This is consistent given poorer kidney function, which is associated with an increase
in risk of CV disease (and vice versa).
• Lower levels of eGFR are associated with taking vitamin D supplement, and also higher
levels of PO and PTH. Vitamin D deficiency is associated with poor kidney function.
Similarly higher levels of PO and PTH are associated with poor kidney function.
• Higher levels of Hb and total CO2 are associated with higher levels of eGFR. Note that low
levels of both these biochemicals are associated with poor kidney function.
• Patients who are older at baseline have poorer kidney function.
Considering the effects with a significance of 0.01-0.05 we find that drinking more than 1 unit of
alcohol per week and a previous cancer are both associated with lower eGFR levels. Note that
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( ∆r Y^  *)%  = 100(exp( β^ 'r θ 'r )−1)  with θ 'r = 1
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 24: Average effects - relative change in eGFR for standardised model using 95% CIs: HKD
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Temporal effects
The key temporal effects are:
• A high number of clinic visits is associated with a more rapid decline in kidney function.
This would imply that patients with poorer health visit the clinic more frequently.
• Pu is associated with a more rapid decline in kidney function. The presence of protein in
the urine is associated with poor kidney function.
In addition, follow-up time is negative and significant at the 0.01-0.05 level. This means that the
level of eGFR is dropping off over time, which is to be expected. The significance of follow-up
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Table 14: Standardised model summary for disease HKD
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 4.2133 1.8e-01 0.000 ***
age0 0.97 -0.0100 2.4e-03 0.000 *** -1.00
CC 0.57 -0.0216 1.2e-02 0.079 -2.14
CC:followupTime 0.0017 3.4e-03 0.628 0.17
comorbidityCancercurrent 0.77 0.0606 1.0e-01 0.553 6.24
comorbidityCancercurrent:followupTime 0.0174 2.8e-02 0.536 1.75
comorbidityCancerprevious 0.77 -0.1753 7.0e-02 0.013 * -16.08
comorbidityCancerprevious:followupTime 0.0284 1.5e-02 0.064 2.88
comorbidityCV1 0.70 -0.0991 3.8e-02 0.010 * -9.43
comorbidityCV1:followupTime 0.0174 1.1e-02 0.111 1.75
comorbidityCVover 1 0.70 -0.0810 4.1e-02 0.048 * -7.78
comorbidityCVover 1:followupTime 0.0012 1.1e-02 0.908 0.12
comorbidityOther 0.61 0.0377 4.7e-02 0.423 3.84
comorbidityOther:followupTime -0.0046 9.9e-03 0.645 -0.46
DBP 0.0143 1.0e-02 0.158 1.44
DBP:followupTime 0.0009 3.4e-03 0.788 0.09
ethnicitynonWhite 0.55 0.1617 1.2e-01 0.185 17.55
followupTime 0.67 -0.0267 1.3e-02 0.039 * -2.63
Hb 1.00 0.0508 1.2e-02 0.000 *** 5.22
Hb:followupTime 0.0023 4.5e-03 0.603 0.23
med.ACE.ARB 0.0138 3.1e-02 0.657 1.39
med.ACE.ARB:followupTime -0.0025 9.0e-03 0.783 -0.25
med.CCBs 0.64 -0.0413 3.1e-02 0.180 -4.04
med.CCBs:followupTime 0.0087 8.6e-03 0.307 0.88
med.Epo -0.0075 3.6e-02 0.836 -0.74
med.Epo:followupTime -0.0052 1.1e-02 0.642 -0.52
med.Iron 0.0509 3.3e-02 0.129 5.22
med.Iron:followupTime -0.0139 1.2e-02 0.255 -1.38
med.ParenteralIron -0.0261 3.1e-02 0.402 -2.58
med.ParenteralIron:followupTime 0.0106 1.0e-02 0.303 1.07
med.VitaminD 0.75 -0.1115 3.3e-02 0.001 ** -10.55
med.VitaminD:followupTime 0.0102 1.1e-02 0.334 1.03
numberAKIepisodes 0.69 -0.0109 9.7e-03 0.263 -1.08
numberAKIepisodes:followupTime -0.0003 3.1e-03 0.925 -0.03
numberAntihypertensives 0.64 -0.0469 1.7e-02 0.007 ** -4.59
numberAntihypertensives:followupTime 0.0091 4.8e-03 0.059 0.92
numberClinicVisits 0.70 -0.0041 9.1e-03 0.654 -0.41
numberClinicVisits:followupTime -0.0131 3.5e-03 0.000 *** -1.30
PO 1.00 -0.0763 1.3e-02 0.000 *** -7.35
PO:followupTime -0.0052 3.8e-03 0.180 -0.51
PP 0.0037 1.1e-02 0.736 0.37
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Table 14: Standardised model summary for disease HKD (continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
PP:followupTime 0.0033 3.5e-03 0.345 0.33
PTH 1.00 -0.0593 1.6e-02 0.000 *** -5.76
PTH:followupTime -0.0032 4.8e-03 0.505 -0.32
Pu 1.00 -0.0353 1.9e-02 0.058 -3.47
Pu:followupTime -0.0167 4.8e-03 0.000 *** -1.65
smokingStatus0active 0.94 -0.1210 9.0e-02 0.182 -11.40
smokingStatus0ex-smoker 0.94 -0.1001 5.4e-02 0.063 -9.52
totalCO2 0.85 0.0344 1.2e-02 0.005 ** 3.50
totalCO2:followupTime -0.0030 3.6e-03 0.406 -0.30
weeklyAlcohol01 to 14 0.65 -0.1232 5.3e-02 0.021 * -11.59
weeklyAlcohol0over 14 0.65 -0.0767 6.8e-02 0.263 -7.38
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *




The key average effects are:
• Lower levels of eGFR are associated with taking a vitamin D supplement and also higher
levels of PO and PTH. This is reasonable since vitamin D deficiency and high levels of PO
and PTH are associated with poor kidney function.
• Higher levels of Hb and total CO2 are associated with higher levels of eGFR, meaning that
the kidney function is better. Poor kidney function is associated with low levels of both of
these biochemicals.
• Patients who are older at baseline have poorer kidney function.
We also note, at the 0.01-0.05 significance level, that a higher number of clinic visits is associated
with higher levels of eGFR. This may indicate that the decline in renal function for these patients
is being better controlled by more frequent monitoring of their condition. Furthermore we observe






















( ∆r Y^  *)%  = 100(exp( β^ 'r θ 'r )−1)  with θ 'r = 1
p−value significance:  <0.001    0.01−0.05    >0.05
Figure 26: Average effects - relative change in eGFR for standardised model using 95% CIs: other
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Temporal effects
The key temporal effects are:
• PO is associated with a more rapid decline in kidney function.
• PTH is associated with slower progression of kidney disease. This result is counterintuitive
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Table 15: Standardised model summary for disease other
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 4.0023 1.0e-01 0.000 ***
age0 1.00 -0.0077 1.7e-03 0.000 *** -0.76
CC -0.0269 1.2e-02 0.030 * -2.66
CC:followupTime 0.0057 3.6e-03 0.110 0.57
comorbidityCV1 0.65 -0.0227 3.7e-02 0.540 -2.24
comorbidityCV1:followupTime -0.0167 9.7e-03 0.085 -1.65
comorbidityCVover 1 0.65 -0.0195 4.7e-02 0.681 -1.93
comorbidityCVover 1:followupTime 0.0098 1.3e-02 0.442 0.99
comorbidityDiabetestype1 0.68 -0.1038 2.4e-01 0.660 -9.86
comorbidityDiabetestype1:followupTime -0.0342 6.5e-02 0.596 -3.36
comorbidityDiabetestype2 0.91 0.0844 4.7e-02 0.076 8.81
comorbidityDiabetestype2:followupTime 0.0033 1.1e-02 0.767 0.34
CRP 0.60 0.0179 1.3e-02 0.168 1.81
CRP:followupTime -0.0055 4.4e-03 0.218 -0.55
followupTime 0.99 -0.0133 8.6e-03 0.122 -1.32
Hb 1.00 0.0995 1.5e-02 0.000 *** 10.47
Hb:followupTime -0.0054 4.3e-03 0.212 -0.54
med.BetaBlockers 0.52 -0.0468 3.7e-02 0.206 -4.57
med.BetaBlockers:followupTime -0.0071 9.1e-03 0.437 -0.70
med.Epo 0.89 -0.0422 3.7e-02 0.259 -4.13
med.Epo:followupTime -0.0186 1.1e-02 0.101 -1.84
med.Iron -0.0477 4.0e-02 0.238 -4.66
med.Iron:followupTime -0.0020 1.2e-02 0.867 -0.20
med.ParenteralIron -0.0075 3.8e-02 0.845 -0.75
med.ParenteralIron:followupTime -0.0169 1.1e-02 0.118 -1.68
med.VitaminD 0.96 -0.1557 3.9e-02 0.000 *** -14.42
med.VitaminD:followupTime 0.0115 1.1e-02 0.313 1.15
numberAKIepisodes 0.65 -0.0034 1.5e-02 0.819 -0.34
numberAKIepisodes:followupTime -0.0032 4.3e-03 0.454 -0.32
numberClinicVisits 0.86 0.0236 9.6e-03 0.014 * 2.39
numberClinicVisits:followupTime -0.0022 2.9e-03 0.432 -0.22
PO 1.00 -0.0875 1.5e-02 0.000 *** -8.38
PO:followupTime -0.0124 3.8e-03 0.001 ** -1.23
PTH 0.98 -0.1054 1.7e-02 0.000 *** -10.01
PTH:followupTime 0.0145 4.2e-03 0.001 ** 1.46
totalCholesterol 0.52 0.0281 1.5e-02 0.059 2.84
totalCholesterol:followupTime -0.0022 4.3e-03 0.608 -0.22
totalCO2 1.00 0.0440 1.2e-02 0.000 *** 4.50
totalCO2:followupTime 0.0021 3.7e-03 0.574 0.21
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Table 15: Standardised model summary for disease other (continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *




The key average effects are:
• Older age is associated with lower levels of eGFR.
• Lower levels of eGFR are associated with higher levels of PTH. Note that higher PTH is
associated with poorer kidney function.
At a statistical significance of 0.01-0.05 we also note the following results:
• Lower levels of eGFR are associated with patients receiving parenteral iron and also higher
levels of PO and Pu. Kidney disease can result in anaemia so patients receiving parenteral
iron would be expected to have lower levels of eGFR. Higher levels of PO and Pu are
associated with poorer kidney function.
• Total CO2 is associated with higher levels of eGFR, note that poor kidney function can
cause low levels of total CO2.
• PP is associated with higher levels of eGFR. It is expected that PP will increase with both
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( ∆r Y^  *)%  = 100(exp( β^ 'r θ 'r )−1)  with θ 'r = 1
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 28: Average effects - relative change in eGFR for standardised model using 95% CIs: PKD
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Temporal effects
The key temporal effects are:
• Follow-up time is negative which indicates that the level of eGFR is dropping off over time.
Follow-up time is very strongly associated with lower levels of eGFR. This may suggest that
the model is missing at least one risk factor. In PKD patients the continued growth of cysts
in the kidneys progressively impairs their function. Our model does not include variables for
the size, growth rate, and/or number of cysts in the kidneys. If it included such variables it
is possible that follow-up time would be either less significant or not significant.
• Hb, although only significant at the 0.01-0.05 level, is associated with slower progression of
CKD. This result is consistent with PKD patients tending to maintain good levels of Hb
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Table 16: Standardised model summary for disease polycystic kidney disease
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 4.3665 2.1e-01 0.000 ***
age0 0.98 -0.0190 3.5e-03 0.000 *** -1.88
CC 0.90 -0.0214 1.6e-02 0.186 -2.12
CC:followupTime -0.0053 4.4e-03 0.228 -0.53
comorbidityCV1 0.70 0.0029 4.9e-02 0.954 0.29
comorbidityCV1:followupTime -0.0153 1.3e-02 0.250 -1.52
comorbidityCVover 1 0.70 -0.0832 9.1e-02 0.360 -7.99
comorbidityCVover 1:followupTime 0.0073 2.0e-02 0.718 0.74
CRP 0.60 -0.0335 2.1e-02 0.109 -3.29
CRP:followupTime 0.0140 7.8e-03 0.074 1.41
DBP 0.59 0.0195 1.3e-02 0.141 1.97
DBP:followupTime -0.0010 4.1e-03 0.811 -0.10
familyHistoryIHD0 0.58 -0.0645 8.8e-02 0.465 -6.24
followupTime 1.00 -0.0972 2.2e-02 0.000 *** -9.26
Hb 0.90 0.0353 2.1e-02 0.095 3.60
Hb:followupTime 0.0138 5.8e-03 0.019 * 1.39
med.ACE.ARB 0.0087 4.9e-02 0.860 0.87
med.ACE.ARB:followupTime -0.0069 1.2e-02 0.572 -0.69
med.CCBs 0.64 0.0856 4.7e-02 0.069 8.93
med.CCBs:followupTime -0.0147 1.2e-02 0.229 -1.46
med.Diuretics 0.56 0.0149 4.1e-02 0.718 1.50
med.Diuretics:followupTime -0.0188 1.3e-02 0.154 -1.86
med.Epo 0.54 0.0060 7.2e-02 0.934 0.60
med.Epo:followupTime -0.0260 1.8e-02 0.148 -2.57
med.Iron -0.0658 7.0e-02 0.346 -6.37
med.Iron:followupTime 0.0170 2.0e-02 0.403 1.71
med.ParenteralIron 0.69 -0.1571 6.4e-02 0.015 * -14.54
med.ParenteralIron:followupTime 0.0245 1.8e-02 0.171 2.48
med.VitaminD 0.81 -0.0877 5.7e-02 0.125 -8.40
med.VitaminD:followupTime 0.0109 1.2e-02 0.367 1.10
numberAntihypertensives -0.0409 2.9e-02 0.165 -4.00
numberAntihypertensives:followupTime 0.0115 7.7e-03 0.139 1.15
numberClinicVisits 0.64 0.0009 1.6e-02 0.952 0.09
numberClinicVisits:followupTime 0.0000 3.7e-03 0.996 0.00
occupation0ManagerialProfessional 0.59 0.1336 9.8e-02 0.178 14.29
occupation0Intermediate 0.59 0.0491 1.2e-01 0.684 5.04
occupation0NeverWorkedUnemployed 0.59 0.0082 2.0e-01 0.968 0.83
PO 0.98 -0.0471 2.0e-02 0.020 * -4.60
PO:followupTime -0.0059 5.7e-03 0.302 -0.58
PP 0.92 0.0366 1.7e-02 0.033 * 3.73
PP:followupTime 0.0014 4.5e-03 0.759 0.14
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Table 16: Standardised model summary for disease polycystic kidney disease
(continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
PTH 1.00 -0.0786 2.8e-02 0.006 ** -7.56
PTH:followupTime 0.0007 6.9e-03 0.917 0.07
Pu 0.75 -0.0533 2.3e-02 0.023 * -5.19
Pu:followupTime 0.0049 5.9e-03 0.401 0.50
totalCO2 0.79 0.0415 1.6e-02 0.011 * 4.23
totalCO2:followupTime -0.0074 4.9e-03 0.132 -0.74
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *




The key average effects are:
• Lower levels of eGFR are associated with patients taking vitamin D supplements, larger
numbers of antihypertensives, and also PO. Kidney disease can cause vitamin D deficiency
and hypertension so patients taking Vitamin D and a higher number of antihypertensives
are expected to have lower levels of eGFR. Patients with higher levels PO will have poorer
kidney function and therefore lower levels of eGFR.
• Total CO2 is associated with higher levels of eGFR. Note that poor kidney function can
cause lower levels of total CO2.
• An older age at baseline is associated with a lower level of eGFR.
Factors at the 0.01-0.05 significance level are as follows:
• Hb is associated with higher levels of eGFR. Note that poor kidney function may cause low
levels of Hb.
• Drinking more than 14 units of alcohol per week is associated with higher levels of kidney
function. We consider this to be an anomaly due to the wide confidence intervals and the
fact that alcohol consumption is not expected to be associated with higher levels of eGFR.
We also note, although it is not significant, that this model selected the sexfemale variable. Being
female is weakly associated with lower levels of eGFR. This is reasonable because urinary tract
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The key temporal effects are:
• Hb is associated with a slower progression of kidney disease.
• Pu and total CO2 are associated with a more rapid progression of kidney disease.
Note that although not statistically significant the follow-up time regression parameter is negative.
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Table 17: Standardised model summary for disease pyelonephritis
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 3.9291 1.8e-01 0.000 ***
age0 0.86 -0.0081 2.4e-03 0.001 ** -0.81
bodyMassIndex 0.74 0.0233 3.3e-02 0.486 2.36
bodyMassIndex:followupTime 0.0084 6.0e-03 0.164 0.84
CC -0.0212 1.6e-02 0.194 -2.10
CC:followupTime 0.0007 4.5e-03 0.867 0.07
comorbidityCancercurrent 0.70 -0.2215 1.2e-01 0.063 -19.87
comorbidityCancercurrent:followupTime 0.0481 2.9e-02 0.103 4.93
comorbidityCancerprevious 0.71 -0.0708 1.1e-01 0.526 -6.83
comorbidityCancerprevious:followupTime 0.0443 2.3e-02 0.054 4.53
comorbidityCV1 0.53 -0.0553 5.3e-02 0.295 -5.38
comorbidityCV1:followupTime 0.0076 1.3e-02 0.573 0.76
comorbidityCVover 1 0.53 0.0026 7.2e-02 0.971 0.26
comorbidityCVover 1:followupTime -0.0194 1.5e-02 0.202 -1.92
comorbidityDiabetestype2 0.58 0.0616 7.5e-02 0.415 6.35
comorbidityDiabetestype2:followupTime 0.0221 1.7e-02 0.187 2.24
comorbidityGastrointestinal 0.84 0.0851 1.5e-01 0.570 8.88
comorbidityGastrointestinal:followupTime 0.0227 2.1e-02 0.283 2.30
DBP 0.59 0.0211 1.3e-02 0.105 2.13
DBP:followupTime -0.0034 3.8e-03 0.383 -0.33
familyHistoryIHD0 0.55 0.0570 7.7e-02 0.460 5.87
followupTime 0.51 -0.0253 1.5e-02 0.098 -2.50
Hb 0.98 0.0354 1.6e-02 0.027 * 3.60
Hb:followupTime 0.0136 5.3e-03 0.011 * 1.37
med.ACE.ARB 0.0083 4.4e-02 0.850 0.84
med.ACE.ARB:followupTime -0.0091 1.2e-02 0.433 -0.91
med.AlphaBlockers 0.66 -0.0607 5.9e-02 0.303 -5.89
med.AlphaBlockers:followupTime 0.0044 1.5e-02 0.767 0.44
med.CCBs 0.61 0.0521 5.0e-02 0.296 5.35
med.CCBs:followupTime -0.0079 1.2e-02 0.514 -0.79
med.Epo -0.0960 6.4e-02 0.133 -9.15
med.Epo:followupTime 0.0142 1.9e-02 0.448 1.43
med.Iron -0.0292 6.9e-02 0.675 -2.87
med.Iron:followupTime 0.0026 1.5e-02 0.865 0.26
med.ParenteralIron 0.0051 4.6e-02 0.912 0.51
med.ParenteralIron:followupTime -0.0329 2.2e-02 0.128 -3.23
med.VitaminD 0.99 -0.1185 4.3e-02 0.006 ** -11.17
med.VitaminD:followupTime 0.0159 1.0e-02 0.132 1.60
numberAKIepisodes 0.60 -0.0226 1.7e-02 0.174 -2.23
numberAKIepisodes:followupTime 0.0017 6.0e-03 0.770 0.17
numberAntihypertensives 0.85 -0.0922 3.1e-02 0.003 ** -8.81
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Table 17: Standardised model summary for disease pyelonephritis (continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
numberAntihypertensives:followupTime 0.0034 8.0e-03 0.672 0.34
numberClinicVisits 0.52 0.0037 1.2e-02 0.768 0.37
numberClinicVisits:followupTime 0.0006 4.5e-03 0.897 0.06
occupation0ManagerialProfessional 0.72 -0.1897 1.0e-01 0.062 -17.28
occupation0Intermediate 0.72 0.1509 9.9e-02 0.130 16.28
occupation0NeverWorkedUnemployed 0.72 -0.0892 1.7e-01 0.609 -8.53
PO 1.00 -0.0630 1.5e-02 0.000 *** -6.10
PO:followupTime -0.0046 4.3e-03 0.291 -0.45
PP -0.0023 1.7e-02 0.893 -0.23
PP:followupTime 0.0065 4.8e-03 0.178 0.66
PTH 0.74 -0.0280 3.4e-02 0.407 -2.76
PTH:followupTime 0.0072 6.1e-03 0.241 0.72
Pu 0.93 0.0070 1.9e-02 0.715 0.71
Pu:followupTime -0.0252 6.1e-03 0.000 *** -2.49
sexfemale 0.81 -0.1501 8.0e-02 0.064 -13.94
smokingStatus0active 0.93 -0.1343 1.2e-01 0.276 -12.56
smokingStatus0ex-smoker 0.93 0.0052 8.8e-02 0.954 0.52
totalCO2 0.67 0.0551 1.7e-02 0.001 ** 5.66
totalCO2:followupTime -0.0109 4.8e-03 0.023 * -1.08
weeklyAlcohol01 to 14 0.82 -0.1031 8.9e-02 0.251 -9.79
weeklyAlcohol0over 14 0.82 0.2773 1.2e-01 0.021 * 31.96
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *




The key average effects are:
• Hb is associated with higher levels of eGFR. Note that poor kidney function can result in
lower levels of Hb.
• EPO treatment is all associated with lower levels of eGFR. Patients requiring this treatment
will generally have poorer kidney function.
• Higher levels of PO and PTH are associated with lower levels of eGFR and poorer kidney
function.
• PP is associated with higher levels of eGFR. It is expected that PP will increase with both
age and worsening renal function therefore this result is counterintuitive.
Although not as significant as the factors listed above, having more then one cardiovascular
(CV) disease, taking diuretic medications, having an older baseline age and taking vitamin D
supplements are all associated with lower levels of eGFR. Similarly taking parenteral iron is
associated with better kidney function.
Note that the very wide confidence interval on baseline occupation NeverWorkedUnemplyed is
due to there being very few realisations of this factor level. Out of about 560 realisations this
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The key temporal effects are:
• Alpha and/or beta blockers are associated with a less rapid decline in kidney function.
• Total cholesterol is associated with a more rapid decline in kidney function.
DBP, with significance level of 0.01-0.05, is relatively weakly associated with a less rapid decline
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Table 18: Standardised model summary for disease renovascular
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 4.3841 3.3e-01 0.000 ***
age0 0.73 -0.0109 4.2e-03 0.011 * -1.08
CC -0.0129 1.7e-02 0.453 -1.28
CC:followupTime 0.0003 4.6e-03 0.947 0.03
comorbidityCV1 0.69 -0.0688 7.2e-02 0.339 -6.64
comorbidityCV1:followupTime 0.0262 2.0e-02 0.189 2.66
comorbidityCVover 1 0.69 -0.1726 7.0e-02 0.014 * -15.86
comorbidityCVover 1:followupTime 0.0122 1.9e-02 0.525 1.22
comorbidityDiabetestype1 0.58 -0.0527 2.1e-01 0.800 -5.13
comorbidityDiabetestype1:followupTime 0.0317 5.2e-02 0.544 3.22
comorbidityDiabetestype2 0.65 0.0450 5.0e-02 0.365 4.60
comorbidityDiabetestype2:followupTime 0.0080 1.3e-02 0.538 0.81
comorbidityGastrointestinal 0.60 0.1229 8.6e-02 0.154 13.08
comorbidityGastrointestinal:followupTime -0.0217 2.0e-02 0.288 -2.15
CRP 0.63 0.0307 2.0e-02 0.129 3.12
CRP:followupTime -0.0074 6.0e-03 0.221 -0.74
DBP 1.00 0.0059 1.4e-02 0.672 0.59
DBP:followupTime 0.0107 4.2e-03 0.012 * 1.07
familyHistoryIHD0 0.61 0.0449 6.5e-02 0.493 4.59
followupTime 0.63 -0.0448 2.3e-02 0.056 -4.38
Hb 0.96 0.0465 1.6e-02 0.004 ** 4.76
Hb:followupTime 0.0053 6.0e-03 0.373 0.54
med.ACE.ARB -0.0119 4.0e-02 0.764 -1.19
med.ACE.ARB:followupTime 0.0164 1.2e-02 0.162 1.66
med.AlphaBlockers 0.51 0.0054 3.9e-02 0.889 0.54
med.AlphaBlockers:followupTime 0.0341 1.3e-02 0.008 ** 3.47
med.Diuretics 0.69 -0.0889 3.6e-02 0.015 * -8.50
med.Diuretics:followupTime 0.0065 1.1e-02 0.538 0.66
med.Epo 1.00 -0.1739 5.0e-02 0.001 ** -15.96
med.Epo:followupTime -0.0124 1.7e-02 0.470 -1.23
med.Iron 0.83 -0.0300 3.9e-02 0.444 -2.95
med.Iron:followupTime -0.0183 1.1e-02 0.106 -1.81
med.ParenteralIron 0.0935 4.7e-02 0.049 * 9.80
med.ParenteralIron:followupTime -0.0328 1.7e-02 0.059 -3.22
med.VitaminD 0.85 -0.0931 4.2e-02 0.027 * -8.89
med.VitaminD:followupTime -0.0153 1.6e-02 0.337 -1.52
numberAntihypertensives 0.0048 2.2e-02 0.828 0.48
numberAntihypertensives:followupTime -0.0083 6.9e-03 0.229 -0.82
occupation0ManagerialProfessional 0.55 0.0590 8.3e-02 0.479 6.08
occupation0Intermediate 0.55 0.0224 9.1e-02 0.805 2.27
occupation0NeverWorkedUnemployed 0.3974 4.0e-01 0.319 48.80
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Table 18: Standardised model summary for disease renovascular (continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
PO 1.00 -0.0929 1.6e-02 0.000 *** -8.88
PO:followupTime 0.0049 5.0e-03 0.329 0.49
PP 0.87 0.0411 1.5e-02 0.005 ** 4.19
PP:followupTime -0.0032 4.7e-03 0.490 -0.32
PTH 0.96 -0.0522 2.0e-02 0.009 ** -5.09
PTH:followupTime 0.0075 7.3e-03 0.304 0.75
Pu 0.88 -0.0121 2.4e-02 0.620 -1.21
Pu:followupTime -0.0056 4.6e-03 0.220 -0.56
smokingStatus0active 0.65 -0.2123 1.2e-01 0.074 -19.12
smokingStatus0ex-smoker 0.65 -0.1537 8.9e-02 0.087 -14.25
totalCholesterol 0.79 0.0076 1.7e-02 0.649 0.77
totalCholesterol:followupTime -0.0153 5.6e-03 0.007 ** -1.52
weeklyAlcohol01 to 14 0.68 -0.0555 8.0e-02 0.491 -5.40
weeklyAlcohol0over 14 0.68 0.1141 9.5e-02 0.229 12.09
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *




The key average effects are:
• Higher levels of Hb and total CO2 are associated with higher levels of eGFR. Note that
poor kidney function may result in low levels of Hb and total CO2.
• Vitamin D supplements are associated with lower levels of eGFR. Poor kidney function is
associated with vitamin D deficiency.
• Higher levels of PO and PTH are associated with lower levels of eGFR. Poor kidney function
is often associated with higher levels of these biochemicals.
• Older age at baseline is associated with a lower level of eGFR.
Weaker associations with a significance level of 0.01-0.05 are:
• Higher levels of Pu are associated with lower levels of eGFR. Poor kidney function is often
associated with higher levels of protein in the urine.
• DBP is associated with a less rapid decline in kidney function. This is unexpected because
as PP rises, for example with older age and worsening kidney function, the clinicians expect
DBP to fall.
• Higher numbers of AKI episodes are associated with higher levels of eGFR. This is an
anomalous result given AKI would typically be associated with poor kidney function.
However this disease group unknown is heterogeneous so perhaps the results are being
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The key temporal effects are:
• PO is associated with a more rapid decline in eGFR.
• PTH is associated with slower progression of kidney disease. This result is counterintuitive
as higher levels of PTH tend to occur with worsening kidney function.
There is also a relatively weak association between the number of antihypertensives and slower
progression. However given the heterogeneous nature of this disease group it is perhaps plausible
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Table 19: Standardised model summary for disease unknown
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 3.8130 1.4e-01 0.000 ***
age0 0.86 -0.0067 1.8e-03 0.000 *** -0.67
CC 0.57 -0.0162 1.5e-02 0.282 -1.60
CC:followupTime -0.0036 4.5e-03 0.422 -0.36
comorbidityCancercurrent 0.55 0.1650 1.3e-01 0.211 17.94
comorbidityCancercurrent:followupTime 0.0123 5.2e-02 0.814 1.23
comorbidityCancerprevious 0.55 0.0629 6.8e-02 0.356 6.49
comorbidityCancerprevious:followupTime -0.0224 1.9e-02 0.232 -2.21
DBP 0.0265 1.3e-02 0.045 * 2.68
DBP:followupTime -0.0059 4.8e-03 0.225 -0.59
followupTime 0.0238 1.6e-02 0.147 2.41
Hb 0.99 0.0633 1.8e-02 0.000 *** 6.53
Hb:followupTime 0.0021 5.7e-03 0.716 0.21
med.ACE.ARB 0.55 -0.0189 3.8e-02 0.619 -1.88
med.ACE.ARB:followupTime -0.0216 1.3e-02 0.092 -2.14
med.BetaBlockers 0.54 0.0093 4.1e-02 0.820 0.93
med.BetaBlockers:followupTime -0.0163 1.3e-02 0.226 -1.62
med.CCBs 0.70 0.0137 3.6e-02 0.700 1.38
med.CCBs:followupTime -0.0247 1.3e-02 0.057 -2.44
med.Epo 0.85 -0.0755 3.8e-02 0.046 * -7.27
med.Epo:followupTime 0.0075 1.4e-02 0.597 0.76
med.Iron -0.0240 4.0e-02 0.545 -2.37
med.Iron:followupTime 0.0151 1.3e-02 0.237 1.52
med.ParenteralIron 0.67 -0.0176 3.9e-02 0.653 -1.75
med.ParenteralIron:followupTime 0.0110 1.7e-02 0.516 1.11
med.VitaminD 0.99 -0.1207 4.3e-02 0.005 ** -11.37
med.VitaminD:followupTime -0.0134 1.3e-02 0.308 -1.33
numberAKIepisodes 0.63 0.0394 1.7e-02 0.018 * 4.02
numberAKIepisodes:followupTime -0.0054 4.8e-03 0.259 -0.54
numberAntihypertensives -0.0432 2.4e-02 0.067 -4.23
numberAntihypertensives:followupTime 0.0189 7.8e-03 0.016 * 1.91
PO 1.00 -0.0808 1.6e-02 0.000 *** -7.76
PO:followupTime -0.0206 5.3e-03 0.000 *** -2.04
PP 0.0002 1.4e-02 0.987 0.02
PP:followupTime -0.0008 5.0e-03 0.868 -0.08
PTH 0.98 -0.1248 2.0e-02 0.000 *** -11.74
PTH:followupTime 0.0208 5.8e-03 0.000 *** 2.10
Pu 0.82 -0.0377 1.5e-02 0.012 * -3.70
Pu:followupTime -0.0019 6.5e-03 0.765 -0.19
totalCholesterol 0.58 0.0016 1.6e-02 0.922 0.16
totalCholesterol:followupTime 0.0093 5.3e-03 0.079 0.93
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Table 19: Standardised model summary for disease unknown (continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
totalCO2 1.00 0.0528 1.6e-02 0.001 ** 5.43
totalCO2:followupTime -0.0080 5.1e-03 0.119 -0.79
weeklyAlcohol01 to 14 0.51 -0.0494 5.2e-02 0.343 -4.82
weeklyAlcohol0over 14 0.51 0.0834 6.4e-02 0.192 8.70
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *
c (∆rYˆ ∗)% = 100(exp(βˆ′rθ′r)− 1) with θ′r = 1
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7.3.9 Single model all diseases
As shown in Table 20 the model for this category has disease as an explanatory variable. As this
explanatory variable is not directly of interest we do not include it in Figures 36 and 37.
Average effects
The key average effects are:
• High levels of the biochemicals CC, PO and PTH are associated with lower levels of eGFR.
• A higher count of cardiovascular (CV) diseases is associated with lower levels of eGFR.
• Higher levels of Hb and total CO2 are associated with higher levels of eGFR. (Note that
poor kidney function may result in low levels of Hb and total CO2.)
• The ACE inhibitors and ARBs (med.ACE.ARB) are associated with higher levels of eGFR.
• The treatments EPO, diuretics and vitamin D are associated with lower levels of eGFR
• Older age at baseline is associated with a lower level of eGFR.
Weaker associations at the 0.01-0.05 significance level are:
• The treatments CCBs and ‘other medications’ are associated with lower levels of eGFR.
• Higher values of PP are associated with higher levels of eGFR. This result is counterintuitive
as it is expected that PP will increase with age, worsening kidney function and poorer
cardiovascular health.
• Higher levels of total cholesterol are associated with higher levels of eGFR. It is unclear why
this should be the case when higher cholesterol is typically associated with poorer health.
• Higher values of DBP are associated with higher levels of eGFR. This is not expected as





























( ∆r Y^  *)%  = 100(exp( β^ 'r θ 'r )−1)  with θ 'r = 1
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05




The key temporal effects are:
• A negative value of follow-up time indicates that eGFR is falling off over time. The
dominance of follow-up time may indicate that our model and the SKS dataset are missing
at least one key factor.
• Hb is associated with a less rapid decline in eGFR.
• PO, Pu and total CO2 are associated in a more rapid decline in eGFR.
• PTH is associated with a less rapid decline in eGFR. This is an unexpected result as the
risk of increased PTH is associated with poorer kidney function.
We also note that iron taken orally is relatively weakly associated with a more rapid decline in
eGFR. As kidney function reduces there is an increased likelihood of anaemia. One treatment
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Figure 37: Temporal effects - relative change in eGFR for standardised model using 95% CIs:
single model all diseases
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Parameter values
Table 20: Standardised model summary for single model all diseases
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
(Intercept) 1.00 3.9816 5.5e-02 0.000 ***
age0 1.00 -0.0070 7.1e-04 0.000 *** -0.69
CC 0.89 -0.0155 4.9e-03 0.002 ** -1.54
CC:followupTime -0.0007 1.3e-03 0.592 -0.07
comorbidityCancercurrent 0.72 0.0259 3.8e-02 0.495 2.62
comorbidityCancercurrent:followupTime -0.0009 9.8e-03 0.926 -0.09
comorbidityCancerprevious 0.72 -0.0488 2.5e-02 0.053 -4.76
comorbidityCancerprevious:followupTime 0.0056 6.2e-03 0.367 0.56
comorbidityCV1 0.80 -0.0329 1.5e-02 0.031 * -3.23
comorbidityCV1:followupTime 0.0003 4.3e-03 0.947 0.03
comorbidityCVover 1 0.80 -0.0485 1.8e-02 0.007 ** -4.74
comorbidityCVover 1:followupTime 0.0059 4.7e-03 0.211 0.60
DBP 1.00 0.0107 4.3e-03 0.013 * 1.08
DBP:followupTime 0.0011 1.4e-03 0.419 0.11
disease diabetic nephropathy 1.00 -0.0963 3.2e-02 0.003 ** -9.18
disease glomerulonephritis 1.00 0.0091 3.4e-02 0.788 0.91
disease HKD 1.00 -0.0536 3.5e-02 0.124 -5.22
disease obstruction 1.00 -0.3433 8.5e-02 0.000 *** -29.05
disease polycystic kidney disease 1.00 -0.1782 4.4e-02 0.000 *** -16.32
disease pyelonephritis 1.00 -0.1395 4.4e-02 0.001 ** -13.02
disease renovascular disease 1.00 -0.0197 4.1e-02 0.633 -1.95
disease unknown 1.00 -0.0556 3.5e-02 0.110 -5.41
followupTime 1.00 -0.0357 8.9e-03 0.000 *** -3.51
Hb 1.00 0.0546 5.5e-03 0.000 *** 5.61
Hb:followupTime 0.0057 1.7e-03 0.001 ** 0.57
med.ACE.ARB 0.97 0.0447 1.4e-02 0.001 ** 4.57
med.ACE.ARB:followupTime -0.0063 3.8e-03 0.099 -0.63
med.AlphaBlockers 0.83 -0.0169 1.4e-02 0.240 -1.67
med.AlphaBlockers:followupTime -0.0052 4.2e-03 0.214 -0.52
med.CCBs 0.72 -0.0311 1.3e-02 0.018 * -3.06
med.CCBs:followupTime -0.0007 3.8e-03 0.847 -0.07
med.Diuretics 0.85 -0.0426 1.3e-02 0.001 ** -4.17
med.Diuretics:followupTime 0.0058 3.9e-03 0.138 0.58
med.Epo 1.00 -0.0745 1.3e-02 0.000 *** -7.18
med.Epo:followupTime -0.0052 3.9e-03 0.184 -0.52
med.Iron 0.54 0.0077 1.4e-02 0.586 0.77
med.Iron:followupTime -0.0090 4.3e-03 0.035 * -0.90
med.Other 0.58 -0.0507 2.4e-02 0.035 * -4.95
med.Other:followupTime 0.0133 7.3e-03 0.067 1.34
med.ParenteralIron 0.71 -0.0228 1.3e-02 0.076 -2.26
med.ParenteralIron:followupTime 0.0007 4.1e-03 0.860 0.07
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Table 20: Standardised model summary for single model all diseases (continued)
parameter propa βˆ′r se p-value starsb (∆rYˆ ∗)% c
med.VitaminD 1.00 -0.1429 1.4e-02 0.000 *** -13.32
med.VitaminD:followupTime 0.0064 3.8e-03 0.093 0.64
numberAKIepisodes 0.77 -0.0045 4.9e-03 0.360 -0.45
numberAKIepisodes:followupTime -0.0010 1.2e-03 0.408 -0.10
numberAntihypertensives 0.62 -0.0126 9.9e-03 0.202 -1.25
numberAntihypertensives:followupTime -0.0012 2.7e-03 0.675 -0.12
numberClinicVisits 0.99 -0.0065 4.3e-03 0.129 -0.65
numberClinicVisits:followupTime -0.0006 1.2e-03 0.599 -0.06
PO 1.00 -0.1023 5.5e-03 0.000 *** -9.72
PO:followupTime -0.0050 1.6e-03 0.002 ** -0.50
PP 0.92 0.0123 4.8e-03 0.011 * 1.24
PP:followupTime 0.0002 1.5e-03 0.874 0.02
PTH 1.00 -0.0836 6.4e-03 0.000 *** -8.02
PTH:followupTime 0.0093 1.5e-03 0.000 *** 0.94
Pu 0.93 0.0033 5.7e-03 0.561 0.33
Pu:followupTime -0.0116 1.7e-03 0.000 *** -1.15
totalCholesterol 0.62 0.0117 5.6e-03 0.036 * 1.18
totalCholesterol:followupTime -0.0014 1.8e-03 0.421 -0.14
totalCO2 1.00 0.0488 5.1e-03 0.000 *** 5.00
totalCO2:followupTime -0.0059 1.5e-03 0.000 *** -0.59
a proportion of bootstraps in which variable was selected
b p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *
c (∆rYˆ ∗)% = 100(exp(βˆ′rθ′r)− 1) with θ′r = 1
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7.4 Rates of change over time
Here we estimate the average, population level, rates of change over time using the time derivative
method described in Section 4.2. We use the explanatory variables selected in section 5 but do
not standardise them when fitting the LME model described by Equation 2 in Section 3. The
estimated regression coefficients are used when computing the expected rates over time. Note
that we do not fit the time derivative of the LME model. All rates of change estimates are based
on patients with more than 2 follow-up records. For a given variable the average rates over time
for each individual are computed, after which we use bootstrapping to obtain summary statistics;
we resample with replacement 2,000 times. The 95% confidence intervals are calculated using a
non-parametric bootstrap confidence interval method. Specifically, they are computed using the
adjusted bootstrap percentile method (in particular the bias-corrected and accelerated method,
BCa) provided by the boot::boot.ci() R-function, for details see (83,84). In Sections 7.4.2 to
7.4.11 a quantity is significant if these confidence intervals do not cover zero.
First, in Section 7.4.1 we give the expected rate of change of the outcome variable eGFR for
each disease category. This is estimated with E( ˙ˆY ∗i ) as described in Section 4.2.2. These results
constitute our main findings regarding rates. Secondly, in Sections 7.4.2 to 7.4.11 we show the
breakdown of the estimated rates for each disease category. In particular we compute E( ˙ˆY ∗(r)i )
with Equation 23. These results are shown in Figures 39 to 47 and tabulated in Tables 22 to 30.
These results are supplementary to those reported in Section 7.4.1.
7.4.1 Overall average rate of decline for each disease
Figure 38 shows the average annual rate of decline in eGFR for each disease category; details
are given in Table 21. We consider all these rates to be significant in so much as the confidence
intervals do not cover zero. As shown the entire cohort, ‘single model all diseases’ labelled ‘All’,
is on average loosing eGFR at a rate of -1.1 mL/min/1.73m2/year. In contrast PKD has the
highest rate at -3.5 mL/min/1.73m2/year.
In 2013, using the SKS data, Hoefield (85) reported that PKD and diabetic nephropathy patients
exhibited on average a 2.7 (± 0.3) and 0.7 (± 0.3) ml/min/1.73m2/year faster rate of decline
in eGFR, respectively, compared to patients with glomerulonephritis. In these terms, with our
model, we report patients with PKD and diabetic nephropathy have on average a 2.5 (± 0.1)
and 0.6 (± 0.05) ml/min/1.73m2/year faster rate of decline in eGFR, respectively, compared
to those with glomerulonephritis. Given the whole cohort Hoefield (85) reports a median of
-1.2 (IQR: -3.6, 0.2) ml/min/1.73m2/year whereas we report a median of -0.9 (IQR: -2.1, 0.1)
mL/min/1.73m2/year. Furthermore our estimates for average annual rates of decline of diabetic
nephropathy and PKD, 1.5 mL/min/1.73m2/year and 3.5 mL/min/1.73m2/year, respectively,
are similar to those reported elsewhere. For example (32) reports the average rate of decline for
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diabetic nephropathy as 1.7 mL/min/1.73m2/year (32), and (33) reports ~3 mL/min/1.73m2/year

















Figure 38: Estimated rate of decline in eGFR by disease
Table 21: Summary for rates of change in eGFR across all diseases
disease category E( ˙ˆY ∗i ) CI






renovascular disease -0.33 (-0.60,-0.08)
unknown -0.42 (-0.70,-0.11)
single model all diseases -1.08 (-1.20,-0.97)
Note:
E( ˙ˆY ∗i ) has units mL/min/1.73m2/year
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7.4.2 Diabetic nephropathy
On average across the population the dominant terms:
• bodyMassIndex:followupTime, CC:followupTime, Hb:followupTime, PO:followupTime con-
tribute to a less rapid decline in kidney function; i.e. terms have positive slope.
• DBP:followupTime, med.ACE.ARB:followupTime, numberAntihypertensives:followupTime,
PP:followupTime, PTH and Pu:followupTime contribute to a more rapid decline in kidney
function; i.e. terms have negative slope.
Note that each term is comprised of a regression parameter multiplied by the averaged time




































p−value significance:  significant not significant
Figure 39: Rate estimates with 95% CIs for diabetic nephropathy
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Table 22: Estimated average rate of change over time for disease diabetic
nephropathy
parameter E( ˙ˆY ∗(r)i ) CI
overall trend

































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.3 Glomerulonephritis
On average across the population the dominant terms:
• DBP:followupTime, Hb:followupTime and PTH:followupTime contribute to a less rapid
decline in kidney function.
• med.ACE.ARB:followupTime, PO:followupTime, PTH, Pu:followupTime and to-






































p−value significance:  significant not significant
Figure 40: Rate estimates with 95% CIs for glomerulonephritis
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Table 23: Estimated average rate of change over time for disease glomeru-
lonephritis
parameter E( ˙ˆY ∗(r)i ) CI
overall trend



































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.4 Hypertensive kidney disease
On average across the population the dominant terms:
• CC:followupTime, Hb:followupTime, PP:followupTime and numberAntihyperten-
sives:followupTime contribute to a less rapid decline in kidney function.
• numberClinicVisits:followupTime, PO:followupTime, Pu:followupTime and to-









































p−value significance:  significant not significant
Figure 41: Rate estimates with 95% CIs for HKD
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Table 24: Estimated average rate of change over time for disease HKD
parameter E( ˙ˆY ∗(r)i ) CI
overall trend






































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.5 Other
On average across the population the dominant terms:
• CC:followupTime, numberClinicVisits, PTH:followupTime and totalCO2:followupTime
contribute to a less rapid decline in kidney function.




































p−value significance:  significant not significant
Figure 42: Rate estimates with 95% CIs for disease other
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Table 25: Estimated average rate of change over time for disease other
parameter E( ˙ˆY ∗(r)i ) CI
overall trend
































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.6 PKD
On average across the population the dominant terms:
• Hb:followupTime and numberAntihypertensives:followupTime contribute to a less rapid
decline in kidney function.
• CC:followupTime, PO:followupTime and totalCO2:followupTime contribute to a more rapid







































p−value significance:  significant not significant
Figure 43: Rate estimates with 95% CIs for PKD
120
Table 26: Estimated average rate of change over time for disease PKD
parameter E( ˙ˆY ∗(r)i ) CI
overall trend




































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.7 Pyelonephritis
On average across the population the dominant terms:
• bodyMassIndex:followupTime, Hb:followupTime and PP:followupTime contribute to a less
rapid decline in kidney function.













































p−value significance:  significant not significant
Figure 44: Rate estimates with 95% CIs for pyelonephritis
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Table 27: Estimated average rate of change over time for disease pyelonephritis
parameter E( ˙ˆY ∗(r)i ) CI
overall trend










































Table 27: Estimated average rate of change over time for disease pyelonephritis
(continued)
parameter E( ˙ˆY ∗(r)i ) CI
Note:
E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
7.4.8 Renovascular
On average across the population the dominant terms:
• DBP:followupTime, Hb:followupTime and PO:followupTime contribute to a less rapid
decline in kidney function.
• numberAntihypertensives:followupTime and totalCholesterol:followupTime contribute to a








































p−value significance:  significant not significant
Figure 45: Rate estimates with 95% CIs for renovascular
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Table 28: Estimated average rate of change over time for disease renovascular
disease
parameter E( ˙ˆY ∗(r)i ) CI
overall trend





































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.9 Unknown disease
On average across the population the dominant terms:
• Hb:followupTime, numberAntihypertensives:followupTime, PTH:followupTime and totalC-
holesterol:followupTime contribute to a less rapid decline in kidney function.
• CC:followupTime, DBP:followupTime, PO:followupTime and totalCO2:followupTime con-







































p−value significance:  significant not significant
Figure 46: Rate estimates with 95% CIs for disease unknown
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Table 29: Estimated average rate of change over time for disease unknown
parameter E( ˙ˆY ∗(r)i ) CI
overall trend




































E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
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7.4.10 Single model all diseases
On average across the population the dominant terms:
• DBP:followupTime, Hb:followupTime, med.Other:followupTime and PTH:followupTime
contribute to a less rapid decline in kidney function.
• CC:followupTime, med.ACE.ARB:followupTime, PO, PO:followupTime, PTH,
Pu:followupTime, totalCholesterol:followupTime and totalCO2:followupTime contribute to













































p−value significance:  significant not significant
Figure 47: Rate estimates with 95% CIs for single model all diseases
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Table 30: Estimated average rate of change over time for single model all
diseases
parameter E( ˙ˆY ∗(r)i ) CI
overall trend









































Table 30: Estimated average rate of change over time for single model all
diseases (continued)
parameter E( ˙ˆY ∗(r)i ) CI
PP:followupTime 0.03 (0.02,0.03)
Note:
E( ˙ˆY ∗(r)i ) has units mL/min/1.73m2/year
7.4.11 Summary
The terms which most frequently occurred overall the disease categories were:
• Hb:followupTime contributing to a less rapid decline in kidney function.
• CC:followupTime, PO:followupTime and totalCO2:followupTime contributing to a more
rapid decline in kidney function.
7.5 Counterintuitive results
There are a few clinically counterintuitive results reported above, two of the most commonly
occurring relate to PP and DBP. Given the variety and quantity of blood pressure moderating
drugs that most patients are taking it is difficult, and beyond the scope of this current work, to
draw any conclusions regarding these results. The other frequently occurring unexpected result
relates to the interaction term for PTH with follow-up time, we focus on this below.
As reported in Sections 7.2 and 7.3 we consistently found the counterintuitive result that the
interaction of PTH with follow-up time is associated with a slower progression of kidney disease,
hence it is associated with a shallower slope in eGFR over time. This result is, for example,
observed in Table 11. In some LME models the interaction term for PTH with follow-up time
(denoted as PTH:followupTime) has a regression parameter with a positive sign and is also
statistically significant at the 0.05 level. We seek to determine if this effect is an artefact of the
LME model or a real effect present in the SKS data. Throughout this analysis we use the ‘single
model all diseases’ data.
We begin by exploring the data. We compute the average time derivative per patient of a given
variable by applying the techniques described in Section 4.2. That is for a given patient and
variable with values at discrete time points, we compute the derivative of the spline and then
find its expected value to obtain the average slope over time. This allows us to generate Figures
48 and 49 both of which show the average quantities per patient. Figure 48 shows that steeper
slopes in log(eGFR) are associated with higher levels of PTH; correlation -0.35. In Figure 49 we
observe that steeper slopes in log(eGFR) are associated with steeper slopes in PTH; correlation
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-0.43. The results in these figures are clinically plausible, but inconsistent with the aforementioned
counterintuitive LME model results relating to the interaction term for PTH with follow-up time.





























Figure 49: Average time derivative of log(eGFR) per patient versus average time derivative of
PTH per patient
We now seek to identify the reason why our LME model may be giving a clinically counterintuitive
result for the interaction term relating to PTH and follow-up time. We modify our intercept-and-
slope LME model such that the fixed effects are reduced to the following terms β0 + β1XPTH +
β2XPTHt + β3t; note that t is follow-up time and the outcome variable is log(eGFR). With
this reduced model we again find the counterintuitive result that the regression coefficient of
the interaction term, β2, is positive and statistically significant at the 0.01 level. If we use this
reduced model but instead use a subset of the data for which the average rate of change of eGFR
is negative for each patient, we find that the regression coefficient β2 is positive but is no longer
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statistically significant at the 0.05 level. When the PTH:followupTime regression coefficient is
not statistically significant we interpret this to mean that PTH does not markedly influence the
progression of disease, that is at population level PTH does not significantly increase or decrease
the slope of eGFR.
We conclude, taking into account the reduced LME model using only negative eGFR slopes,
that the difference between the PTH:followupTime parameter estimate versus the eGFR slopes
in Figure 48 is due to the former being a population level estimate and the latter being an
individual level estimate. In the former case our LME model is estimating the effect of PTH on
the average slope of log(eGFR) given the population, but this average slope may not actually exist
for any individual. In the latter case we are considering the average effect of PTH on individual
log(eGFR) slopes, this is what the clinicians are interested in and what informs their clinical
intuition. In summary, the so-called ‘counterintuitive’ result regarding PTH:followupTime is a
consequence of the way our model is summarising the data at population level.
7.6 Correlation between baseline eGFR and its rate of change
In 2013, using the SKS data, Hoefield (85) reported a link between the rate of change of eGFR
and baseline eGFR, in particular patients with a higher baseline eGFR had on average a faster
decline in kidney function. Disease categories considered were PKD, diabetic nephropathy and
glomerulonephritis. In the Results section of (85) Hoefield states, “Patients with stage 3a CKD at
inception into the cohort were associated with more rapid median rates of decline in renal function
at -2.06 ml/min/year compared with -1.24, -1.15 and -0.93 ml/min/year in those with CKD
stages 3b, 4 and 5, respectively. . . . Estimated average decline in eGFR was between 0.8 and 1.6
ml/min/year slower in those patients with eGFR <45 ml/min compared to those with eGFR >45
ml/min at baseline.” However, as discussed in the following, this appears to be inconsistent with
our analysis. Note that 45 ml/min equates to 3.8 on the log(eGFR) scale.
By using the techniques described in Section 4.2 we calculated the average time derivative of
log(eGFR) per patient, i.e. E( ˙ˆY i). That is for given values at discrete time points we computed
the derivative of the spline and then found its expected value to obtain the average slope over
time of log(eGFR). For each patient in each disease group Figure 50 displays the average slope
in log(eGFR) against baseline log(eGFR). This figure indicates that for most disease categories
patients with lower baseline eGFR tend to have faster rates of decline in kidney function. For
patients within each kidney disease category we computed the correlation between baseline
log(eGFR) and average slope in log(eGFR). Excluding PKD we found that no disease had a
correlation greater than 0.27. In contrast PKD had a relatively high correlation of 0.47. It follows
that PKD patients with the steepest negative slopes and fastest rates of decline on average enter
the study with lower log(eGFR) values; this correlation is directionally different from Hoefield
(85). Similarly, as shown in Figure 50, other diseases in our study also have weak correlations
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which are also directionally different from Hoefield (85). We therefore conclude that our results
appear inconsistent with Hoefield (85). Future work could investigate the exact details of the






























































































































single model all diseases
cor = 0.12
Figure 50: Average slope in log(eGFR) per patient versus baseline log(eGFR)
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8 Discussion
8.1 Summary of main results
The aim of this research was to identify key risk factors associated with the progression of kidney
disease both across and within eight primary kidney diseases. We used data collected from more
than 3000 secondary care patients who had moderate to severe chronic kidney disease and were
followed up until they reached an end point of dialysis, kidney transplant or death. Potential
risk factors recorded at each annual follow-up appointment included comorbidities, medications,
lifestyle factors, socio-demographic information and biochemical marker measurements.
To assess the importance of each of these potential risk factors for each disease we used standard
longitudinal modelling techniques, specifically the LME model. We employed commonly used
techniques, including bootstrapping, to access model fit and select the pertinent regression
parameters for each model. Our main interest was in the fixed effects regression parameters which
were used to identify key population level risk factors for each disease category.
First, given our LME for each disease category, we considered the population average level of
eGFR: in our models these were the non-interaction terms. We found the risk factors for lower
levels of eGFR included biochemical markers and medications, in contrast lifestyle parameters and
physical attributes were less important. From a biological perspective we expect the biochemical
markers to reflect worsening kidney function, this is consistent with our findings. It may be of
future interest to examine the biochemical markers more closely as the differences we observed
between diseases could be of clinical value in terms of potential treatment options. Medications
play an important role, most notably ACE inhibitors and/or ARBs result in higher levels of
eGFR for diabetic nephropathy and glomerulonephritis but not in the other diseases. Also of
clinical interest is the role of anaemia management, this enters into our results through iron and
EPO medications which we have shown to be strongly associated with diabetic nephropathy. In
our results lifestyle parameters did not play a significant role, this could be because these risk
factors contained so much missing data that we found it necessary to reduce them to baseline
variables (e.g. smoking status, occupation, alcohol intake). As expected, baseline age was a
clear risk factor. Body mass index was only strongly associated with diabetic nephropathy, this
association is unsurprising in light of the fact that being overweight is a risk factor for type 2
diabetes. Interestingly, although not significant, the model did identify sex as associated with
pyelonephritis. This association is clinically plausible given females are more susceptible to urinary
track infections which can contribute to pyelonephritis.
Secondly, given our LME for each disease category, we consider the rate of progression of eGFR
over time. In our models these are the interaction terms with time, i.e. explanatoryVariable
: followupTime. These temporal effects are harder to interpret clinically as they relate to a
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population trajectory which may never be observed in clinical practice where the focus is on
individuals. This population level effect has in part led to results which go against clinical intuition,
e.g. high levels of PTH being associated with less rapid decline in kidney disease. However our
model did identify that rapid progression of kidney disease is associated with biochemical markers
including PO, PTH and total CO2: this is biologically plausible. In general we found that
medications and comorbidities were not key in rapid disease progression. In the future more work
is needed to consider a wider range of statistical methods which could lead to clearer identification
of risk factors relating to the progression of kidney disease over time. Perhaps a more nuanced
approach could better identify risk factors such as comorbidities and/or medications.
Thirdly, we used a more novel approach towards understanding disease progression by considering
time derivative of the fitted LME model. We found, given all disease categories, that PKD had the
most rapid progression of kidney disease, with a loss in eGFR of 3.5 mL/min/1.73m2/year whereas
the rest of the categories show a loss of around 0.5-1.5 mL/min/1.73m2/year: these results are
consistent with previous work. In addition we also reported the breakdown of rates for each risk
factor: these results were consistent with our aforementioned results. This is unsurprising given
they have the same model at their foundation. Given each continuous variable it may have been
more informative to combine the non-interaction and interaction term into a single term, this
would then describe all time variability of the given risk factor in single quantity. This approach
might better describe the relative importance of the risk factors and could lead to a resolution of
the counterintuitive results mentioned in the previous paragraph. Further research is needed into
the best approaches for determining risk factors in relation to rates of change over time of an
outcome of interest.
Many of the risk factors we identified match clinical intuition and thereby confirm what is already
known in clinical practice. However in some instances our results point towards a need for further
clinical studies, most notably the common clinical practice of prescribing ACE inhibitors and
ARBs regardless of the kidney disease type. Our identification of key risk factors relating to kidney
disease progression has implications for the monitoring and treatment of future chronic kidney
disease patients. Below in Sections 8.4 and 8.5 we discuss these in more detail, specifically potential




Since 2002 the ongoing SKS study has recruited over 3000 secondary care patients who are
followed-up annually. SKS has well defined end-points which in part ensures patients have
comparable stages of kidney disease; patients are removed from the study once they commence
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RRT or die. In addition biochemical data is collected outside follow-up appointments, during
routine clinic visits and during acute episodes of illness e.g. AKI. This is a very rich dataset
containing, after cleaning and before imputation, 1,103,163 distinct units of information. SKS is
one of the largest and longest ongoing studies of its kind in the world. There is a similar ongoing
study, The Chronic Renal Insufficiency Cohort (CRIC), which since 2001 has recruited about 5500
adult CKD patients from 11 clinical sites across the United States, this study also has the core
aims of investigating risk factors for CKD progression and links to cardiovascular disease (86,87).
There is a significant ethnic difference between SKS and CRIC in that by design CRIC has 40%
African American and 10% Latino/Hispanic or Asian/Pacific Islander. Both studies capture a
broad range of potential risk factors for each patient, these include biochemical, comorbidity,
medication, lifestyle and socio-economic demographic data.
8.2.2 Limitations and weaknesses
There is clearly a limit on that which can reasonably be recorded at a follow-up appointment
by a clinician whose first priority is to patient care rather than data collection. This trade-off
has resulted in considerable incomplete records in the data, in total about 71% of all follow-up
appointment data has at least one field missing; mostly because it was not recorded but sometimes
because it was incorrect so was deleted by our ‘data cleaning’ procedures. In addition the
biochemical data collected from each patient at their follow-up appointment typically takes several
days to be processed and is recorded in a separate database. This makes matching the biochemical
data with the SKS data non-trivial, if no match is found and imputation is not possible the whole
follow-up appointment record is unusable when modelling. If creatinine is not measured at a
follow-up then all the data from that appointment will be discarded as we do not impute the
model outcome variable.
The significant quantity of missing data resulted in us resorting to imputation methods to gain
statistical power in our models. This meant we had to make several pragmatic decisions as
follows. If a patient is recorded as having a comorbidity we assume they have the condition for
all future time, which is a reasonable assumption for all chronic conditions. We relied on the first
instance of a comorbidity being recorded correctly; if a given patient was mistakenly recorded
as having a particular comorbidity we then propagate this error through all their subsequent
follow-ups since there is no mechanism by which we can determine the recording mistake. At a
given follow-up, if at least one medication is recorded then we assign the patient as either taking,
or not taking, medications in all of the aforementioned medication categories. We therefore
assume all medications have been correctly recorded in the SKS data at the follow-up. Only at
follow-up appointments where no medications are recorded do we impute this data.
Where possible continuous variables are imputed using the Kalman method as described in
Section 2.7. However this does not allow upper and lower bounds on the values it returns so
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potentially it could return negative values. This would lead to erroneous imputed values since all
our continuous variables are take positive values. Our pragmatic solution was first to transform
each field onto the log scale, secondly perform imputation by the Kalman method, and finally
transform back to the original scale. We expect this to cause some minor dependencies since a
log transformation will result in an approximately linear imputation on the log scale instead of
on the original scale. However if the measured values are falling or rising according to a power
law on their original scale, as many biological systems/markers do, they will be linear on the log
scale in which case linear imputation is ideal.
8.2.3 Recommendations
We used imputation to replace missing values, but this was performed on each subject separately
where each field for which we imputed values was treated as a timeseries. All subjects and fields
were therefore treated as if they were mutually independent and all values once imputed were
treated as if they were real measured values with no acknowledgement of uncertainty; clearly this
could lead to over-confidence in the model results and future work should consider addressing
this. It would be of interest to investigate more sophisticated imputation methods. Multiple
Imputation by Chained Equations (MICE), e.g. see (58,88), is a very popular method which uses
a series of regression models where each variable with missing values is modelled conditional on
the other variables within the data. As such each variable can be modelled with respect to its
distribution; e.g. continuous variables are modelled with linear regression and binary variables
with logistic regression. Assuming we believe all values are missing at random then a timeseries
extension of MICE should improve our imputation, but to the author’s knowledge no such method
exists. Perhaps in the future such a method could be developed. With a view to improving upon
our strategy of transforming to a log scale prior to imputation, future work should also consider
imputation methods that would assure the imputed (biochemical) values were always positive.
For categories, such as medications, where drugs could be prescribed intermittently rather than
attempting to impute data it may of interest to investigate if it would be more appropriate to
give a medication category three levels ‘taking drug’, ‘not taking drug’ and ‘unknown if taking
drug’. The final level ‘unknown if taking drug’ may allow for the model to take better account of
the missing data.
The original raw SKS dataset was far from clean as detailed in Appendix A.1. As a result
considerable time and effort was spent cleaning it before any analysis could commence. We
recommend, for example, recording all measured values of a given variable in the same units.
Furthermore many issues with poorly recorded or missing data could relatively easily be overcome
by incorporating user-friendly front-end software on the SKS Microsoft Access database. This
front-end software could be used by the clinician or nurse to enter the data into the database;
Figure 51 shows an illustrative example.
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Figure 51: Illustration of front-end software for entering data to database
Benefits of front-end software include:
• when appropriate, automatically update fields using data from previous follow-ups
(e.g. chronic comorbities, such as amputation) so that once it is recorded it is automatically
recorded at all future appointments unless the user takes action to remove it (e.g. if
amputation was erroneously recorded)
• appointment dates would be accurate and use a consistent format i.e. free from reverse
ordering year/month/day
• units of measurements would be consistent e.g. height in metres and weight in kilograms
• database table names and table column headings would by default use consistent naming
conventions
• the front-end software could automatically run checks to make sure certain types of data
were realistic e.g. dates of birth, DBP is less than SBP, remove erroneous characters
• where possible drop-down menus would contain lists (e.g. of comorbidities, medications) to
ensure consistent data and avoid erroneous character entries and misspellings
• free text boxes could be used for additional information e.g. less common medications or
rarer comorbidities
• the medications the patients were taking at the last follow-up could be displayed on the
screen, the accuracy of the patient self-reporting or a clinician reading other medical notes
could perhaps be improved if the medication changes since the last follow-up were more
obvious.
However such a front-end would not be without its drawbacks. The front-end would need
142
maintaining, for example it may need updating if the underlying structure of the database changes
e.g. a new field is added. Moreover if the front-end constrains the range of values too much this
could potentially make it impossible to record unusual/unexpected values. Such outliers could
represent vital information from both a medical and/or research perspective.
Front-end software can be added to any Microsoft Access Database, in the past the author of
this thesis has programmed such software using SQL embedded in Visual Basic. Such software
could not guarantee clean data but it could hope to reduce both missing values and recording
mistakes. Overall, front-end software could dramatically improve the data quality, reduce the
need to impute data, substantially decrease the quantity of intricate data cleaning code, and
crucially improve the statistical power of the models.
8.3 Statistical model
8.3.1 Strengths
We have shown that our models have good fits for all disease categories and where known that
our parameter estimates are clinically plausible. These claims are in part supported by both
the literature and expertise of the SKS clinicians. We used multiple bootstrap samples during
the model selection procedure to help guard against overfitting to our data. This also allowed
us to take into account parameter uncertainty when selecting the final model for each disease.
We were able to utilise the LME model which is a long-standing standard framework frequently
used for longitudinal analysis. This allowed us to use established software for fitting our models.
Unlike the Generalised Estimating Equation (GEE) framework, another standard approach for
estimating parameters in longitudinal linear regression models, the LME can accommodate
missing longitudinal data (e.g. missing annual follow-ups) and differing lengths of time in the
study; these characteristics are abundant in our data.
8.3.2 Limitations and weaknesses
For model selection we used a stepwise regression procedure with AIC as there were a large
number of potential explanatory variables and no underlying theory on which to base model
selection beyond some advice from the clinicians. To make selecting explanatory variables from
a large pool more robust to overfitting we repeated the stepwise regression procedure on 100
bootstrap samples for each disease model. We consider this an acceptable number of bootstrap
samples. However, although more bootstrap samples would obviously add greater statistical
weight to our parameter selection, we were constrained by computation time. The largest dataset
was for ‘single model all diseases’ which took ~100 hours to process with 100 bootstrap samples
on a single processor (Intel(R) Core(TM) i7 CPU @ 2.70GHz); we parallel processed by disease
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model. The final model for each disease was chosen using parameters which occurred in more
than 50% of all bootstrap samples but this percentage was an arbitrary choice. Note that the
lengthy computation time meant we only split our data into training and validation data as
cross-validation was impractical. If future work aims to check overfitting on a subset(s) of data it
should consider using cross-validation techniques.
Fitting the final selected model obtained using stepwise regression has a long history of being
criticised in the literature especially when parameter estimates, p-values and confidence intervals
are reported without adjusting them to account for the model building process e.g. see (89,90).
For example, Harrell (91), states that parameter estimates are biased away from zero, while
standard errors and p-values are biased toward zero. In practice there may be no reasonable way
of correcting for these problems. We acknowledge the stepwise regression procedure with AIC
is imperfect which is why we employed it within a bootstrapping scheme. A deep analysis of
uncertainties which accounts for the model building procedure is beyond the scope of this thesis,
hence our final selected models are reported without incorporating model selection uncertainty.
We also note that we report results without accounting for uncertainty induced by imputing
missing values.
Machine learning involves using algorithms which can learn from, and make predictions on, data.
In this context it is commonplace to fit a model to training data and assess the relevant aspects
of the fit using validation data; for example see (92) for a review relating to the evaluation of
regression models. In terms of a regression model, such as an LME, if predictions are the aim
then it is reasonable to fit the model to the training data and assess the quality of predictions
using validation data. Here our focus is on identifying the regression parameters pertinent to
each disease category. However we have a large pool of regression parameters each of which may,
or may not, be selected in each of our final disease models; as a result overfitting to our data is a
potential hazard. We would like our model to generalise to future SKS data and new datasets,
therefore in our context a legitimate concern is overfitting to the current SKS data. To this end
we undertook model selection on the training data and then determined if the final model selected
also fitted within reason to the validation data. In Section 6.2, we examined parameter estimates,
confidence intervals and residuals, given each disease’s final model for each dataset (training
and validation). This approach is open to criticism, the small sample size of the validation data,
as compared to the training data, will always result in wide confidence intervals on parameter
estimates. As a result a comparison of parameter estimate confidence intervals between these
two datasets is a weak test of overfitting. Although for LME models the maximum likelihood
estimates are consistent, the bias in a small sample is potentially large. As a consequence differing
estimates between training and validation datasets are a necessary but not sufficient condition for
concluding that overfitting has occurred. If one of our models had failed to fit to the validation
data then this would have alerted us to the possibility of a potential problem with that model fit
and would have prompted further investigations into the selected model. After selecting the model
144
with our bootstrapping procedure we used training and validation data on the understanding
that it offers no more than a final weak test of overfitting. Future work should consider the use of
training and validation datasets in greater detail, if the decision is made to use them, then robust
evaluation procedures, such as those described by (92), should be implemented.
A further shortcoming of the use of training and validation datasets was that it would have
prevented us from creating a model for disease ‘obstruction’ as there was insufficient data; in
total (before splitting) there were 23 patients with a total of 49 follow-up records. It was beyond
the scope of this thesis to consider constructing a separate model for this small group of patients.
We acknowledge that the LME model assumes any measurement error in explanatory variables is
negligible compared with the within-group errors ij (see Equation 2), in essence we are treating
explanatory variable observations as exact; this is the usual assumption in the literature. Although
beyond the scope of this thesis, it would not be unreasonable in the future to consider the extent
to which this assumption is reasonable in clinical practice particularly in relation to biochemical
measurements and other biological measurements such as blood pressure. If this assumption
was shown to be suboptimal then such explanatory variables may be both time-dependent and
stochastic; for example see (65) Chapter 12.3 for a framework relating to longitudinal models
with stochastic covariates. A way forward would be with a joint modelling framework where each
such variable in our existing LME model is replaced by a stochastic process; this could be fitted
using a 2-stage process which first fits each explanatory variable model and secondly fits the
longitudinal LME model.
We observe a noteworthy quantity of autocorrelation in the residual plots of Figures 8-16. We
explored all relevant predefined correlation structures (compound symmetry (CS), first order
continuous-time autoregressive (CAR1) and a general correlation matrix with no additional
structure) available in the software we used (i.e. R-package nlme (66,67)) but none of these
substantially reduced the residual autocorrelation. In the following we refer to two of the models,
Model C and Model D, defined in Section 5.4 Step 4.; note that thesis results are based on Model
C. Both models have identical fixed effect terms along with intercept-and-slope random effect
terms. These models differ only in their correlation structure. In Model C the within-group
correlation structure Ci is not defined, whereas Model D has correlation Ci defined as the CAR1
model. We use as an exemplar renovascular disease to plot the autocorrelation for Models C and
D, see Figure 52. Model D with correlation structure CAR1 is barely an improvement on Model
C in which a correlation structure is not defined. Within the scope of this thesis we were unable
to better, or more fully, account for the correlation structure inherent in the data.
As previously described, when selecting the model in Section 5.4 we encountered problems
specifically relating to difficulties fitting multiple bootstrap samples when using a CAR1 model
(i.e. Model D). Future work should consider in far greater detail the within-group correlation
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Figure 52: Residual autocorrelation for Models C and D
overcome then likelihood ratio tests, rather than pragmatic decisions, should be used to determine,
for each disease separately, the model which best describes the data. Different within-group
correlation structures may be optimal for different diseases.
In Section 4.2 we considered the time derivative of the LME model. By focusing on the fitted
model we were able to ignore the stochastic nature of the LME model given in Equation 2. It
would be of future interest to consider in much greater detail the time derivative of the LME model
prior to fitting. This would involve taking into account the stochastic nature of the model which
is encoded in the within-group error term; this term may also include an explicit within-group
correlation structure. If the time derivative of the LME model can be fitted this may better
address the issue of understanding the progression of kidney disease on an individual level and
circumvent the population level counterintuitive results discussed in Section 7.5.
The residual plots in Figures 8-16 show that our LME models do not account well for all patients
as there are some outliers. This does not cause us concern in relation to determining fixed effects
which is our main focus but it would be problematic if we were interested in predictions; we could
not make reliable predictions for outliers. Our models assume that random effects and within-
group errors follow multivariate normal distributions. However if we replaced these distributions
by their corresponding multivariate t-distributions with identical means and variance-covariance
matrices then the random effects and within-group errors should be more robust to outliers;
heavier/longer tails will better accommodate some, if not all, outliers. If we were interested in
predictions this would almost certainly result in more robust inference; e.g. see (93) Chapter 9
for details.
8.3.3 Recommendations
The correlation structure chosen for an LME model will directly affect any predictions made using
the model. If in the future our LME models were to be applied to patient-specific predictions of
kidney disease progression then it would be necessary to determine an appropriate correlation
structure for each LME model presented in this thesis; it may be that different diseases require
different correlation structures.
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Sometimes the biochemical markers measured at annual follow-up appointments are also measured
between these appointments when the patient attends a clinic or is admitted into hospital. At
present we are not including these SKS data in our analysis. It may be of interest to investigate
ways of utilising this additional information in our models, especially when it is possible to confirm
that the measurements did not relate to an acute episode of illness, such as AKI. One way to
utilise this extra data would be to use it to aid the imputation of biochemical measurements at
follow-up appointments.
In instances where the model could maintain sufficient statistical power it would be of interest to
sub-divide the heterogeneous disease categories used in this thesis. In particular the clinicians
advised that it would be of future interest to sub-divide the heterogeneous disease category
‘other’ and also sub-divide glomerulonephritis into about 4 sub-categories. Likewise some of the
comorbidity categories could be sub-divided, notably the cardiovascular category is particularly
heterogeneous with a mix of chronic and acute conditions. Similarly it may prove informative to
include more medication categories; this is a very rich data source within the SKS dataset which
in the future could be exploited more fully.
8.4 Implications regarding disease progression
8.4.1 Mental Health
It may be of interest to consider recording each patient’s mental heath state despite, to the
author’s knowledge, a directional causal link from mental to physical health not being clearly
identified in the literature. Such a link may be difficult or impossible to identify, given a person’s
mental and physical health may interact with each other in very complex ways; future scientific
advances can hope to precisely identify the biological mechanisms. For example (94) investigates
how past physical/mental health influences current physical/mental health (a clear directional
link was not found) and (95) discusses how negative emotions could be responsible for diseases
whose onset and course may be influenced by the immune system. Scott et. al. (96) uses data
from 40,000 adults from 17 countries to assess the relationship of depression and/or anxiety with
chronic physical conditions. They conclude that their work points towards: a) mental health
disorders leading to physical conditions; or b) the same factors being conducive to both multiple
mental health disorders and physical conditions. Poor mental health, e.g. depression or anxiety,
may contribute towards a patient making poor lifestyle choices, such as insufficient exercise, poor
diet, drinking too much alcohol, etc. In terms of CKD these choices could in turn contribute to
an increase in the patient’s risk of CKD and/or rapid kidney disease progression. For instance
(97) studies how anxiety and depression are associated with unhealthy lifestyle in patients at risk
of cardiovascular disease. To the author’s knowledge there is no equivalent study for CKD.
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8.4.2 Socio-economic factors
In our models we did not find a strong connection with socio-economic risk factors, although these
are likely to influence patient lifestyle choices, therefore perhaps further consideration could be
given to these factors as alluded to in the previous section. For example perhaps for each patient
it may be of interest to record their Index of Multiple Deprivation (IMD), lifetime earnings,
education level, level of engagement with primary care health services, and so on.
8.4.3 Disease progression with respect to baseline eGFR
In Section 7.6 we reported our finding that on average PKD patients with lowest baseline eGFR
also had the fastest rates of decline in kidney function. Ideally these patients need to be referred
from primary to secondary care much sooner so as to explore treatment (medication) options
which could slow their rapid kidney function decline to end point (RRT or death).
Our observation of steeper eGFR decline correlating with lower baseline values relates to most
disease categories which we studied. On a population wide level, as shown in Figure 50, this
relation does not apply to every patient. Although it does seem reasonable to expect more rapid
decline to be associated with low baseline eGFR, this correlation would appear to be in conflict
with the findings of Hoefield (85). Given Hoefield and ourselves both used SKS datasets, future
work could compare the differences between our respective models and data. For example such
analysis should include: a) evaluation of differences in data cleaning procedure; b) the effect of
the updates carried out by the SKS clinicians in 2019, which were applied to our dataset, that
related to confirming or reassigning the primary disease category of each patient; and c) the
consequences of our study using an extra four years of data.
8.5 Future work
8.5.1 Joint longitudinal and survival modelling
A natural extension of the work presented in this thesis would be to give consideration to
survival analysis which accounts for time until a pre-specified event occurs, i.e. time-to-event;
such methodology is widely used, for example see textbook by Hosmer (98) and reviews (99,100).
In survival analysis the ‘risk set’ contains patients at risk of experiencing an event, this consists
of patients who have been followed-up until a certain time but have not yet experienced the
event of interest e.g. death. Survival analysis accounts for the fact that the survival time is
censored for patients who do not experience the outcome of interest within the observation period,
furthermore it is unknown when, or whether, such patients will experience the event in the future.
Consequently censored time-to-events are a type of incomplete data, specifically they occur
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when the patient: a) is lost to follow-up; b) experiences another event which makes follow-up
impossible or meaningless; c) has not experienced the event of interest within the observation
period. Censoring is assumed to be independent and randomly occurring, that is at a given time
point patients who are censored are representative of those still at risk; e.g. it is assumed to be a
random occurrence if a patient is lost to follow-up due to migrating a significant distance and
that such a patient will be at a similar risk of experiencing the event of interest as one who is
still in the study.
In the SKS data the time-to-event would be time from baseline to RRT or death. There is
significant censoring in this data given 99 patients were recorded as lost to follow-up and a further
699 patients had a gap of 2.5 years or more since their most recent follow-up appointment. Our
longitudinal models take no account of these events so they overlook this potentially informative
source of censored information. Survival analysis provides an appropriate framework to account
for time-to-event data.
Given the SKS data we propose that survival analysis is undertaken with a variant of the Cox
model (101,102) that allows for time-varying explanatory variables e.g. see discussions (103),
(104), and Hosmer book (98) Chapter 7.3. We note that Asar (105) demonstrates for kidney
data, similar to ours, that joint modelling with a Cox proportional hazard regression model and a
longitudinal LME model is better than performing separate longitudinal and survival analyses.
This is because the joint model makes optimal use of all available data and correctly handles
irregularly measured time-varying explanatory variables, thus the joint model achieves unbiased
estimates of model parameters (105). Consequently future work could investigate the use of this
joint modelling framework to develop, for each kidney disease category, an understanding of how
the typical pattern of disease progression is influenced by time-to-event data along with baseline
and time-varying explanatory variables. In addition it may also be informative to investigate
constructing a joint model that is specifically designed to investigate how treatment effects
influence time-to-event outcomes.
In the context of CKD progression it would also be interesting to study the effects of competing
risks. These occur when patients could potentially experience one or more events or outcomes
which ‘compete’ with the outcome of interest. The competing risk either modifies the chance
that the event of interest occurs, or masks/hinders its observation. Of particular clinical interest
in our case are the competing risks of cardiovascular disease, initiation of RRT and/or mortality.
However these competing risks are asymmetric in that cardiovascular disease and RRT would
precede death, but death automatically censors cardiovascular disease and initiation of RRT.
Likewise in the SKS study initiation of RRT automatically censors cardiovascular disease. See
Lau (106) for a general discussion of competing risk methods, Noordzij (107) for a discussion
of competing risks methods for survival analysis applied to kidney disease and (108) for details
regarding joint modelling of longitudinal and survival data in the presence of competing risks.
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It would be of interest to consider extending our LME models for longitudinal data to latent
class linear mixed models which additionally account for unobserved heterogeneity within a
population (patients in a disease category). This heterogeneity is modelled by classifying ‘similar’
individuals into unobserved sub-groups (latent classes) each of which is less heterogeneous
(i.e. more homogeneous). In the longitudinal case each latent class is characterised by its own
mean trajectory; e.g. see overview by Berlin in the two part article (109) and (110). Furthermore,
it could also be informative to consider a joint modelling framework of a latent class mixed
model for longitudinal data with a survival model for time-to-event data. In such a joint model
individuals would be characterised by a class-specific linear mixed model (with fixed and random
effects) for their longitudinal data along with a class-specific survival model for their time-to-event
data. Details of this type of joint modelling where time-to-event data is accounted for using
proportional hazard models are given by Proust-Lima (111) and implemented in the R-package
LCMM (112). At present we do not know if there are any informative latent classes within our
disease models but it would be worth exploring this avenue. For example if a clear indication
of latent classes was found in the glomerulonephritis disease category this could suggest that
this category, which we know to be heterogeneous, should be split by the clinicians into several
sub-disease categories; these sub-categories could then be modelled separately. Alternatively, if
we found that a well-defined homogeneous disease category, e.g. PKD, appeared to have two or
more latent sub-classes we would consider, in conjunction with the SKS clinicians, the possibility
that there were one or more key explanatory variables missing from this disease model.
8.5.2 Personalised healthcare
An area of increasing interest throughout the health sector, including the NHS, is personalised
healthcare (113), that is the individualisation of treatment by identifying patients who are most
likely to respond positively to a particular treatment regime. This is beneficial to patients as
they receive the most appropriate treatment plan and has the added advantage that healthcare
providers do not waste funding on treatments that deliver insignificant benefit, no benefit or cause
harm to the patient; for example see discussions (114–116). The models in this thesis have the
potential to contribute towards personalised healthcare. For example we have shown that ACE-
inhibitors and ARBs are particularly beneficial to diabetic nephropathy and glomerulonephritis
patients but on average are not beneficial to the remainder of the cohort; the clinicians advise us
that they routinely prescribe these drugs across the entire cohort regardless of primary kidney
disease. Future work could hope to more accurately identify each patient that would benefit from
ACE-inhibitors and/or ARBs.
In the future our models could be used to pave the way towards personalised real-time predictions
of kidney disease progression, assuming the following issues can be adequately resolved: outliers;
LME model within-group correlation structure; and cleaner recording of patient data in the SKS
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database. This thesis uses longitudinal LME models to explore population effects but such models
have also been considered for personalised predictions; for example a longitudinal LME model
for personalised real-time predictions of primary care CKD patients which uses a few covariates
(e.g. baseline age, comorbidity indicators and sex) is proposed by Diggle (117).
However, if personalised prediction is a future aim, it is commonly advised in the literature that
joint modelling of longitudinal and time-to-event data improves the predictive capability and so
leads to more informative inferences; e.g. see review by Hickey (118) and also Brankovic (119)
who focuses on joint models for personalised prognosis in CKD patients. In this context for each
kidney disease category we would envisage a joint model consisting of a Cox proportional hazard
model and a longitudinal LME model of the kind explored in this thesis. However for personalised
prediction models to be of use in clinical practice they will need to be straightforward to interpret
by the clinician, the underlying data will need to be sufficiently clean and up-to-date, and the
models will need to undergo rigorous validation (120).
We envisage personalised predictions could, using a web page linked to the SKS data, display
a graph of the predicted rate of decline of kidney function for a given patient at the time of
their follow-up appointment; illustration given in Figure 53. Furthermore an algorithm could
be embedded in the web page to predict which treatments would be most likely be beneficial to
the patient conditional on the population average for their given primary kidney disease type;
e.g. how would the patient’s trajectory change if they started taking a β-blocker. Provided the
web page was designed to be user-friendly there is no reason why the clinician, and perhaps an
interested patient, could not look at the predicted trajectories during the follow-up appointment.
Such a system would not replace the expertise of the clinician but it could contribute towards
better patient outcomes.
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Figure 53: Illustration of web app for predicting personalised kidney disease progression
8.5.3 Treatment specific investigations
From a patient care perspective it would be useful to build further models which could give more
insight into which treatments slow progression. Possible lines of inquiry are:
• A more detailed investigations with respect to our ACE-inhibitors and/or ARBs medication
category; for example we could split this category in two subcategories. The SKS clinicians
inform us that clinical practice assumes ACE inhibitors and ARBs will slow progression in
all primary kidney disease categories. This assumption is based on two clinical studies (121)
and (122) which showed improvements in renal patients with type 2 diabetes; in clinical
practice it is assumed that this applies to all renal patients not just those with type 2
diabetes. However we found that ACE-inhibitors and ARBs only strongly affect progression
in diabetic nephropathy. It may be that a clinical trial is needed to confirm what effect if
any these drugs have on progression in other diseases.
• The SKS clinicians inform us that there is particular clinical interest is the area of anaemia
management. Anaemia contributes to both poor quality of life and increases the risk of
adverse outcomes, in particular cardiovascular events and death. Treatment of anaemia
improves quality of life. However there is not sufficient evidence to confirm that it slows the
progression of kidney disease or improves cardiovascular outcomes; for example see review
(123). More detailed modelling of the SKS data could perhaps clarify this.
• It is known that EPO treatment is associated with increased risk of CV events, e.g. see
review article (124). It would be of interest to determine if alternative anaemia treatments
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such as intravenous iron would reduce the risk of CV events. Again more detailed modelling
of the SKS data may shed some light on this.
• During early 2016 the drug Tolvaptan became available on the NHS, it is used to slow the
growth of cysts in PKD patients; for example see review (125). It would therefore be of
future interest, using the SKS data, to investigate the effects of this drug on the progression
of PKD. We anticipate PKD patients treated with Tolvaptan will have slower kidney disease
progression.
8.5.4 Further work relating to counterintuitive results
In Section 7.3 we reported several clinically counterintuitive results. After which, in Section 7.5
we took a deeper look at these results focusing on the interaction term of PTH with follow-up
time. We showed there was not a clinically unexpected artefact in the SKS data relating to
the slope of eGFR with respect to PTH, e.g. see Figures 48 and 49. This meant that clinical
intuition matched the SKS data but not the LME model results in Section 7.3. We concluded
that the counterintuitive result relating to the interaction term for PTH with follow-up time was
a consequence of the way our LME model summarised the data at population level.
Future work should take a deeper look at each clinically counterintuitive result from our LME
models. It should first determine if the data at individual level matches clinical intuition. If this
is the case, then future work should consider alternatives to the LME models presented in this
thesis. One option may be to construct a regression model which makes use of the average slope
of eGFR (as it is computed in Section 4.2).
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9 Conclusion
To study the key risk factors in progression of kidney disease we used data collected from over
3000 secondary care non-dialysis patients with CKD stages 3 to 5; these patients were followed-up
annually until the first occurrence of one of the following end points: dialysis, kidney transplant
or death. We accounted for a wide range of longitudinally recorded risk factors including
comorbidities, medications, lifestyle choices, socio-demographic information and biochemical
marker measurements. The role of these risk factors was considered both, between, and within,
eight primary kidney disease categories including: diabetic nephropathy, glomerulonephritis,
hypertensive kidney disease, pyelonephritis, renovascular disease and polycystic kidney disease.
To identify key risk factors at population level we used standard longitudinal modelling techniques,
in particular a linear mixed effects model with intercept and slope random effects. We robustly
estimated the population level (fixed) effects in all our disease models so were able to identify key
risk factors for the progression of kidney disease.
Key risk factors for lower than average levels of eGFR are biochemical markers and medications,
conversely lifestyle and physical attributes are less important. More rapid progression of kidney
disease is associated with biochemical markers, in contrast medications and comorbidities are not
key in rapid progression. Moreover we find that PKD has the most rapid progression out of all
our categories with a loss in eGFR of 3.5 mL/min/1.73m2/year whereas the remainder have a
loose around 1 mL/min/1.73m2/year.
We suggest future work should include efforts to more cleanly record data as this could substantially
improve statistical power of the statistical models. We also recommend future work should include
more in depth studies of each disease category including splitting them, where appropriate, into
subcategories; this would be particularly pertinent to glomerulonephritis as is contains several
distinct disease types. Additionally we propose consideration should be given to using joint
modelling of longitudinal and time-to-event data. Such models could be used to: study the effects
of ‘time-to-event’ censoring; investigate treatment effects; and potentially make personalised
forecasts of kidney disease progression.
We hope that this thesis research may contribute towards improvements in patient care and
possibly a reduction in the burden of disease at both patient and national level.
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Appendix
A.1 Data cleaning and preparation
We prepared and cleaned the SKS data as follows:
• Fixed common mis-spellings and removed erroneous characters in fields.
• All measurements were converted so they had consistent units
• Matched follow-up appointments with biochemical records by finding closest biochemical
date to follow-up date. Generally the mismatch between dates was less than a few days.
When date difference was larger than six weeks we assumed there was no match.
• At each consultation two measurements of systolic and diastolic were recorded. We sub-
tracted mean systolic from diastolic blood pressure to compute mean pulse pressure.
• After converting units to kilograms and metres BMI was computed as weight/(height)2.
• eGFR was calculated using Equation 1 after ensuring consistent units.
• The urine protein rate (mg/24hr) and PCR (g/mol) measurements were combined into a
single quantity ‘proteinuria’ (mg/24hr); note for example PCR 50mg/mmol=50g/mol is
equivalent to urinary protein rate 0.5g/24hr=500mg/24hr.
• HbA1c measured in %Hb was converted to mmol/mol, where HbA1c(mmol/mol) = 10.929
× ( HbA1c(%Hb) - 2.15 ).
• Units of alcohol per week were summarised into three categories: less than 1, 1 to 14 and
over 14. We defined these categories to be in-line with UK Chief Medical Officers’ guidelines
issued during 2016 (126).
• Smoking status was defined as: ex-smoker, active smoker, non-smoker.
• Ethnicity was defined as follows: white, Asian, black, Chinese, other. Of these categories
the last four contain small numbers of patients so they were grouped into a single category
labelled ‘non-white’.
• The primary occupation of patients, in some cases prior to retirement, was recorded by
SKS using the 8 classes defined by the Office of National Statistics (ONS) under their
socio-economic classification (127). To increase our statistical power we reduced the number
of occupation classes using the ONS guidelines in Section 7 Classes and collapses of (127).
The categories we used are:
– Higher managerial, administrative and professional occupations (abbreviation Manage-
rialProfessional)
– Intermediate occupations (abbreviation Intermediate)
– Routine and manual occupations (abbreviation RoutineManual)
– Never worked and long-term unemployed (abbreviation NeverWorkedUnemployed)
• AKI episodes were identified as at least 3 days of consecutive creatinine measurements; this
implied the patient had been admitted to hospital.
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A.1.1 End of study markers
If a patient withdraw from the study, and the reason was recorded, these reasons were defined as
either lost-to-follow-up, death or RRT. In this thesis we added two additional categories; presumed
lost-to-follow-up and ongoing to capture patients with no recorded reason for leaving. For these
patients, if their last follow-up date was more than than 2 years 6 months before 27 February
2017 (most recent date in data), then we recorded them as presumed lost-to-follow-up, otherwise
we assumed they were still in the study so defined them as ongoing. This cut-off was set to over
2.5 years because some of the cohort had follow-ups which were two years apart and moreover
follow-ups were not separated by precisely one or two calendar years. The date of departure from
the study is usually only known/recorded for patients who die or undergo RRT.
Note that if follow-ups are two years apart then their annual follow-up index skips a year. For
example, if a patient is seen at follow-up ‘1’ (first follow-up) and then is next seen two years later
their follow-up index jumps to ‘3’, i.e. ‘2’ is skipped.
A.1.2 Primary kidney disease categories
Kidney diseases were grouped into 9 primary disease categories:
• diabetic nephropathy: single disease - no subgroups.
• glomerulonephritis: crescentic and focal segmental glomerulonephritis, Goodpasture’s syn-
drome, Henoch-Schonlein purpura, IgA nephropathy, Lupus erythematosus, membranopro-
liferative, membranous nephropathy, Wegener’s Granulomatosis, and renal vascular disease
due to polyarteritis.
• hypertensive kidney disease: renal vascular disease due to hypertension or due to malignant
hypertension, and ischemic renal disease / cholesterol embolism (standard diagnostic (EDTA)
codes 71,72 and 75).
• obstruction: obstructive uropathy - no subgroups.
• other : kidney disease which does not come under any of the other 8 categories.
• polycystic kidney disease: single disease - no subgroups.
• pyelonephritis, due to obstructive uropathy, urolithiasis, vesico-ureteric reflux without
obstruction, associated with neurogenic bladder and other cause.
• renovascular, due to polyarteritis and other reason.
• unknown: type of renal disease not diagnosed.
A very small minority of patients had more than one primary kidney disease recorded. Typically
early during their time in the study they were assigned a diagnosis of ‘unknown’ then later given
a diagnosis from one of the other categories. In such cases we assigned their primary kidney




Comorbidities were collated into 5 groups as follows:
• cardivascular : amputation, angina, cardiac arrest, cerebrovascular disease, coronary inter-
vention, heart failure, myocardial infarction, peripheral vascular disease
• gastrointestinal: peptic ulcer disease, liver disease
• cancer : any type of cancer, not necessarily kidney cancer, which may either be ‘current’ or
‘previous’
• diabetes: type 1 and 2
• other : parathyroidectomy, dementia, chronic obstructive pulmonary disease, congenital
abnormalities
A.1.4 Medication categories
Drugs were categorised as follows:
• ACE inhibitor : captopril, cilazapril, enalapril, fosinopril, imidapril, lisinopril, perindopril,
quinapril, ramipril, trandolapril
• ARB: candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan
• alpha-blocker : alfuzosin, doxazosin, indoramin, mirtazapine, prazosin, tamsulosin, terazosin,
trazodone, yohimbine
• beta-blocker : acebutalol, atenolol, betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol,
propranolol, sotalol, timolol
• combined alpha- and beta-blocker : carvedilol, labetalol
• calcium channel blocker : amlodipine, diltiazem, coracten, felodipine, lacidipine, lercanidipine,
nicardipine, nifedipine, securon, verapamil
• diuretic: amiloride, bendroflumethiazide, bendrofluazide, bumetanide, chlorthalidone,
chlorothiazide, co-amilozide, co-amilofruse, eplerenone, frusemide, hydrochlorothiazide,
indapamide, metolazone, spironolactone, thiazide, torasemide, xipamide
• EPO: treatment using EPO was originally recorded in one of three groups (epoetin alpha,
beta or darbepoetin), here we group them in a single category.
• iron (taken orally): ferrous sulphate, ferrous fumarate, iron, ferrous gluconate, iron sulphate,
ferrograd, fersamal
• vitamin D: alfacalcidol, cholecalciferol, vitamin D
The SKS data records each patient as either taking or not taking parenteral iron. The drugs
administered are not recorded.
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A.2 Trellis plots of eGFR against follow-up for individual patients
Each figure contains Trellis plots based on the first 24 patients in the SKS data with a given
primary disease. The points on each plot are log(eGFR) at each follow-up year for which data
were recorded; a maximum of 10 years are plotted. Superimposed on each plot is a straight line
derived from a linear model for the given patient where the outcome variable is log(eGFR) and
the covariate is follow-up year; this model uses eGFR values from all follow-up years hence is not
truncated at 10 years.
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Figure 54: Progression of disease for 24 patients with diabetic nephropathy
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Figure 55: Progression of disease for 24 patients with glomerulonephritis
StudyID: 69 StudyID: 7 StudyID: 70 StudyID: 73 StudyID: 75 StudyID: 89
StudyID: 199 StudyID: 22 StudyID: 23 StudyID: 37 StudyID: 50 StudyID: 68
StudyID: 128 StudyID: 143 StudyID: 151 StudyID: 155 StudyID: 184 StudyID: 196
StudyID: 100 StudyID: 101 StudyID: 102 StudyID: 107 StudyID: 108 StudyID: 123


























Figure 56: Progression of disease for 24 patients with HKD
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Figure 57: Progression of disease for 24 patients with obstruction
StudyID: 51 StudyID: 54 StudyID: 6 StudyID: 61 StudyID: 71 StudyID: 92
StudyID: 198 StudyID: 201 StudyID: 25 StudyID: 39 StudyID: 40 StudyID: 5
StudyID: 138 StudyID: 140 StudyID: 16 StudyID: 161 StudyID: 165 StudyID: 19
StudyID: 111 StudyID: 117 StudyID: 121 StudyID: 126 StudyID: 129 StudyID: 135


























Figure 58: Progression of disease for 24 patients with disease other
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Figure 59: Progression of disease for 24 patients with polycystic kidney disease
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Figure 60: Progression of disease for 24 patients with pyelonephritis
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Figure 61: Progression of disease for 24 patients with renovascular disease
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Figure 62: Progression of disease for 24 patients with disease unknown
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A.3 Data imputation
We imputed missing values, for each patient, at follow-up appointments, as follows:
• Continuous variables: we used the ‘Kalman smoothing on a structural model’ method to
estimate missing values for: BMI, DBP, number of antihypertensives, SBP. Additionally
using this method we also imputed the following biochemical markers: CC, CRP, Hb,
HbA1c, PO, PTH, Pu, CHO, CO2. This imputation was performed with the na.kalman
function from R-package imputeTS (61). If the timeseries had less than 3 measured values
then imputation with the function na.kalman was not possible so in these instances we
used the spline version of na.interpolation from R-package imputeTS. Before imputation we
transformed all the aforementioned continuous variables using the natural logarithm, then
after imputation transformed back to the original scale using the exponential function; this
ensures all imputed values are positive.
• Catagoical variables: we imputed missing values using Last Observation Carried For-
ward/Backward; when possible Forward was given priority over Backward. This method
was applied to comorbidities and weekly alcohol intake. At a given follow-up, if no medi-
cations were recorded then this method was used to impute values across all medication
categories, otherwise all drugs were assumed to have been recorded leading to the med-
ications’ categories being populated as appropriate. Note that EPO treatment is never
imputed. We used the na.locf function from R-package imputeTS.
A.4 Dependence between all model variables
A.4.1 Correlation
To assess the correlation between all pairs of explanatory variables we computed a single correlation
matrix. This matrix is split into 9 similarly sized sub-matrices which are labelled by (row, column);
for example sub-matrix (1,1) is the top left portion of the correlation matrix, similarly sub-matrix
(1,2) is the top middle portion and so on. Due to symmetry we only tabulated the upper triangular
matrix elements. Tables 31 to 36 show the sub-matrices; correlation values greater than 0.5 are
in boldface.
176




































































































































































































































































































age0 1 -0.1 -0.1 -0.1 0.1 0.1 0 0.3 -0.3 0.3 0.1 0.0 0.1 0.1 -0.2 0.0 -0.2 0.2 0.0 -0.1
bodyMassIndex 1.0 0.0 0.0 0.0 0 0 0.0 0.0 0.2 -0.1 0.0 0.0 0.1 0.1 0.1 0.0 -0.1 0.0 -0.1
CC 1.0 0.0 -0.1 0 0 -0.1 -0.1 0.0 0.0 0.0 -0.1 0.0 0.1 -0.1 0.1 -0.1 0.0 0.0
comorbidityCancerno 1.0 -0.4 -0.9 0 0.0 0.0 0.0 0.0 0.0 0.0 -0.1 0.0 0.1 0.1 0.0 -0.1 0.0
comorbidityCancercurrent 1.0 -0.1 0 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.0 -0.1 0.0 0.0 0.0
comorbidityCancerprevious 1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -0.1 0.1 -0.1
comorbidityCV1 1 -0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 -0.1 0.0 0.0
comorbidityCVover 1 1.0 0.0 0.2 0.1 0.1 0.0 0.0 -0.1 0.1 -0.2 0.1 0.0 -0.1
comorbidityDiabetestype1 1.0 -0.3 -0.1 -0.1 0.1 0.0 0.0 0.3 -0.1 -0.1 0.0 -0.1
comorbidityDiabetestype2 1.0 0.0 0.0 0.1 0.0 -0.2 0.4 -0.2 -0.1 0.0 -0.1
comorbidityGastrointestinalyes 1.0 0.1 -0.1 0.0 0.0 0.0 -0.1 0.0 0.0 0.1
comorbidityOtheryes 1.0 0.0 0.1 0.0 0.0 -0.1 0.0 0.1 0.0
Cr 1.0 0.1 -0.1 0.2 -0.1 0.0 0.0 0.0
CRP 1.0 0.0 0.0 0.0 0.0 0.1 0.0
DBP 1.0 -0.1 0.0 0.0 0.0 0.1
diabetic nephropathy 1.0 -0.3 -0.3 0.0 -0.2
glomerulonephritis 1.0 -0.1 0.0 -0.1





































































































































































































































































age0 -0.1 0.2 0.1 -0.2 0.0 -0.1 -0.1 -0.1 0.1 0.1 -0.3 -0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.2 0.0
bodyMassIndex 0.1 -0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -0.1 0 0.1 0.0 0.1 0.0 0.2 -0.1 0.0 0.0 0.0
CC 0.0 -0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 -0.1 0.0 -0.1 0.0 0.0 0.0
comorbidityCancerno 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 -0.1 0.0 0.0
comorbidityCancercurrent 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 -0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
comorbidityCancerprevious 0.0 0.0 0.0 -0.1 0.0 0.0 0.0 0.0 0.0 0.0 0 -0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0
comorbidityCV1 0.0 -0.1 0.0 0.0 0.0 0.0 0.0 -0.1 0.0 0.0 0 0.0 0.0 -0.1 0.0 0.0 0.0 0.0 0.0 0.0
comorbidityCVover 1 0.0 0.2 0.0 0.0 0.1 0.1 0.1 -0.1 0.1 0.0 -0.1 -0.1 0.0 0.2 0.0 0.1 0.0 0.1 0.1 0.0
comorbidityDiabetestype1 -0.1 -0.1 -0.1 0.0 0.0 -0.1 0.0 -0.1 0.3 0.0 -0.1 0.1 0.0 -0.1 0.0 0.1 0.1 0.0 0.0 0.1
comorbidityDiabetestype2 -0.1 0.0 -0.1 0.0 0.0 -0.1 -0.1 -0.1 0.4 0.0 -0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1
comorbidityGastrointestinalyes 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 -0.1 0.0 0.0 -0.1 -0.1 -0.1 0.0 0.0 0.0
comorbidityOtheryes 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -0.1 0.0 0.0 -0.1 -0.1 0.0 0.0 0.1 0.0 0.0
Cr -0.1 0.0 0.0 -0.1 0.0 0.1 0.1 -0.3 0.0 0.0 -0.9 -0.1 0.1 0.0 0.1 0.2 0.3 0.1 0.1 0.2
CRP 0.0 0.0 0.0 0.0 0.0 0.1 0.0 -0.1 0.0 0.0 -0.1 -0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
DBP 0.1 -0.1 0.0 0.1 0.0 0.0 0.0 0.2 -0.1 0.0 0.2 0.0 -0.1 0.0 -0.1 -0.1 -0.1 -0.1 -0.1 0.0
diabetic nephropathy -0.2 -0.2 -0.2 0.0 0.0 -0.1 -0.1 -0.2 0.5 0.0 -0.2 0.1 0.1 -0.1 0.1 0.2 0.2 0.1 0.1 0.1
glomerulonephritis -0.1 -0.1 -0.1 0.0 -0.1 0.1 0.1 0.0 -0.2 0.0 0.1 0.1 0.0 -0.1 0.0 -0.1 0.0 -0.1 0.0 0.0
HKD -0.1 -0.1 -0.1 0.0 0.0 0.0 0.0 0.1 -0.2 0.0 -0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 -0.1 0.0
obstruction 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
polycystic kidney -0.1 -0.1 -0.1 0.0 -0.1 0.1 0.1 0.0 -0.1 0.0 0.1 0.0 0.0 0.0 0.0 -0.1 -0.1 0.0 -0.1 0.0
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age0 0.1 0.0 0.1 0.0 0.0 0.1 -0.2 0 0.3 0.0 -0.1 0.2 0.0 -0.2 0.2 -0.2 0.0 -0.1 -0.1
bodyMassIndex 0.1 0.0 0.2 0.0 0.0 -0.1 0.1 -0.1 0.0 0.1 0.0 0 0.1 -0.1 0.0 0.0 0.1 0.0 -0.1
CC 0.0 0.0 -0.1 0.0 0.0 0.0 0.0 -0.1 0.0 -0.1 0.0 0.1 0.1 0.0 -0.1 0.1 0.1 0.0 0.0
comorbidityCancerno 0.0 0.0 0.0 0.0 -0.1 0.1 0.0 0 0.0 0.0 0.0 0 0.0 0.1 0.0 0.0 0.0 0.0 0.0
comorbidityCancercurrent 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 -0.1 0.1 0.0 0.0 0.0 0.0
comorbidityCancerprevious 0.0 0.0 0.0 0.0 0.1 -0.1 0.0 0 0.0 0.0 0.0 0 0.0 -0.1 0.0 0.0 0.0 -0.1 0.0
comorbidityCV1 0.0 0.0 0.0 0.0 0.0 -0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
comorbidityCVover 1 0.1 0.1 0.1 0.0 -0.1 0.0 -0.1 0 0.1 0.0 -0.1 0 -0.1 0.0 0.1 -0.1 0.1 -0.1 -0.1
comorbidityDiabetestype1 0.1 0.0 0.1 0.0 0.1 -0.1 0.1 0.1 0.0 0.1 0.1 0 0.1 0.0 -0.1 0.0 0.0 0.0 0.1
comorbidityDiabetestype2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.1 -0.1 -0.1 0.1 -0.2 0.0 -0.1 -0.1
comorbidityGastrointestinalyes 0.0 0.1 -0.1 0.0 -0.1 0.1 -0.1 -0.1 0.0 0.0 0.0 0 0.0 0.1 0.0 0.0 0.0 -0.1 0.0
comorbidityOtheryes 0.1 0.1 -0.1 0.0 -0.1 0.0 0.0 0 0.0 0.1 -0.1 0 0.1 0.0 0.1 0.0 0.0 0.0 -0.1
Cr 0.4 0.1 0.1 0.2 0.0 -0.1 0.0 0.6 0.1 0.5 0.2 0 -0.1 0.0 0.1 -0.2 -0.3 0.0 0.0
CRP 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
DBP 0.0 0.0 -0.1 0.0 0.0 0.0 0.0 -0.1 -0.1 0.0 0.1 0.4 -0.1 0.0 -0.1 0.2 0.0 0.0 0.0
diabetic nephropathy 0.2 0.1 0.2 0.0 0.1 -0.2 0.0 0.2 0.1 0.2 0.1 0.1 0.0 0.0 0.0 -0.2 0.0 0.0 0.0
glomerulonephritis -0.1 0.0 0.0 0.1 0.0 0.1 0.0 0 -0.1 -0.1 0.1 -0.1 0.1 0.0 -0.1 0.1 0.0 0.1 0.0
HKD 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0.0 0.0 -0.1 0 0.0 -0.1 0.0 0.0 0.0 0.0 0.0
obstruction 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
polycystic kidney -0.1 0.0 0.0 0.0 0.0 0.0 0.0 0 -0.1 0.0 -0.1 -0.1 0.0 0.2 -0.1 0.0 0.0 0.0 0.0
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pyelonephritis 1 -0.1 -0.1 0.1 0.1 0 0 0.1 -0.1 0.0 0.1 0.0 0.0 0.0 -0.1 -0.1 -0.1 0.0 0.0 0.0
renovascular 1.0 -0.1 -0.1 0.1 0 0 0.0 -0.1 0.0 0 0.0 0.1 0.1 0.1 0.0 -0.1 0.0 0.0 -0.1
unknown 1.0 -0.1 0.0 0 0 0.0 -0.1 0.0 0 0.0 -0.1 0.0 -0.1 -0.1 0.0 0.0 0.0 0.0
ethnicitynonWhite 1.0 0.0 0 0 0.0 0.0 -0.1 0.1 0.0 -0.1 0.0 0.0 0.0 0.0 0.0 -0.1 0.0
familyHistoryIHD0yes 1.0 0 0 0.0 0.0 0.0 0 0.0 0.0 0.1 -0.1 0.0 0.0 0.0 0.1 0.0
followup 1 1 0.0 -0.1 0.0 -0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
followupTime 1 0.0 -0.1 0.0 -0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Hb 1.0 -0.1 0.0 0.4 0.0 -0.1 0.0 0.0 -0.2 -0.3 -0.1 -0.2 -0.2
HbA1c 1.0 0.1 -0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.1 0.0
livingStatus0alone 1.0 -0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1
logeGFR 1 0.1 -0.1 0.0 -0.1 -0.2 -0.3 -0.1 -0.1 -0.2
med.ACE.ARByes 1.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0
med.AlphaBlockersyes 1.0 0.0 0.2 0.2 0.1 0.1 0.1 0.0
med.BetaBlockersyes 1.0 0.1 0.1 -0.1 0.0 0.0 0.0
med.CCBsyes 1.0 0.1 0.1 0.1 0.0 0.0
med.Diureticsyes 1.0 0.2 0.1 0.1 0.1
med.Epoyes 1.0 0.1 0.1 0.3





































































































































































































































































































pyelonephritis 0.0 0.0 -0.1 0.0 -0.1 -0.1 0.1 -0.1 -0.1 0.0 0.0 -0.1 0.1 0.0 0.0 0.1 -0.1 -0.1 0.0
renovascular 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0 0.1 0.0 -0.1 0 -0.1 0.1 0.1 0.0 0.0 -0.1 0.0
unknown 0.0 0.0 -0.1 0.0 0.0 0.0 0.0 0 0.0 0.0 -0.1 0 0.0 -0.1 0.0 0.0 0.0 0.0 0.0
ethnicitynonWhite 0.0 0.0 0.0 0.0 0.1 0.0 0.1 -0.1 -0.1 0.1 0.0 -0.1 0.0 0.0 0.0 0.1 0.0 -0.1 0.0
familyHistoryIHD0yes 0.0 0.0 0.0 0.0 0.0 -0.1 0.0 0 0.0 0.0 0.0 0 0.1 0.0 0.0 0.0 0.0 -0.1 0.0
followup 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1
followupTime 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1
Hb -0.2 -0.1 -0.1 -0.1 0.0 0.0 0.0 -0.4 -0.2 -0.2 -0.1 0 -0.2 0.0 0.0 0.1 0.1 0.0 0.1
HbA1c 0.1 0.0 0.1 0.0 0.0 -0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 -0.1 -0.1
livingStatus0alone 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.0 -0.1 0.0 0.0 -0.1 0.0
logeGFR -0.4 -0.1 -0.2 -0.2 0.0 0.1 0.0 -0.5 -0.2 -0.5 -0.2 -0.1 -0.1 0.0 -0.1 0.1 0.3 0.0 0.1
med.ACE.ARByes -0.1 -0.1 0.3 0.0 0.0 0.0 0.1 0 0.0 0.0 0.0 -0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1
med.AlphaBlockersyes 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 -0.1 -0.1 0.1 -0.1 0.0 0.1 0.0
med.BetaBlockersyes 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0 0.1 0.1 0.0 0 -0.1 0.0 0.0 -0.1 0.0 0.0 0.1
med.CCBsyes 0.0 -0.1 0.5 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 -0.1 0.0 0.1 -0.1 -0.1 0.1 0.0
med.Diureticsyes 0.1 0.0 0.5 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 -0.1 0.1 -0.1 0.1 0.0 -0.1
med.Epoyes 0.2 0.0 0.1 0.2 0.1 0.0 0.0 0.2 0.0 0.2 0.1 0 0.1 -0.1 0.1 -0.1 -0.1 0.0 0.0
med.Ironyes 0.1 0.0 0.1 0.0 0.0 -0.1 0.0 0.1 0.1 0.1 0.0 0 0.0 0.0 0.0 -0.1 0.0 0.0 0.0
med.Otheryes 0.1 0.0 0.1 0.1 0.0 0.0 -0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 -0.1 0.0 0.0 0.0
med.ParenteralIronyes 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0 0.1 0.0 0.0 0.0 -0.1 0.0 0.0
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med.VitaminDyes 1 0.1 0.0 0.1 0.0 -0.1 0.0 0.2 0.1 0.3 0.0 0 0.1 0.0 0.0 -0.1 -0.1 0.0 -0.1
numberAKIepisodes 1.0 -0.1 0.0 0.0 0.0 0.0 0 0.0 0.1 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 -0.1
numberAntihypertensives 1.0 0.1 0.1 -0.1 0.0 0.1 0.2 0.1 0.1 0.1 -0.1 -0.1 0.1 -0.2 0.0 0.1 0.1
numberClinicVisits 1.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0 0.0 0.0 0.0 0.0 -0.1 0.0 0.0
occupation0ManagerialProfessional 1.0 -0.3 -0.1 0 0.0 0.0 0.0 0 -0.2 -0.1 0.1 -0.1 0.0 0.1 0.2
occupation0Intermediate 1.0 -0.1 -0.1 -0.1 -0.1 0.0 -0.1 0.1 0.0 -0.1 0.0 0.0 0.1 0.0
occupation0NeverWorkedUnemployed 1.0 0 0.0 0.0 0.0 0 0.1 0.1 -0.1 0.0 0.0 -0.1 0.0
PO 1 0.1 0.4 0.2 0 0.1 0.1 0.0 0.0 -0.2 0.0 0.0
PP 1.0 0.1 0.2 0.9 0.0 0.0 0.1 0.0 0.0 -0.1 0.0
PTH 1.0 0.2 0.1 0.0 0.0 0.0 -0.1 -0.1 -0.1 0.0
Pu 1.0 0.2 0.0 0.1 -0.1 0.2 -0.1 0.0 -0.1
SBP 1 0.0 0.0 0.0 0.1 0.0 -0.1 0.0
sexfemale 1.0 0.0 -0.2 0.2 0.0 -0.1 -0.2
smokingStatus0active 1.0 -0.4 0.1 -0.1 -0.1 0.0
smokingStatus0ex-smoker 1.0 -0.2 0.0 0.0 0.1
totalCholesterol 1.0 0.0 -0.1 0.0
totalCO2 1.0 0.0 0.0
weeklyAlcohol01 to 14 1.0 -0.3
weeklyAlcohol0over 14 1.0
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A.4.2 Variance inflation factor
We computed the VIF with the vifstep function from R-package usdm (69). As described in
Section 5.1 the function uses a stepwise procedure to exclude highly correlated variables with a
VIF above a given threshold. Here we do not include eGFR or Cr.
With a VIF threshold of 5 the method excluded: disease other, SBP, followupTime. With these
variables excluded, the VIF values for the remaining variables are given in Table 37.
Reducing the threshold to 2.5 results in the method excluding: disease other, SBP, followupTime,
numberAntihypertensives, disease diabetic nephropathy. With these variables excluded, the VIF
values for the remaining variables are given in Table 38.
Table 37: Variance inflation factor using all data: threshold 5
Variables VIF
numberAntihypertensives 4.7
















































































































A.5 Linear mixed effects model: residuals by follow-up year
Figures 63-71 show the standardised residual distributions at each follow-up year, they confirm














lag for follow−up year












0 1 2 3 4 5 6 7
n=229 n=198 n=145 n=106 n=72 n=50 n=29 n=22
















lag for follow−up year












0 1 2 3 4 5 6 7
n=273 n=228 n=177 n=130 n=92 n=71 n=52 n=38











lag for follow−up year












0 1 2 3 4 5 6 7
n=248 n=186 n=141 n=101 n=67 n=51 n=34 n=23












lag for follow−up year












0 1 2 3 4 5 6 7
n=267 n=202 n=151 n=115 n=85 n=56 n=43 n=25








lag for follow−up year












0 1 2 3 4 5 6 7
n=110 n=78 n=56 n=46 n=40 n=17 n=19 n=13



















lag for follow−up year












0 1 2 3 4 5 6 7
n=110 n=93 n=72 n=51 n=40 n=32 n=25 n=18
















lag for follow−up year












0 1 2 3 4 5 6 7
n=141 n=107 n=100 n=70 n=45 n=38 n=24 n=15

















lag for follow−up year












0 1 2 3 4 5 6 7
n=242 n=177 n=120 n=88 n=54 n=37 n=24 n=12











lag for follow−up year












0 1 2 3 4 5 6 7
n=1794 n=1366 n=1014 n=741 n=509 n=363 n=256 n=170
Figure 71: Residuals for single model all diseases by follow-up year with 95% CIs
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A.6 Observation counts per factor level for each disease category
The distribution of observations among factor levels for each disease category are tabulated in
Tables 39-47; the column labelled reference is the factor reference level used in the LME models.
Table 39: Count of observations in each factor level for disease diabetic nephropa-
thy
factors reference
level no current previouscomorbidityCancer
count 794 13 72
level no 1 over 1comorbidityCV

































level RoutMan ManaProf Interm Unemploccupation0*
count 502 308 53 16
level male femalesex
count 604 275
level non-smoker active ex-smokersmokingStatus0
count 283 101 495
level under 1 1 to 14 over 14weeklyAlcohol0
count 491 246 142
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 40: Count of observations in each factor level for disease glomerulonephri-
tis
factors reference
level no current previouscomorbidityCancer
count 997 16 109
level no 1 over 1comorbidityCV
count 699 256 167
level no type1 type2comorbidityDiabetes































level RoutMan ManaProf Interm Unemploccupation0*
count 479 367 250 26
level male femalesex
count 743 379
level non-smoker active ex-smokersmokingStatus0
count 442 116 564
level under 1 1 to 14 over 14weeklyAlcohol0
count 412 458 252
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 41: Count of observations in each factor level for disease HKD
factors reference
level no current previouscomorbidityCancer
count 771 20 90
level no 1 over 1comorbidityCV

































level RoutMan ManaProf Interm Unemploccupation0*
count 424 263 171 23
level male femalesex
count 580 301
level non-smoker active ex-smokersmokingStatus0
count 333 64 484
level under 1 1 to 14 over 14weeklyAlcohol0
count 429 301 151
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 42: Count of observations in each factor level for disease other
factors reference
level no current previouscomorbidityCancer
count 733 62 187
level no 1 over 1comorbidityCV
count 459 284 239
level no type1 type2comorbidityDiabetes































level RoutMan ManaProf Interm Unemploccupation0*
count 484 280 172 46
level male femalesex
count 606 376
level non-smoker active ex-smokersmokingStatus0
count 371 134 477
level under 1 1 to 14 over 14weeklyAlcohol0
count 486 320 176
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 43: Count of observations in each factor level for disease PKD
factors reference
level no current previouscomorbidityCancer
count 383 5 14
level no 1 over 1comorbidityCV

































level RoutMan ManaProf Interm Unemploccupation0*
count 153 150 75 24
level male femalesex
count 202 200
level non-smoker active ex-smokersmokingStatus0
count 160 49 193
level under 1 1 to 14 over 14weeklyAlcohol0
count 162 136 104
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 44: Count of observations in each factor level for disease pyelonephritis
factors reference
level no current previouscomorbidityCancer
count 416 10 34
level no 1 over 1comorbidityCV

































level RoutMan ManaProf Interm Unemploccupation0*
count 211 116 111 22
level male femalesex
count 216 244
level non-smoker active ex-smokersmokingStatus0
count 200 63 197
level under 1 1 to 14 over 14weeklyAlcohol0
count 242 143 75
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 45: Count of observations in each factor level for disease renovascular
factors reference
level no current previouscomorbidityCancer
count 472 25 65
level no 1 over 1comorbidityCV
count 82 100 380
level no type1 type2comorbidityDiabetes





























level RoutMan ManaProf Interm Unemploccupation0*
count 337 130 90 5
level male femalesex
count 371 191
level non-smoker active ex-smokersmokingStatus0
count 84 101 377
level under 1 1 to 14 over 14weeklyAlcohol0
count 305 147 110
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 46: Count of observations in each factor level for disease unknown
factors reference
level no current previouscomorbidityCancer
count 677 14 75
level no 1 over 1comorbidityCV
count 304 190 272
level no type1 type2comorbidityDiabetes































level RoutMan ManaProf Interm Unemploccupation0*
count 363 229 147 27
level male femalesex
count 441 325
level non-smoker active ex-smokersmokingStatus0
count 262 69 435
level under 1 1 to 14 over 14weeklyAlcohol0
count 453 209 104
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, In-
term=Intermediate, Unempl=NeverWorkedUnemployed
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Table 47: Count of observations in each factor level for single model all diseases
factors reference
level no current previouscomorbidityCancer
count 5563 183 701
level no 1 over 1comorbidityCV
count 2752 1600 2095
level no type1 type2comorbidityDiabetes





level Ot DN GN Ob PKD PN RVD HKD Undisease†































level RoutMan ManaProf Interm Unemploccupation0*
count 3150 1961 1139 197
level male femalesex
count 4014 2433
level non-smoker active ex-smokersmokingStatus0
count 2247 743 3457
level under 1 1 to 14 over 14weeklyAlcohol0
count 3211 2065 1171
* abbreviations: RoutMan=RoutineManual, ManaProf=ManagerialProfessional, Interm=Intermediate, Un-
empl=NeverWorkedUnemployed
† abbreviations: DN=diabetic nephropathy, GN=glomerulonephritis, Ob=obstruction, Ot=other, PKD=polycystic kidney disease,
PN=pyelonephritis, RVD=renovascular, HKD=hypertensive kidney disease, Un=unknown
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A.7 Unstandardised model
We now consider the unstandardised model fixed effect regression parameters for our disease
categories. Unlike the standardised model we work in the original units of measure for each
explanatory variable i.e. there is no re-scaling. For the sake of comparability with the standard-
ised results we set the step change in each parameter equal to one standard deviation of the
corresponding explanatory variable i.e. θr = σr relates to θ
′
r = 1 since θ
′
r = θr/σr (Section 4.5
gives more details). The advantage here is that we do not make an arbitrary rescaling of any
regression parameters and therefore the results are easier to interpret, particularly in relation
to rates of change with respect to time (see Section 4.4). As discussed in Section 4.5 we report
results in terms of the relative change in eGFR induced by a step change in the parameter of
interest. As previously p-values are reported at the 0.05 significance level.
For each disease model the details of the fixed effect parameter estimates are given in Tables 48
to 57. Additionally Figures 72 to 80 summarise the relative change in eGFR for θr = σr and also
indicate the clinically significant level of a 5% change in eGFR.
A.7.1 Overview
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(Intercept) (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗ (+)∗∗∗
age0 (−)∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗ (−)∗ (−)∗∗∗ (−)∗∗∗
bodyMassIndex (−)∗∗ (+)∼
bodyMassIndex:followupTime (+)∼ (+)∼
CC (−)∗∗ (+)∼ (−)∼ (−)∗ (−)∼ (−)∼ (−)∼ (−)∼ (−)∗∗
CC:followupTime (+)∼ (−)∼ (+)∼ (+)∼ (−)∼ (+)∼ (+)∼ (−)∼ (−)∼
comorbidityCancercurrent (+)∼ (−)∼ (+)∼ (+)∼
comorbidityCancercurrent:followupTime (+)∼ (+)∼ (+)∼ (−)∼
comorbidityCancerprevious (−)∗ (−)∼ (+)∼ (−)∼
comorbidityCancerprevious:followupTime (+)∼ (+)∼ (−)∼ (+)∼
comorbidityCV1 (−)∗ (−)∼ (+)∼ (−)∼ (−)∼ (−)∗
comorbidityCV1:followupTime (+)∼ (−)∼ (−)∼ (+)∼ (+)∼ (+)∼
comorbidityCVover 1 (−)∗ (−)∼ (−)∼ (+)∼ (−)∗ (−)∗∗
comorbidityCVover 1:followupTime (+)∼ (+)∼ (+)∼ (−)∼ (+)∼ (+)∼
comorbidityDiabetestype1 (−)∼ (−)∼
comorbidityDiabetestype1:followupTime (−)∼ (+)∼
comorbidityDiabetestype2 (+)∼ (+)∼ (+)∼





CRP (+)∼ (+)∼ (−)∼ (+)∼
CRP:followupTime (+)∼ (−)∼ (+)∼ (−)∼
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DBP (+)∗ (−)∼ (+)∼ (+)∼ (+)∼ (+)∼ (+)∗ (+)∗
DBP:followupTime (−)∼ (+)∗ (+)∼ (−)∼ (−)∼ (+)∗ (−)∼ (+)∼




disease polycystic kidney disease (−)∗∗∗
disease pyelonephritis (−)∗∗
disease renovascular disease (−)∼
disease unknown (−)∼
ethnicitynonWhite (+)∼
familyHistoryIHD0 (−)∼ (+)∼ (+)∼
followupTime (−)∗∗ (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼
Hb (+)∼ (+)∗∗ (+)∗∗∗ (+)∗∗∗ (+)∼ (+)∗ (+)∗∗ (+)∗∗∗ (+)∗∗∗
Hb:followupTime (+)∗∗ (+)∼ (+)∼ (−)∼ (+)∗ (+)∗ (+)∼ (+)∼ (+)∗∗
med.ACE.ARB (+)∗∗∗ (+)∗∗ (+)∼ (+)∼ (+)∼ (−)∼ (−)∼ (+)∗∗
med.ACE.ARB:followupTime (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼ (−)∼
med.AlphaBlockers (−)∼ (−)∼ (+)∼ (−)∼
med.AlphaBlockers:followupTime (−)∼ (+)∼ (+)∗∗ (−)∼
med.BetaBlockers (+)∼ (−)∼ (−)∼ (+)∼
med.BetaBlockers:followupTime (−)∼ (−)∼ (−)∼ (−)∼
med.CCBs (−)∗∗ (−)∼ (+)∼ (+)∼ (+)∼ (−)∗
med.CCBs:followupTime (+)∼ (+)∼ (−)∼ (−)∼ (−)∼ (−)∼
med.Diuretics (+)∼ (−)∗ (−)∗∗
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med.Diuretics:followupTime (−)∼ (+)∼ (+)∼
med.Epo (−)∗∗ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼ (−)∗∗ (−)∗ (−)∗∗∗
med.Epo:followupTime (+)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼ (−)∼ (+)∼ (−)∼
med.Iron (−)∼ (+)∼ (+)∼ (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∼
med.Iron:followupTime (+)∼ (−)∼ (−)∼ (−)∼ (+)∼ (+)∼ (−)∼ (+)∼ (−)∗
med.Other (−)∗
med.Other:followupTime (+)∼
med.ParenteralIron (−)∗ (−)∼ (−)∼ (−)∼ (−)∗ (+)∼ (+)∗ (−)∼ (−)∼
med.ParenteralIron:followupTime (+)∗∗ (−)∼ (+)∼ (−)∼ (+)∼ (−)∼ (−)∼ (+)∼ (+)∼
med.VitaminD (−)∗∗∗ (−)∗∗∗ (−)∗∗ (−)∗∗∗ (−)∼ (−)∗∗ (−)∗ (−)∗∗ (−)∗∗∗
med.VitaminD:followupTime (+)∼ (−)∼ (+)∼ (+)∼ (+)∼ (+)∼ (−)∼ (−)∼ (+)∼
numberAKIepisodes (−)∼ (−)∼ (−)∼ (−)∼ (−)∼ (+)∗ (−)∼
numberAKIepisodes:followupTime (+)∼ (+)∼ (−)∼ (−)∼ (+)∼ (−)∼ (−)∼
numberAntihypertensives (−)∗ (−)∼ (−)∗∗ (−)∼ (−)∗∗ (+)∼ (−)∼ (−)∼
numberAntihypertensives:followupTime (−)∼ (−)∼ (+)∼ (+)∼ (+)∼ (−)∼ (+)∗ (−)∼
numberClinicVisits (−)∼ (+)∗ (+)∼ (+)∼ (−)∼
numberClinicVisits:followupTime (−)∗∗∗ (−)∼ (+)∼ (+)∼ (−)∼
occupation0ManagerialProfessional (+)∼ (−)∼ (+)∼
occupation0Intermediate (+)∼ (+)∼ (+)∼
occupation0NeverWorkedUnemployed (+)∼ (−)∼ (+)∼
PO (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗
PO:followupTime (+)∼ (−)∼ (−)∼ (−)∗∗ (−)∼ (−)∼ (+)∼ (−)∗∗∗ (−)∗∗
PP (+)∗ (+)∼ (+)∼ (+)∗ (−)∼ (+)∗∗ (+)∼ (+)∗
PP:followupTime (−)∼ (+)∼ (+)∼ (+)∼ (+)∼ (−)∼ (−)∼ (+)∼
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PTH (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (−)∗∗ (−)∼ (−)∗∗ (−)∗∗∗ (−)∗∗∗
PTH:followupTime (+)∼ (+)∗∗∗ (−)∼ (+)∗∗ (+)∼ (+)∼ (+)∼ (+)∗∗∗ (+)∗∗∗
Pu (+)∼ (+)∗∗ (−)∼ (−)∗ (+)∼ (−)∼ (−)∗ (+)∼
Pu:followupTime (−)∗∗∗ (−)∗∗∗ (−)∗∗∗ (+)∼ (−)∗∗∗ (−)∼ (−)∼ (−)∗∗∗
sexfemale (−)∼
smokingStatus0active (−)∼ (−)∼ (−)∼
smokingStatus0ex-smoker (−)∼ (+)∼ (−)∼
totalCholesterol (+)∼ (+)∼ (+)∼ (+)∼ (+)∗
totalCholesterol:followupTime (−)∼ (−)∼ (−)∗∗ (+)∼ (−)∼
totalCO2 (+)∗∗∗ (+)∗∗ (+)∗∗∗ (+)∗ (+)∗∗ (+)∗∗ (+)∗∗∗
totalCO2:followupTime (−)∼ (−)∼ (+)∼ (−)∼ (−)∗ (−)∼ (−)∗∗∗
weeklyAlcohol01 to 14 (−)∗ (−)∼ (−)∼ (−)∼
weeklyAlcohol0over 14 (−)∼ (+)∗ (+)∼ (+)∼
Note:
regression parameter sign: positive (+); negative (-)
p-value significance levels: <0.001 ***; 0.001-0.01 **; 0.01-0.05 *; >0.05 ∼
1 ‘all’ denotes ‘single model all diseases’
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A.7.2 Diabetic nephropathy
Table 49: Estimated changes in outcome for changes in parameters for disease
diabetic nephropathy
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.2360 8.4e-02 0.1 -3.42 -1.03
CC:followupTime 0.0124 2.4e-02 5.6 7.15 2.15
Hb 0.0010 8.6e-04 17.1 1.64 0.49
Hb:followupTime 0.0009 3.0e-04 304.5 32.22 9.67
PO -0.3684 5.3e-02 0.3 -9.93 -2.98
PO:followupTime 0.0210 1.5e-02 2.9 6.27 1.88
PTH -0.0060 1.2e-03 11.8 -6.82 -2.05
PTH:followupTime 0.0002 2.2e-04 52.3 0.83 0.25
Pu 0.0134 8.2e-03 1.6 2.10 0.63
Pu:followupTime -0.0091 2.5e-03 5.3 -4.69 -1.41
totalCholesterol 0.0181 1.3e-02 1.1 2.10 0.63
biochemical
totalCholesterol:followupTime -0.0005 4.5e-03 11.0 -0.56 -0.17
med.ACE.ARB 0.1268 3.4e-02 1.0 13.51 4.05
med.ACE.ARB:followupTime -0.0178 1.1e-02 1.0 -1.76 -0.53
med.BetaBlockers 0.0583 3.3e-02 1.0 6.01 1.80
med.BetaBlockers:followupTime -0.0073 9.9e-03 1.0 -0.73 -0.22
med.Epo -0.0865 2.8e-02 1.0 -8.28 -2.48
med.Epo:followupTime 0.0082 8.4e-03 1.0 0.82 0.25
med.Iron -0.0285 3.1e-02 1.0 -2.81 -0.84
med.Iron:followupTime 0.0078 1.1e-02 1.0 0.79 0.24
med.ParenteralIron -0.0518 2.6e-02 1.0 -5.04 -1.51
med.ParenteralIron:followupTime 0.0260 9.0e-03 1.0 2.64 0.79
med.VitaminD -0.1334 3.0e-02 1.0 -12.49 -3.75
catagorical
med.VitaminD:followupTime 0.0035 8.5e-03 1.0 0.35 0.10
age0 -0.0057 1.8e-03 1.0 -0.56 -0.17
bodyMassIndex -0.0099 2.9e-03 5.9 -5.67 -1.70
bodyMassIndex:followupTime 0.0015 9.0e-04 69.8 10.86 3.26
DBP 0.0021 1.0e-03 11.3 2.44 0.73
DBP:followupTime -0.0001 3.4e-04 178.3 -2.22 -0.67
followupTime -0.2179 7.9e-02 1.0 -19.58 -5.87
numberAKIepisodes -0.0324 2.6e-02 0.4 -1.14 -0.34
numberAKIepisodes:followupTime 0.0034 5.8e-03 1.4 0.50 0.15
numberAntihypertensives -0.0277 1.2e-02 1.4 -3.84 -1.15
numberAntihypertensives:followupTime -0.0017 3.6e-03 7.5 -1.29 -0.39
PP 0.0014 5.8e-04 19.3 2.83 0.85
general
PP:followupTime -0.0001 2.1e-04 171.0 -1.21 -0.36
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( ∆r Y^  *)%  = 100(exp( β^r θr )−1)  with θr = σr
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05




Table 50: Estimated changes in outcome for changes in parameters for disease
glomerulonephritis
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC 0.0523 9.0e-02 0.1 0.77 0.23
CC:followupTime -0.0135 2.2e-02 5.6 -7.28 -2.18
CRP 0.0018 1.3e-03 19.9 3.55 1.07
CRP:followupTime 0.0001 3.2e-04 71.0 0.50 0.15
Hb 0.0027 8.1e-04 17.1 4.69 1.41
Hb:followupTime 0.0002 2.3e-04 304.5 7.85 2.36
PO -0.4846 5.0e-02 0.3 -12.86 -3.86
PO:followupTime -0.0058 1.4e-02 2.9 -1.67 -0.50
PTH -0.0091 1.7e-03 11.8 -10.20 -3.06
PTH:followupTime 0.0017 4.7e-04 52.3 9.36 2.81
Pu 0.0190 6.3e-03 1.6 3.00 0.90
Pu:followupTime -0.0081 2.0e-03 5.3 -4.19 -1.26
totalCO2 0.0154 3.8e-03 3.5 5.61 1.68
biochemical
totalCO2:followupTime -0.0013 1.0e-03 56.0 -6.94 -2.08
med.ACE.ARB 0.1015 3.6e-02 1.0 10.69 3.21
med.ACE.ARB:followupTime -0.0137 9.2e-03 1.0 -1.37 -0.41
med.AlphaBlockers -0.0294 3.8e-02 1.0 -2.90 -0.87
med.AlphaBlockers:followupTime -0.0052 1.0e-02 1.0 -0.52 -0.16
med.BetaBlockers -0.0569 3.6e-02 1.0 -5.53 -1.66
med.BetaBlockers:followupTime -0.0019 1.1e-02 1.0 -0.19 -0.06
med.CCBs -0.1106 3.4e-02 1.0 -10.47 -3.14
med.CCBs:followupTime 0.0002 8.8e-03 1.0 0.02 0.01
med.Epo -0.0417 3.3e-02 1.0 -4.09 -1.23
med.Epo:followupTime -0.0064 8.4e-03 1.0 -0.63 -0.19
med.Iron 0.0350 4.1e-02 1.0 3.56 1.07
med.Iron:followupTime -0.0173 1.2e-02 1.0 -1.71 -0.51
med.ParenteralIron -0.0136 3.4e-02 1.0 -1.35 -0.41
med.ParenteralIron:followupTime -0.0062 9.6e-03 1.0 -0.62 -0.19
med.VitaminD -0.1598 3.8e-02 1.0 -14.77 -4.43
catagorical
med.VitaminD:followupTime -0.0112 1.0e-02 1.0 -1.11 -0.33
age0 -0.0060 1.7e-03 1.0 -0.60 -0.18
DBP -0.0015 1.1e-03 11.3 -1.70 -0.51
DBP:followupTime 0.0007 2.9e-04 178.3 12.36 3.71
followupTime -0.0286 6.7e-02 1.0 -2.82 -0.85
numberAKIepisodes -0.0269 4.7e-02 0.4 -0.94 -0.28
numberAKIepisodes:followupTime 0.0077 1.4e-02 1.4 1.12 0.34
numberAntihypertensives -0.0040 1.6e-02 1.4 -0.56 -0.17
numberAntihypertensives:followupTime -0.0004 3.9e-03 7.5 -0.32 -0.10
PP 0.0008 7.1e-04 19.3 1.57 0.47
general
PP:followupTime 0.0000 2.0e-04 171.0 0.10 0.03
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p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 73: Relative change in eGFR for un-standardised model using 95% CIs: glomerulonephritis
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A.7.4 Hypertensive kidney disease
Table 51: Estimated changes in outcome for changes in parameters for disease
HKD
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1470 8.3e-02 0.1 -2.14 -0.64
CC:followupTime 0.0113 2.3e-02 5.6 6.51 1.95
Hb 0.0031 7.5e-04 17.1 5.40 1.62
Hb:followupTime 0.0001 2.7e-04 304.5 4.41 1.32
PO -0.3039 5.2e-02 0.3 -8.27 -2.48
PO:followupTime -0.0206 1.5e-02 2.9 -5.77 -1.73
PTH -0.0057 1.6e-03 11.8 -6.53 -1.96
PTH:followupTime -0.0003 4.6e-04 52.3 -1.60 -0.48
Pu -0.0345 1.8e-02 1.6 -5.22 -1.57
Pu:followupTime -0.0163 4.6e-03 5.3 -8.24 -2.47
totalCO2 0.0104 3.7e-03 3.5 3.73 1.12
biochemical
totalCO2:followupTime -0.0009 1.1e-03 56.0 -4.91 -1.47
comorbidityCancercurrent 0.0606 1.0e-01 1.0 6.24 1.87
comorbidityCancercurrent:followupTime 0.0174 2.8e-02 1.0 1.75 0.53
comorbidityCancerprevious -0.1753 7.0e-02 1.0 -16.08 -4.82
comorbidityCancerprevious:followupTime 0.0284 1.5e-02 1.0 2.88 0.86
comorbidityCV1 -0.0991 3.8e-02 1.0 -9.43 -2.83
comorbidityCV1:followupTime 0.0174 1.1e-02 1.0 1.75 0.53
comorbidityCVover 1 -0.0810 4.1e-02 1.0 -7.78 -2.33
comorbidityCVover 1:followupTime 0.0012 1.1e-02 1.0 0.12 0.04
comorbidityOther 0.0377 4.7e-02 1.0 3.84 1.15
comorbidityOther:followupTime -0.0046 9.9e-03 1.0 -0.46 -0.14
ethnicitynonWhite 0.1617 1.2e-01 1.0 17.55 5.26
med.ACE.ARB 0.0138 3.1e-02 1.0 1.39 0.42
med.ACE.ARB:followupTime -0.0025 9.0e-03 1.0 -0.25 -0.07
med.CCBs -0.0413 3.1e-02 1.0 -4.04 -1.21
med.CCBs:followupTime 0.0087 8.6e-03 1.0 0.88 0.26
med.Epo -0.0075 3.6e-02 1.0 -0.74 -0.22
med.Epo:followupTime -0.0052 1.1e-02 1.0 -0.52 -0.16
med.Iron 0.0509 3.3e-02 1.0 5.22 1.57
med.Iron:followupTime -0.0139 1.2e-02 1.0 -1.38 -0.42
med.ParenteralIron -0.0261 3.1e-02 1.0 -2.58 -0.77
med.ParenteralIron:followupTime 0.0106 1.0e-02 1.0 1.07 0.32
med.VitaminD -0.1115 3.3e-02 1.0 -10.55 -3.17
med.VitaminD:followupTime 0.0102 1.1e-02 1.0 1.03 0.31
smokingStatus0active -0.1210 9.0e-02 1.0 -11.40 -3.42
smokingStatus0ex-smoker -0.1001 5.4e-02 1.0 -9.52 -2.86
weeklyAlcohol01 to 14 -0.1232 5.3e-02 1.0 -11.59 -3.48
catagorical
weeklyAlcohol0over 14 -0.0767 6.8e-02 1.0 -7.38 -2.21
age0 -0.0100 2.4e-03 1.0 -1.00 -0.30
DBP 0.0013 9.2e-04 11.3 1.48 0.44
DBP:followupTime 0.0001 3.1e-04 178.3 1.50 0.45
followupTime -0.0391 7.6e-02 1.0 -3.83 -1.15
numberAKIepisodes -0.0409 3.6e-02 0.4 -1.43 -0.43
numberAKIepisodes:followupTime -0.0011 1.2e-02 1.4 -0.16 -0.05
numberAntihypertensives -0.0391 1.4e-02 1.4 -5.36 -1.61
numberAntihypertensives:followupTime 0.0076 4.0e-03 7.5 5.86 1.76
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Table 51: Estimated changes in outcome for changes in parameters for disease
HKD (continued)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
numberClinicVisits -0.0020 4.5e-03 2.4 -0.48 -0.14
numberClinicVisits:followupTime -0.0064 1.7e-03 10.4 -6.42 -1.93
PP 0.0002 6.0e-04 19.3 0.39 0.12
general
PP:followupTime 0.0002 1.9e-04 171.0 3.14 0.94
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p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 74: Relative change in eGFR for un-standardised model using 95% CIs: HKD
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A.7.5 Other
Table 52: Estimated changes in outcome for changes in parameters for disease
other
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1869 8.6e-02 0.1 -2.72 -0.82
CC:followupTime 0.0396 2.5e-02 5.6 24.74 7.42
CRP 0.0009 6.6e-04 19.9 1.84 0.55
CRP:followupTime -0.0003 2.3e-04 71.0 -1.97 -0.59
Hb 0.0057 8.6e-04 17.1 10.30 3.09
Hb:followupTime -0.0003 2.5e-04 304.5 -9.04 -2.71
PO -0.3167 5.5e-02 0.3 -8.60 -2.58
PO:followupTime -0.0448 1.4e-02 2.9 -12.14 -3.64
PTH -0.0087 1.4e-03 11.8 -9.85 -2.95
PTH:followupTime 0.0012 3.5e-04 52.3 6.48 1.94
totalCholesterol 0.0237 1.3e-02 1.1 2.76 0.83
totalCholesterol:followupTime -0.0019 3.7e-03 11.0 -2.04 -0.61
totalCO2 0.0124 3.5e-03 3.5 4.50 1.35
biochemical
totalCO2:followupTime 0.0006 1.0e-03 56.0 3.32 1.00
comorbidityCV1 -0.0227 3.7e-02 1.0 -2.24 -0.67
comorbidityCV1:followupTime -0.0167 9.7e-03 1.0 -1.65 -0.50
comorbidityCVover 1 -0.0195 4.7e-02 1.0 -1.93 -0.58
comorbidityCVover 1:followupTime 0.0098 1.3e-02 1.0 0.99 0.30
comorbidityDiabetestype1 -0.1038 2.4e-01 1.0 -9.86 -2.96
comorbidityDiabetestype1:followupTime -0.0342 6.5e-02 1.0 -3.36 -1.01
comorbidityDiabetestype2 0.0844 4.7e-02 1.0 8.81 2.64
comorbidityDiabetestype2:followupTime 0.0033 1.1e-02 1.0 0.34 0.10
med.BetaBlockers -0.0468 3.7e-02 1.0 -4.57 -1.37
med.BetaBlockers:followupTime -0.0071 9.1e-03 1.0 -0.70 -0.21
med.Epo -0.0422 3.7e-02 1.0 -4.13 -1.24
med.Epo:followupTime -0.0186 1.1e-02 1.0 -1.84 -0.55
med.Iron -0.0477 4.0e-02 1.0 -4.66 -1.40
med.Iron:followupTime -0.0020 1.2e-02 1.0 -0.20 -0.06
med.ParenteralIron -0.0075 3.8e-02 1.0 -0.75 -0.22
med.ParenteralIron:followupTime -0.0169 1.1e-02 1.0 -1.68 -0.50
med.VitaminD -0.1557 3.9e-02 1.0 -14.42 -4.33
catagorical
med.VitaminD:followupTime 0.0115 1.1e-02 1.0 1.15 0.35
age0 -0.0077 1.7e-03 1.0 -0.76 -0.23
followupTime -0.0273 7.4e-02 1.0 -2.70 -0.81
numberAKIepisodes -0.0095 4.1e-02 0.4 -0.33 -0.10
numberAKIepisodes:followupTime -0.0090 1.2e-02 1.4 -1.28 -0.39
numberClinicVisits 0.0102 4.2e-03 2.4 2.48 0.74
general
numberClinicVisits:followupTime -0.0010 1.2e-03 10.4 -1.01 -0.30
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p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 75: Relative change in eGFR for un-standardised model using 95% CIs: other
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A.7.6 PKD
Table 53: Estimated changes in outcome for changes in parameters for disease
PKD
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1517 1.1e-01 0.1 -2.21 -0.66
CC:followupTime -0.0375 3.1e-02 5.6 -18.89 -5.67
CRP -0.0027 1.7e-03 19.9 -5.32 -1.60
CRP:followupTime 0.0011 6.4e-04 71.0 8.46 2.54
Hb 0.0023 1.3e-03 17.1 3.92 1.18
Hb:followupTime 0.0009 3.7e-04 304.5 30.68 9.21
PO -0.1898 8.1e-02 0.3 -5.25 -1.57
PO:followupTime -0.0236 2.3e-02 2.9 -6.59 -1.98
PTH -0.0071 2.5e-03 11.8 -8.03 -2.41
PTH:followupTime 0.0001 6.2e-04 52.3 0.34 0.10
Pu -0.0998 4.4e-02 1.6 -14.37 -4.31
Pu:followupTime 0.0093 1.1e-02 5.3 5.02 1.51
totalCO2 0.0135 5.2e-03 3.5 4.88 1.47
biochemical
totalCO2:followupTime -0.0024 1.6e-03 56.0 -12.59 -3.78
comorbidityCV1 0.0029 4.9e-02 1.0 0.29 0.09
comorbidityCV1:followupTime -0.0153 1.3e-02 1.0 -1.52 -0.46
comorbidityCVover 1 -0.0832 9.1e-02 1.0 -7.99 -2.40
comorbidityCVover 1:followupTime 0.0073 2.0e-02 1.0 0.74 0.22
familyHistoryIHD0 -0.0645 8.8e-02 1.0 -6.24 -1.87
med.ACE.ARB 0.0087 4.9e-02 1.0 0.87 0.26
med.ACE.ARB:followupTime -0.0069 1.2e-02 1.0 -0.69 -0.21
med.CCBs 0.0856 4.7e-02 1.0 8.93 2.68
med.CCBs:followupTime -0.0147 1.2e-02 1.0 -1.46 -0.44
med.Diuretics 0.0149 4.1e-02 1.0 1.50 0.45
med.Diuretics:followupTime -0.0188 1.3e-02 1.0 -1.86 -0.56
med.Epo 0.0060 7.2e-02 1.0 0.60 0.18
med.Epo:followupTime -0.0260 1.8e-02 1.0 -2.57 -0.77
med.Iron -0.0658 7.0e-02 1.0 -6.37 -1.91
med.Iron:followupTime 0.0170 2.0e-02 1.0 1.71 0.51
med.ParenteralIron -0.1571 6.4e-02 1.0 -14.54 -4.36
med.ParenteralIron:followupTime 0.0245 1.8e-02 1.0 2.48 0.74
med.VitaminD -0.0877 5.7e-02 1.0 -8.40 -2.52
med.VitaminD:followupTime 0.0109 1.2e-02 1.0 1.10 0.33
occupation0ManagerialProfessional 0.1336 9.8e-02 1.0 14.29 4.29
occupation0Intermediate 0.0491 1.2e-01 1.0 5.04 1.51
catagorical
occupation0NeverWorkedUnemployed 0.0082 2.0e-01 1.0 0.83 0.25
age0 -0.0190 3.5e-03 1.0 -1.88 -0.56
DBP 0.0020 1.4e-03 11.3 2.30 0.69
DBP:followupTime -0.0001 4.2e-04 178.3 -1.77 -0.53
followupTime -0.0662 1.1e-01 1.0 -6.40 -1.92
numberAntihypertensives -0.0305 2.2e-02 1.4 -4.21 -1.26
numberAntihypertensives:followupTime 0.0085 5.8e-03 7.5 6.61 1.98
numberClinicVisits 0.0005 7.5e-03 2.4 0.11 0.03
numberClinicVisits:followupTime 0.0000 1.8e-03 10.4 0.01 0.00
PP 0.0024 1.1e-03 19.3 4.73 1.42
general
PP:followupTime 0.0001 2.9e-04 171.0 1.55 0.47
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Table 53: Estimated changes in outcome for changes in parameters for disease
PKD (continued)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
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p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 76: Relative change in eGFR for un-standardised model using 95% CIs: PKD
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A.7.7 Pyelonephritis
Table 54: Estimated changes in outcome for changes in parameters for disease
pyelonephritis
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1468 1.1e-01 0.1 -2.14 -0.64
CC:followupTime 0.0052 3.1e-02 5.6 2.93 0.88
Hb 0.0023 1.0e-03 17.1 3.98 1.19
Hb:followupTime 0.0009 3.4e-04 304.5 30.72 9.22
PO -0.2828 6.7e-02 0.3 -7.72 -2.31
PO:followupTime -0.0204 1.9e-02 2.9 -5.74 -1.72
PTH -0.0019 2.3e-03 11.8 -2.25 -0.68
PTH:followupTime 0.0005 4.2e-04 52.3 2.60 0.78
Pu 0.0061 1.7e-02 1.6 0.95 0.29
Pu:followupTime -0.0218 5.3e-03 5.3 -10.91 -3.27
totalCO2 0.0154 4.8e-03 3.5 5.61 1.68
biochemical
totalCO2:followupTime -0.0031 1.3e-03 56.0 -15.73 -4.72
comorbidityCancercurrent -0.2215 1.2e-01 1.0 -19.87 -5.96
comorbidityCancercurrent:followupTime 0.0481 2.9e-02 1.0 4.93 1.48
comorbidityCancerprevious -0.0708 1.1e-01 1.0 -6.83 -2.05
comorbidityCancerprevious:followupTime 0.0443 2.3e-02 1.0 4.53 1.36
comorbidityCV1 -0.0553 5.3e-02 1.0 -5.38 -1.61
comorbidityCV1:followupTime 0.0076 1.3e-02 1.0 0.76 0.23
comorbidityCVover 1 0.0026 7.2e-02 1.0 0.26 0.08
comorbidityCVover 1:followupTime -0.0194 1.5e-02 1.0 -1.92 -0.58
comorbidityDiabetestype2 0.0616 7.5e-02 1.0 6.35 1.91
comorbidityDiabetestype2:followupTime 0.0221 1.7e-02 1.0 2.24 0.67
comorbidityGastrointestinal 0.0851 1.5e-01 1.0 8.88 2.66
comorbidityGastrointestinal:followupTime 0.0227 2.1e-02 1.0 2.30 0.69
familyHistoryIHD0 0.0570 7.7e-02 1.0 5.87 1.76
med.ACE.ARB 0.0083 4.4e-02 1.0 0.84 0.25
med.ACE.ARB:followupTime -0.0091 1.2e-02 1.0 -0.91 -0.27
med.AlphaBlockers -0.0607 5.9e-02 1.0 -5.89 -1.77
med.AlphaBlockers:followupTime 0.0044 1.5e-02 1.0 0.44 0.13
med.CCBs 0.0521 5.0e-02 1.0 5.35 1.61
med.CCBs:followupTime -0.0079 1.2e-02 1.0 -0.79 -0.24
med.Epo -0.0960 6.4e-02 1.0 -9.15 -2.75
med.Epo:followupTime 0.0142 1.9e-02 1.0 1.43 0.43
med.Iron -0.0292 6.9e-02 1.0 -2.87 -0.86
med.Iron:followupTime 0.0026 1.5e-02 1.0 0.26 0.08
med.ParenteralIron 0.0051 4.6e-02 1.0 0.51 0.15
med.ParenteralIron:followupTime -0.0329 2.2e-02 1.0 -3.23 -0.97
med.VitaminD -0.1185 4.3e-02 1.0 -11.17 -3.35
med.VitaminD:followupTime 0.0159 1.0e-02 1.0 1.60 0.48
occupation0ManagerialProfessional -0.1897 1.0e-01 1.0 -17.28 -5.18
occupation0Intermediate 0.1509 9.9e-02 1.0 16.28 4.88
occupation0NeverWorkedUnemployed -0.0892 1.7e-01 1.0 -8.53 -2.56
sexfemale -0.1501 8.0e-02 1.0 -13.94 -4.18
smokingStatus0active -0.1343 1.2e-01 1.0 -12.56 -3.77
smokingStatus0ex-smoker 0.0052 8.8e-02 1.0 0.52 0.16
weeklyAlcohol01 to 14 -0.1031 8.9e-02 1.0 -9.79 -2.94
catagorical
weeklyAlcohol0over 14 0.2773 1.2e-01 1.0 31.96 9.59
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Table 54: Estimated changes in outcome for changes in parameters for disease
pyelonephritis (continued)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
age0 -0.0081 2.4e-03 1.0 -0.81 -0.24
bodyMassIndex 0.0037 5.3e-03 5.9 2.20 0.66
bodyMassIndex:followupTime 0.0013 9.6e-04 69.8 9.74 2.92
DBP 0.0020 1.2e-03 11.3 2.31 0.69
DBP:followupTime -0.0003 3.7e-04 178.3 -5.57 -1.67
followupTime -0.0892 9.4e-02 1.0 -8.53 -2.56
numberAKIepisodes -0.0926 6.8e-02 0.4 -3.21 -0.96
numberAKIepisodes:followupTime 0.0072 2.4e-02 1.4 1.04 0.31
numberAntihypertensives -0.0748 2.5e-02 1.4 -10.01 -3.00
numberAntihypertensives:followupTime 0.0027 6.5e-03 7.5 2.07 0.62
numberClinicVisits 0.0021 7.0e-03 2.4 0.50 0.15
numberClinicVisits:followupTime 0.0003 2.5e-03 10.4 0.34 0.10
PP -0.0001 1.0e-03 19.3 -0.26 -0.08
general
PP:followupTime 0.0004 2.9e-04 171.0 6.88 2.06
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p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 77: Relative change in eGFR for un-standardised model using 95% CIs: pyelonephritis
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A.7.8 Renovascular
Table 55: Estimated changes in outcome for changes in parameters for disease
renovascular
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1076 1.4e-01 0.1 -1.57 -0.47
CC:followupTime 0.0025 3.8e-02 5.6 1.41 0.42
CRP 0.0013 8.4e-04 19.9 2.59 0.78
CRP:followupTime -0.0003 2.5e-04 71.0 -2.18 -0.65
Hb 0.0031 1.1e-03 17.1 5.40 1.62
Hb:followupTime 0.0004 4.0e-04 304.5 11.38 3.41
PO -0.4033 6.8e-02 0.3 -10.82 -3.25
PO:followupTime 0.0213 2.2e-02 2.9 6.35 1.91
PTH -0.0071 2.7e-03 11.8 -8.06 -2.42
PTH:followupTime 0.0010 9.9e-04 52.3 5.47 1.64
Pu -0.0169 3.4e-02 1.6 -2.60 -0.78
Pu:followupTime -0.0079 6.4e-03 5.3 -4.08 -1.22
totalCholesterol 0.0072 1.6e-02 1.1 0.83 0.25
biochemical
totalCholesterol:followupTime -0.0143 5.3e-03 11.0 -14.59 -4.38
comorbidityCV1 -0.0688 7.2e-02 1.0 -6.64 -1.99
comorbidityCV1:followupTime 0.0262 2.0e-02 1.0 2.66 0.80
comorbidityCVover 1 -0.1726 7.0e-02 1.0 -15.86 -4.76
comorbidityCVover 1:followupTime 0.0122 1.9e-02 1.0 1.22 0.37
comorbidityDiabetestype1 -0.0527 2.1e-01 1.0 -5.13 -1.54
comorbidityDiabetestype1:followupTime 0.0317 5.2e-02 1.0 3.22 0.97
comorbidityDiabetestype2 0.0450 5.0e-02 1.0 4.60 1.38
comorbidityDiabetestype2:followupTime 0.0080 1.3e-02 1.0 0.81 0.24
comorbidityGastrointestinal 0.1229 8.6e-02 1.0 13.08 3.92
comorbidityGastrointestinal:followupTime -0.0217 2.0e-02 1.0 -2.15 -0.65
familyHistoryIHD0 0.0449 6.5e-02 1.0 4.59 1.38
med.ACE.ARB -0.0119 4.0e-02 1.0 -1.19 -0.36
med.ACE.ARB:followupTime 0.0164 1.2e-02 1.0 1.66 0.50
med.AlphaBlockers 0.0054 3.9e-02 1.0 0.54 0.16
med.AlphaBlockers:followupTime 0.0341 1.3e-02 1.0 3.47 1.04
med.Diuretics -0.0889 3.6e-02 1.0 -8.50 -2.55
med.Diuretics:followupTime 0.0065 1.1e-02 1.0 0.66 0.20
med.Epo -0.1739 5.0e-02 1.0 -15.96 -4.79
med.Epo:followupTime -0.0124 1.7e-02 1.0 -1.23 -0.37
med.Iron -0.0300 3.9e-02 1.0 -2.95 -0.89
med.Iron:followupTime -0.0183 1.1e-02 1.0 -1.81 -0.54
med.ParenteralIron 0.0935 4.7e-02 1.0 9.80 2.94
med.ParenteralIron:followupTime -0.0328 1.7e-02 1.0 -3.22 -0.97
med.VitaminD -0.0931 4.2e-02 1.0 -8.89 -2.67
med.VitaminD:followupTime -0.0153 1.6e-02 1.0 -1.52 -0.46
occupation0ManagerialProfessional 0.0590 8.3e-02 1.0 6.08 1.82
occupation0Intermediate 0.0224 9.1e-02 1.0 2.27 0.68
occupation0NeverWorkedUnemployed 0.3974 4.0e-01 1.0 48.80 14.64
smokingStatus0active -0.2123 1.2e-01 1.0 -19.12 -5.74
smokingStatus0ex-smoker -0.1537 8.9e-02 1.0 -14.25 -4.28
weeklyAlcohol01 to 14 -0.0555 8.0e-02 1.0 -5.40 -1.62
catagorical
weeklyAlcohol0over 14 0.1141 9.5e-02 1.0 12.09 3.63
age0 -0.0109 4.2e-03 1.0 -1.08 -0.32
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Table 55: Estimated changes in outcome for changes in parameters for disease
renovascular (continued)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
DBP 0.0005 1.2e-03 11.3 0.60 0.18
DBP:followupTime 0.0009 3.7e-04 178.3 18.40 5.52
followupTime -0.0970 1.1e-01 1.0 -9.24 -2.77
numberAntihypertensives 0.0037 1.7e-02 1.4 0.52 0.16
numberAntihypertensives:followupTime -0.0064 5.3e-03 7.5 -4.67 -1.40
PP 0.0019 6.7e-04 19.3 3.70 1.11
general
PP:followupTime -0.0001 2.1e-04 171.0 -2.50 -0.75
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( ∆r Y^  *)%  = 100(exp( β^r θr )−1)  with θr = σr
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 78: Relative change in eGFR for un-standardised model using 95% CIs: renovascular
223
A.7.9 Unknown disease
Table 56: Estimated changes in outcome for changes in parameters for disease
unknown
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1060 9.8e-02 0.1 -1.55 -0.47
CC:followupTime -0.0237 2.9e-02 5.6 -12.39 -3.72
Hb 0.0036 1.0e-03 17.1 6.42 1.93
Hb:followupTime 0.0001 3.3e-04 304.5 3.67 1.10
PO -0.3078 6.2e-02 0.3 -8.37 -2.51
PO:followupTime -0.0787 2.0e-02 2.9 -20.34 -6.10
PTH -0.0123 2.0e-03 11.8 -13.51 -4.05
PTH:followupTime 0.0020 5.7e-04 52.3 11.27 3.38
Pu -0.0342 1.4e-02 1.6 -5.18 -1.55
Pu:followupTime -0.0018 5.9e-03 5.3 -0.93 -0.28
totalCholesterol 0.0015 1.5e-02 1.1 0.17 0.05
totalCholesterol:followupTime 0.0091 5.1e-03 11.0 10.48 3.14
totalCO2 0.0154 4.5e-03 3.5 5.59 1.68
biochemical
totalCO2:followupTime -0.0023 1.5e-03 56.0 -12.17 -3.65
comorbidityCancercurrent 0.1649 1.3e-01 1.0 17.93 5.38
comorbidityCancercurrent:followupTime 0.0123 5.2e-02 1.0 1.23 0.37
comorbidityCancerprevious 0.0629 6.8e-02 1.0 6.49 1.95
comorbidityCancerprevious:followupTime -0.0224 1.9e-02 1.0 -2.21 -0.66
med.ACE.ARB -0.0189 3.8e-02 1.0 -1.88 -0.56
med.ACE.ARB:followupTime -0.0217 1.3e-02 1.0 -2.14 -0.64
med.BetaBlockers 0.0093 4.1e-02 1.0 0.93 0.28
med.BetaBlockers:followupTime -0.0163 1.3e-02 1.0 -1.62 -0.49
med.CCBs 0.0138 3.6e-02 1.0 1.39 0.42
med.CCBs:followupTime -0.0247 1.3e-02 1.0 -2.44 -0.73
med.Epo -0.0755 3.8e-02 1.0 -7.27 -2.18
med.Epo:followupTime 0.0075 1.4e-02 1.0 0.76 0.23
med.Iron -0.0240 4.0e-02 1.0 -2.37 -0.71
med.Iron:followupTime 0.0151 1.3e-02 1.0 1.52 0.45
med.ParenteralIron -0.0176 3.9e-02 1.0 -1.75 -0.52
med.ParenteralIron:followupTime 0.0110 1.7e-02 1.0 1.11 0.33
med.VitaminD -0.1207 4.3e-02 1.0 -11.37 -3.41
med.VitaminD:followupTime -0.0134 1.3e-02 1.0 -1.33 -0.40
weeklyAlcohol01 to 14 -0.0494 5.2e-02 1.0 -4.82 -1.45
catagorical
weeklyAlcohol0over 14 0.0834 6.4e-02 1.0 8.69 2.61
age0 -0.0067 1.8e-03 1.0 -0.67 -0.20
DBP 0.0024 1.2e-03 11.3 2.71 0.81
DBP:followupTime -0.0005 4.3e-04 178.3 -8.92 -2.67
followupTime 0.1521 9.4e-02 1.0 16.43 4.93
numberAKIepisodes 0.1381 5.8e-02 0.4 4.99 1.50
numberAKIepisodes:followupTime -0.0190 1.7e-02 1.4 -2.70 -0.81
numberAntihypertensives -0.0335 1.8e-02 1.4 -4.62 -1.39
numberAntihypertensives:followupTime 0.0147 6.1e-03 7.5 11.60 3.48
PP 0.0000 7.2e-04 19.3 0.02 0.01
general
PP:followupTime 0.0000 2.5e-04 171.0 -0.71 -0.21
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( ∆r Y^  *)%  = 100(exp( β^r θr )−1)  with θr = σr
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 79: Relative change in eGFR for un-standardised model using 95% CIs: unknown
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A.7.10 Single model all diseases
Table 57: Estimated changes in outcome for changes in parameters for single
model all diseases
E(∆rYˆ ∗)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
CC -0.1071 3.4e-02 0.1 -1.57 -0.47
CC:followupTime -0.0050 9.3e-03 5.6 -2.73 -0.82
Hb 0.0033 3.3e-04 17.1 5.74 1.72
Hb:followupTime 0.0003 1.0e-04 304.5 10.89 3.27
PO -0.3825 2.1e-02 0.3 -10.29 -3.09
PO:followupTime -0.0186 5.9e-03 2.9 -5.23 -1.57
PTH -0.0074 5.6e-04 11.8 -8.34 -2.50
PTH:followupTime 0.0008 1.3e-04 52.3 4.39 1.32
Pu 0.0021 3.7e-03 1.6 0.33 0.10
Pu:followupTime -0.0075 1.1e-03 5.3 -3.88 -1.16
totalCholesterol 0.0102 4.9e-03 1.1 1.18 0.35
totalCholesterol:followupTime -0.0012 1.5e-03 11.0 -1.35 -0.41
totalCO2 0.0142 1.5e-03 3.5 5.17 1.55
biochemical
totalCO2:followupTime -0.0017 4.3e-04 56.0 -9.27 -2.78
comorbidityCancercurrent 0.0259 3.8e-02 1.0 2.62 0.79
comorbidityCancercurrent:followupTime -0.0009 9.8e-03 1.0 -0.09 -0.03
comorbidityCancerprevious -0.0488 2.5e-02 1.0 -4.76 -1.43
comorbidityCancerprevious:followupTime 0.0056 6.2e-03 1.0 0.56 0.17
comorbidityCV1 -0.0329 1.5e-02 1.0 -3.23 -0.97
comorbidityCV1:followupTime 0.0003 4.3e-03 1.0 0.03 0.01
comorbidityCVover 1 -0.0485 1.8e-02 1.0 -4.74 -1.42
comorbidityCVover 1:followupTime 0.0059 4.7e-03 1.0 0.60 0.18
disease diabetic nephropathy -0.0963 3.2e-02 1.0 -9.18 -2.75
disease glomerulonephritis 0.0091 3.4e-02 1.0 0.91 0.27
disease HKD -0.0536 3.5e-02 1.0 -5.22 -1.57
disease obstruction -0.3433 8.5e-02 1.0 -29.05 -8.72
disease polycystic kidney disease -0.1782 4.4e-02 1.0 -16.32 -4.90
disease pyelonephritis -0.1395 4.4e-02 1.0 -13.02 -3.91
disease renovascular disease -0.0197 4.1e-02 1.0 -1.95 -0.58
disease unknown -0.0556 3.5e-02 1.0 -5.41 -1.62
med.ACE.ARB 0.0447 1.4e-02 1.0 4.57 1.37
med.ACE.ARB:followupTime -0.0063 3.8e-03 1.0 -0.63 -0.19
med.AlphaBlockers -0.0169 1.4e-02 1.0 -1.67 -0.50
med.AlphaBlockers:followupTime -0.0052 4.2e-03 1.0 -0.52 -0.16
med.CCBs -0.0311 1.3e-02 1.0 -3.06 -0.92
med.CCBs:followupTime -0.0007 3.8e-03 1.0 -0.07 -0.02
med.Diuretics -0.0426 1.3e-02 1.0 -4.17 -1.25
med.Diuretics:followupTime 0.0058 3.9e-03 1.0 0.58 0.17
med.Epo -0.0745 1.3e-02 1.0 -7.18 -2.15
med.Epo:followupTime -0.0052 3.9e-03 1.0 -0.52 -0.16
med.Iron 0.0077 1.4e-02 1.0 0.77 0.23
med.Iron:followupTime -0.0090 4.3e-03 1.0 -0.90 -0.27
med.Other -0.0507 2.4e-02 1.0 -4.95 -1.48
med.Other:followupTime 0.0133 7.3e-03 1.0 1.34 0.40
med.ParenteralIron -0.0228 1.3e-02 1.0 -2.26 -0.68
med.ParenteralIron:followupTime 0.0007 4.1e-03 1.0 0.07 0.02
med.VitaminD -0.1429 1.4e-02 1.0 -13.32 -4.00
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Table 57: Estimated changes in outcome for changes in parameters for single
model all diseases (continued)
category parameter βˆr se θr (∆rYˆ ∗)% E(Yˆ ∗ij) = 30
catagorical
med.VitaminD:followupTime 0.0064 3.8e-03 1.0 0.64 0.19
age0 -0.0070 7.1e-04 1.0 -0.69 -0.21
DBP 0.0010 3.9e-04 11.3 1.10 0.33
DBP:followupTime 0.0001 1.2e-04 178.3 1.80 0.54
followupTime -0.0079 3.0e-02 1.0 -0.78 -0.24
numberAKIepisodes -0.0134 1.5e-02 0.4 -0.47 -0.14
numberAKIepisodes:followupTime -0.0030 3.7e-03 1.4 -0.44 -0.13
numberAntihypertensives -0.0088 6.9e-03 1.4 -1.24 -0.37
numberAntihypertensives:followupTime -0.0008 1.9e-03 7.5 -0.60 -0.18
numberClinicVisits -0.0025 1.7e-03 2.4 -0.60 -0.18
numberClinicVisits:followupTime -0.0002 4.7e-04 10.4 -0.26 -0.08
PP 0.0006 2.5e-04 19.3 1.24 0.37
general
PP:followupTime 0.0000 7.7e-05 171.0 0.21 0.06























































( ∆r Y^  *)%  = 100(exp( β^r θr )−1)  with θr = σr
p−value significance:  <0.001    0.001−0.01    0.01−0.05    >0.05
Figure 80: Relative change in eGFR for un-standardised model using 95% CIs for single model
all diseases
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